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introduction
1.1: Diabetes mellitus
Diabetes mellitus is a chronic metabolic disease which is characterized by chronic
hyperglycemia. Five to ten percent of patients have type 1 diabetes, formerly known as
insulin-dependent diabetes mellitus or juvenile onset diabetes mellitus (1) Type 1
diabetes represents insulin deficiency or absence of insulin primarily due to
autoimmune destruction of pancreatic islet beta-cells. In 85-90% of the subjects with
type 1 diabetes, islet cell autoantibodies, and/or autoantibodies to insulin and
autoantibodies to glutamic acid decarboxylase (GAD) are present which identify the
autoimmune processes that lead to beta-cell destruction (1.2). Subjects with type 1
diabetes require insulin for their survival to prevent the development of ketoacidosis.
coma and death. Type 2 diabetes mellitus represents the most common form,
responsible for over 85% of the cases in the Netherlands
(www.rivm.nl/vtVdata/site.kompas). Other specific types of diabetes mellitus such as
type 3 and type 4 refer to specific situations such as pancreatic disease, surgery, and
gestational diabetes (1.2).
1.1.1: Type 2 diabetes mellitus
Type 2 diabetes mellitus represents a metabolic disorder of multiple aetiology, which is
characterized by chronic hyperglycemia caused by impaired insulin action and
secretion, either of which may be the predominant feature in the pre-diabetic state (1).
These impairements can result in disturbances in carbohydrate, fat and protein
metabolism, which can result in long-term damage, dysfunction and failure of various
organs. The pathological and functional changes caused by hyperglycemia may be
present long before the diagnosis of type 2 diabetes is made, but symptoms of type 2
diabetes are often insidious at the beginning, or even absent (1). Long-term effects of
diabetes mellitus include progressive development of specific microvascular
complications including retinopathy which potentially leads to blindness, nephropathy
which can lead to renal failure, or neuropathy which may affect peripheral nerves or
autonomic dysfunction. Furthermore, patients with type 2 diabetes have an increased
incidence of macrovascular disease, such as coronary heart disease (CHD), stroke or
cerebrovascular accidents, and peripheral vascular disease (PVD) (2). Approximately
60-70% of patients with type 2 diabetes die from vascular disease such as myocardial
infarction or stroke (3). The main theory to explain the increased risk of cardiovascular
disease (CVD) in type 2 diabetes holds that the increased risk is caused by an
increased rate of atherosclerosis.
1.1.2: Prevalence and costs
Increased incidence and prevalence of obesity, arising from energy-rich diets and
sedentary lifestyles, drives a global pandemic of type 2 diabetes (4) The prevalence of
type 2 diabetes worldwide is expected to increase from its present level of 150 million to
300 million by 2025. These figures however, represent only clinically diagnosed
diabetes, and even more cases of diabetes remain undiagnosed and untreated.
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Moreover, approximately 20 to 25% of the subjects in Western populations have the
metabolic syndrome after adjustment for age (1,5). Subjects with the metabolic
syndrome are at high risk of future type 2 diabetes, and therefore can be considered to
represent a pre-diabetic state. The costs of health care of subjects with diabetes
increases with the onset of complications (6). In a United States study, Kaiser
Permanente North-west Division (KPNW), renal and cardiovascular complications were
the most prevalent in subjects with diabetes and were associated with particularly high
costs: an increase of $9385 after the occurrence of a major cardiovascular event, and
$15,675 for renal transplantation over the costs of uncomplicated diabetes (6).
The Cost of Diabetes in Europe - Type II (CODE-2) study also showed that
atherosclerosis in type 2 diabetes accounts for approximately one third of the total
health care costs related to the disease in the eight European countries that
participated in the CODE-2 study, including the Netherlands (7). Overall, the presence
of microvascular complications results in an increase of 70% of the health costs, and
the presence of macrovascular complications results in an increase of 100%, compared
to people without evidence of complications (7). Furthermore, the presence of both
microvascular and macrovascular complications increases the total costs of
management 3.5 times compared to those without evidence of complications (7). The
CODE-2 study also showed that the total direct medical costs of type 2 diabetes was
estimated at €29 billion a year and that the average yearly cost per patient was €2834 a
year in 1999 (8). The Netherlands were found to have the lowest expenditure per
patient, i.e. €1827, which accounted for 1.6% of the total healthcare expenditure. The
prevalence of type 2 diabetes in the Netherlands was 1.7% which is the lowest
prevalence found in the CODE-2 study (8).
T«b«l 1: Glucose tolerance status according to the 1999 WHO criteria (1)
Type 2 diabetes mellitus (DM)
fasting or
2h post load
Impaired Glucose Tolerance (IGT)
fasting and
2h post load
Impaired Fasting Glucose (IFG)
fasting and
2h post load
Normal Glucose Tolerance (NGT)
fasting and
2h post load
Whole blood
venous
(mmol/l)
2 6.1
2 10.0
<6.1
6.7 - < 10.0
5.6-< 6.1
<6.7
<5.6
<6.7
glucose
capillary
(mmol/l)
2 6.1
211.1
<6.1
7.8-< 11.1
5.6 - < 6.1
<7.8
< 5 6
<7.8
Plasma
venous
(mmol/l)
2 7.0
211.1
<7.0
7.8-< 11.1
6.1 -<7.0
<7.8
<6.1
<7.8
glucose
capillary
(mmol/l)
2 7.0
2 12.2
<7.0
8.9-< 12.2
6.1 -<7.0
<8.9
<6.1
<8.9
1.1.3: Diagnosis
In most cases, a clinician diagnoses type 2 diabetes by the severity of symptoms and
overt hyperglycemia (1). However, type 2 diabetes can be present without symptomos.
12
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Therefore, an oral glucose tolerance test (OGTT) is recommended in epidemiological
studies This test measures blood or plasma glucose concentrations in the fasting state
and at regular intervals up to 2h after a 75-g oral glucose load The WHO has adjusted
the diagnostic criteria for interpretation of the results in whole blood and plasma in 1999
(1). The largest change was the lowering of the cut-off value of fasting glucose
concentration from 7 8 mmol/l to 7 0 mmol/l. In addition to the criteria for type 2
diabetes mellitus, the 1999 WHO criteria also defined cut-offs for impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG) (Table 1) It should be noted that the
American Dabetes Association (ADA) recently has proposed to lower the cut-off value
for IFG to optimize its sensitivity and specificity to predict future diabetes (9) A debate
has started what the benefits and consequences would be for patients and health care
costs if this proposal is accepted (10-12).
1.1.4: Pathogenesis
Insulin resistance, defined as a decreased ability of insulin to stimulate glucose uptake
in peripheral tissues, is a key pathogenic parameter observed in the natural history of
type 2 diabetes (13). Another key feature is beta-cell failure, i.e. the inability of the
pancreatic beta-cell to adequately secrete insulin relative to the insulin needs of the
body (14). It is believed that the pathogenesis of type 2 diabetes starts with a gradual
increase in insulin resistance, which results in compensatory hyperinsulinemia. This
state is probably maintained until pancreatic secretory defects occur Consequently,
once beta-cell failure occurs, insulin resistance cannot be compensated any more.
Furthermore, increased hepatic gluconeogenesis may occur (15). Both fasting and
postprandial hyperglycemia result, which is the state of overt diabetes.
It can take many years before type 2 diabetes has fully developed. Both insulin
resistance and beta-cell failure are caused by a combination of genetic and
environmental factors (16). Environmental factors, such as lifestyle habits (i.e. obesity,
physical inactivity and dietary intake), intrauterine malnutrition and toxins may enhance
the progression to type 2 diabetes (16). When insulin resistance cannot be
compensated any more by an increase in insulin secretion because of impaired beta-
cell function, impaired glucose tolerance can occur, which represents the pre-diabetic
stage. It is also at this stage where clustering of risk factors, i.e. the metabolic
syndrome, is observed. Therefore, insulin resistance may be present many years
before the diagnosis of type 2 diabetes and subjects may be predisposed to
accelerated atherosclerosis (17). It is this stage in the natural history towards type 2
diabetes where prevention trials are currently addressing the need to reduce insulin
resistance or insulin secretion defects, both by pharmacological and
nonpharmacological means, in the hope that type 2 diabetes can be prevented or
delayed (18-22). A schematic representation of the natural history of type 2 diabetes,
with insulin resistance, compensatory hyperinsulinemia, and associated risk factors, is
outlined in figure 1.
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Proposed Metabolic Observations in the
Natural History of Type 2 Diabetes
Insulin sensitivity
Insulin secretion
AMOCiated Risk Factors
• Hypertension
• Dyshpidemia
Atherogenesis
Mlcrovascular
complications
Fasting Blood Glucose
Age(y) Type 2 Diabetes
Figure 1: Schematic representation of clinical and laboratory findings in the natural history of type 2 diabetes
(15).
1.1.5: Risk factors for type 2 diabetes
Genetic, environmental, and metabolic risk factors all contribute to the development of
type 2 diabetes mellitus (23). A family history of diabetes mellitus, age, obesity, and
physical inactivity identify those individuals at highest risk. Minority populations are also
at higher risk, because of family history and genetics in combination with adaptation to
Western environmental influences of poor dietary and exercise habits (23). Women with
a history of gestational diabetes, as well as their children, are also at greater risk for
progressing to type 2 diabetes mellitus. Most metabolic risk factors leading to type 2
diabetes are already present in the early insulin resistant conditions. These include
hyperinsulinemia, atherogenic dyslipidemia, glucose intolerance, hypertension, a
prothrombotic state, hyperuricemia, and polycystic ovary syndrome. Clinical and
observational studies have demonstrated the adverse effects of obesity and sedentary
lifestyle, as well as the benefits of moderate weight loss and related behaviours,
including increased levels of physical activity, in maintaining metabolic control and
reducing the incidence of type 2 diabetes (24). Awareness of risk factors for developing
type 2 diabetes will promote screening, early detection of type 2 diabetes, and
treatment in high-risk populations. This will decrease both microvascular and
macrovascular complications.
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1.2: Cardiovascular disease
Cardiovascular disease (CVD) is a term that covers a range of diseases of the heart
and large blood vessels CVD is the major cause of premature death in most European
countries and in the United States (25.26). In the Netherlands. CVD provides the
largest contribution to total mortality for many years now (27). In the year 2002, 34% of
total mortality was ascribed to CVD, with equal representation in men and women.
CVD can be divided into different disease categories The five largest categories in
the Netherlands are ischaemic heart disease (32.7%), other heart diseases including
heart failure (26.6%). cerebrovascular disorders (25.3%). atherosclerosis and/or
hypertension (4.8%), and arterial vascular disease (4.3%) (27). A major risk factor for
CVD is an unhealthy lifestyle, reflected by less healthy dietary habits (28) and less
physical activity (29-31). Other CVD risk factors include increasing age (32-34), male
gender (35,36), obesity (37-41), previous history of CVD (42-45). positive family history
of CHD (36.46-48), smoking (49). hypertension (34.50-53). elevated total (47.54.55)
and low-density lipoprotein (LDL) cholesterol (55-59), reduced high-density lipoprotein
(HDL) cholesterol (59-61), and diabetes mellitus (57.62). More recently, several novel
risk factors have been found such as small dense LDL particles (56.63,64),
hypertriglyceridemia (65-67), hyperinsulinemia (68-70), elevated apolipoprotein B
concentrations (70-75), decreased Ankle/Brachial Index (26.76-78). microalbuminuria
(79,80). elevated C-reactive protein (22.81-84), and elevated homocysteine (85-92).
1.2.1: Description of risk factors
Age: The age-associated changes in cardiac and vascular properties reduce the
threshold that results in clinically significant signs and symptoms of CVD (32). In older
individuals for example, the specific pathophysiological mechanisms that cause clinical
disorders have more effect, because of vascular rarefaction (fewer resistance vessels)
and decreased arteriolar cross-sectional area that will result in increased peripheral
resistance (50). Therefore, age is considered a major risk factor per se for
cardiovascular disease.
Male gender: Male gender is a well-known risk factor for CVD. By the age of 60, every
one out of five men and one out of seventeen women have some form of CHD in
industrialized societies such as Northern Europe and North America (35). In the
Nijmegen Cohort Study, the incidence of CHD was 8.6% in men and 3.0% in women
during 18 years of follow-up (36). Also, the website of "Nationaal Kompas
Volksgezondheid" (www.rivm.nl/vtv/data/site_kompas) indicates that the most recent
incidence numbers for CHD are 5.92 per 1000 men and 4.36 per 1000 women in the
Netherlands. These studies all indicate the higher risk for CVD in men compared to
women.
Body weight and obesity: Many risk factors, such as age, race and the presence of
certain diseases determine the degree of obesity (37). With an increase in prevalence
of risk factors, the risk of obesity increases. Furthermore, severe obesity in both men
and women in all age groups, increases the risk of death from all causes, CVD, cancer,
and other diseases (37). Obesity is a modifiable cardiovascular risk factor that is far
more prevalent in type 2 diabetes than in the general population. However, little or no
correlations were demonstrated between fat mass and coronary atherosclerosis in
15
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angiographic and post mortem studies, except in those with central (upper-body)
obesity (41). Central obesity is strongly associated with traditional risk factors for CVD
such as type 2 diabetes, hypertension and dyslipidemia, and contributes to earlier or
more severe disease manifestations (41). Therefore, central obesity is a stronger risk
factor of CVD than obesity per se
Previous history of cardiovascular disease (CVD): The presence of coronary heart
disease strongly predicts coronary events (43). Furthermore, men with CVD with
frequent or complex arrhythmias had increased cardiac event rates and increased
mortality compared to men without CVD (44). Recurrence of Ml was closely related to
transient atrial fibrillation, previous cerebrovascular accident and dyslipidemia (low ratio
HDL-/LDL-cholesterol). All these findings indicate the significance of previous history of
CVD on the risk of recurrent CVD.
Positive family history of coronary heart disease (CHD): A positive family history of
CHD indicates that a person is at high risk of premature CHD independent of the
presence of classical and non-classical risk factors (46). This observed familial disease
aggregation is not well understood except for the general knowledge that genetic and
environmental factors predisposing to CHD also aggregate in families (47). The
Nijmegen Cohort Study found a risk ratio of 1.8 for CHD when a positive family history
of premature CVD was present (36).
Smoking: Smoking has been associated with a two-to-fourfold increased risk of CHD,
a greater than 70% excess rate of death from CHD, and an elevated risk of sudden
death (49). These risks are aggravated in the presence of hypertension,
hypercholesterolemia, glucose intolerance, and diabetes. Furthermore, smoking
increases the risk of peripheral vascular disease (49). Two main components of
cigarette smoking, nicotine and carbon monoxide, play major roles in endothelial injury
and the development of atherosclerotic plaque (49).
Blood pressure and hypertension: High blood pressure, also called hypertension,
increases the load on the heart, burdens the wall stress of the arteries, and accelerates
cardiovascular degeneration and disease (50). Both systolic and diastolic blood
pressures show a continuous, graded, independent relationship with risk of stroke and
coronary events (34). Furthermore, the difference between systolic and diastolic blood
pressure, i.e. pulse pressure, has been recognized as an independent predictor of
carotid artery plaque ulceration (51), CVD and all cause mortality (52,53). Historically,
therapeutic intervention thresholds for treatment have been based on variable and
somewhat arbitrary cut-off points. Risk factors of CVD are known to cluster in
individuals and the definition of high blood pressure nowadays includes values that may
be considered 'high' in high-risk subjects, but acceptable in individuals at lower risk (34).
Ankle/Brachial Index: The Ankle/Brachial pressure Index (ABI) is a commonly used
non-invasive indicator of CVD (76) and is used to determine to whether peripheral
vascular disease is present. In prospective epidemiological studies, a low ABI was
associated with the extent of atherosclerosis in coronary and noncoronary arterial beds
(76), an increased incidence of ischemic stroke (77), and was found to be an effective
predictor of cardiovascular risk (25). Furthermore, it was associated with an increased
risk of subsequent non-fatal cardiovascular events, independent of age, gender, and
the presence of angina pectoris, myocardial infarction and diabetes at baseline (76). It
reflects generalized atherosclerosis and improves predictions of future cardiovascular
events based on conventional risk factors alone (76,78).
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Microalbuminuria: It has been shown that increased urinary albumin and protein
excretion rates precede, and therefore, predict cardiovascular mortality in subjects with
and without type 2 diabetes (79.80). An increased urinary albumin excretion rate is
often associated with adverse changes in cardiovascular risk factors, and it may be a
marker of widespread andothehal dysfunction or vascular damage, in the kidney or
elsewhere, enhancing atherosclerosis.
Glucose concentration and type 2 diab«t«s: The prospective Cardiovascular Health
Study found that 2h post-load glucose level was better than fasting glucose level alone
at identifying older adults at increased risk of major incident cardiovascular events (93).
Furthermore, a meta-regression analysis showed a continuous positive relationship
between initial fasting and 2h post-load glucose and CVD events that extended below
the current thresholds for IGT (6.1 mmol/L) and IFG (5.6 mmol/L) (94). Moreover, the
DECODE study showed that the relationship between fasting glucose and mortality was
dependent of 2h post-load glucose, but that the relationship of mortality with 2h post-
load glucose was independent of fasting glucose (95). Adjustment for other CVD risk
factors demonstrated a continuous relationship between 2h post-load glucose and
CHD, stroke, all CVD and all-cause mortality, but suggested a possible threshold effect
with fasting glucose at 7.0 mmol/L, i.e. the level at which type 2 diabetes is diagnosed.
Type 2 diabetes increases the risk of CVD 2- to 4-fold compared to the risk in subjects
without diabetes, and approximately 65% of all patients with type 2 diabetes die from
CHD (57). Epidemiological and pathological data document that diabetes is an
independent risk factor for several forms of CVD in both men and women (57). When
CVD develops in patients with type 2 diabetes, they sustain a worse prognosis 6r
survival than do CVD patients without diabetes More about the relationship between
type 2 diabetes and CVD is described in section 1.5.
Total cholesterol, LDL- and HDL-cholesterol: Elevated total serum cholesterol
strongly increases the long-term absolute risk of death in men with CHD (55).
Furthermore, the incidence of definite coronary events increased when total cholesterol
levels were elevated (47). LDL is the principal cholesterol-carrying lipoprotein and
therefore plays a central role in atherosclerosis (56). An elevation of LDL-cholesterol is
a major risk factor for CVD and was associated with an increase in CHD independent of
the usual coronary risk factors such as smoking, blood pressure, total cholesterol, HDL-
cholesterol and diabetes (56-59). In fact, an elevation of LDL-cholesterol appears to be
necessary for the initiation and progression of atherosclerosis (56). This has led to the
lipoprotein retention theory (96), which is described in section 1.3. In contrast with this,
reduction of HDL-cholesterol levels results in the disappearance of the cardioprotective
effect of HDL. This cardioprotective effect is attributed to the role of HDL- cholesterol in
reverse cholesterol transport (97). In this reverse transport, cholesterol is accepted from
peripheral tissues by small, dense HDL particles. When enough cholesterol is
accepted, these particles become larger and less dense and can transfer cholesterol
esters to apolipoprotein B100 or directly to the liver (97). It is known that HDL can
remove diolesterol from macrophages, thus preventing the formation of foam cells
which are part of the development of an atherosclerotic lesion. Other mechanisms by
which HDL inhibits atherosclerosis are prevention of oxidation of LDL and of adhesion
of monocytes to the endothelium (98,99).
Small, dense LDL particles: Krauss and Blanche (100) reviewed LDL structural
heterogeneity and divided the LDL profile into two phenotypes, pattern A and B In
17
Chapter 1
pattern A, large-sized LDL is dominant and in pattern B, a greater proportion of small,
dense LDL exists. The presence of small, dense LDL is mostly associated with
moderate elevation in plasma triglycerides, low levels of HDL-cholesterol, abdominal
obesity, insulin resistance and other metabolic abnormalities predictive of impaired
endothelial function and increased susceptibility to atherothrombosis (63). Small, dense
LDL has been shown to be more readily oxidized than its larger counterparts. Because
of its reduced size it is also more likely to penetrate the arterial wall. In addition, it was
shown that small, dense LDL has an enhanced affinity for arterial wall proteoglycan,
thus prolonging its residence time in the subendothelial space (63). All these features
contribute to the enhanced atherogenicity of small, dense LDL particles and it has been
shown that the presence of small, dense LDL particles was associated with more than a
three-fold increase in the risk of CHD (63).
Apollpoprotein B: Apolipoprotein B (apoB) is an important risk factor of myocardial
infarction (71) and was found to be a better predictor of CHD risk in adults and in
children than total cholesterol, triglycerides, HDL-cholesterol and small, dense LDL (71-
75). Furthermore, apoB was a better predictor of risk than LDL in individuals with LDL
concentrations below the median value (71). Several studies have suggested that apoB
in atherogenic particles (mainly LDL, but also very-low-density lipoprotein (VLDL)) could
improve the prediction of risk of CHD (72-74). Additionally, apoB might be predictive in
subjects with insulin resistance or diabetes because their atherogenicity is mainly seen
when lipid abnormalities, such as abnormal VLDL and intermediate density lipoprotein
(IDL). and small, dense LDL and HDL particles, are present.
Triglycerid**: A high level of triglycerides called hypertriglycendemia reflects an
increase in VLDL and IDL particles and is often found in the presence of small, dense
LDL (73). Hokanson and Austin (65) reported that elevated triglycerides were
associated with a 30% increase in cardiovascular risk in men and a 75% increase in
women, independent of HDL-cholesterol and other risk factors. Furthermore, it is
becoming more and more accepted that hypertriglycendemia acts as a synergistic risk
factor of CHD with other lipid risk factors such as high LDL-cholesterol and low HDL-
cholesterol (66). Moreover, hypertriglycendemia is recognized as a marker among
metabolic and clinical conditions that are associated with increased risk for
atherosclerosis (65).
Insulin: Elevated fasting plasma insulin called hypennsulinemia is one of the
characteristics of the insulin resistant state. Hyperinsulinemia in nondiabetic men is
associated with the greatest relative increase in the risk of CHD irrespective of the
presence or absence of other lipoprotein abnormalities such as elevated apoB,
elevated or presence of small, dense LDL, elevated triglycerides or reduced HDL-
cholesterol (68.69). Hyperinsulinemia appears to have a direct effect on the arterial wall
by changing endothelial cells that synthesize plasminogen activator inhibitor 1 (PAH)
(101). An increase in PAH can result in hypofibrinolysis which increases the risk of
CVD. Furthermore, hyperinsulinemia is most frequently associated with deteriorations
in other CVD risk factors. Clustering of hyperinsulinemia with other risk factors is called
the metabolic syndrome, which is known to increase the risk of CVD (102). Isolated
hyperinsulinemia however, has a low prevalence rate on its own, and currently, no
absolute cut-off point exists to define hyperinsulinemia. Arbitrary cut off points are being
used which are based on the upper normal limit of insulin or on a predefined percentile
of the background population to indicate insulin resistance and hyperinsulinemia. More
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commonly used however, is the homeostasis model assessment (HOMA) to estimate
insulin resistance by the ratio of fasting glucose to insulin concentrations (102). This is
a simple and inexpensive alternative for more sophisticated techniques such as the
clamp technique (103).
C-reactive protein: C-reactive protein (CRP) is an acute phase protein because of the
pronounced rise that is seen in its concentration after tissue injury or inflammation. It is
produced in the liver and is primarily derived via interleukin-6 (IL-6)-dependent hepatic
biosynthesis IL-6 is an important adipocyte signalling molecule released from visceral
and subcutaneous fat stores (104). CRP is also produced in small amounts by normal
blood lymphocytes (105). Furthermore, it is known that CRP stimulates soluble
intercellular cell adhesion molecule 1 (slCAM-1) (105). a suggested marker of
endothelial dysfunction (106) CRP can be seen as an inflammatory biomarker and has
proven to be a strong independent predictor of incident CVD (81) and of future
cardiovascular risk in both men and women (22,82). CRP regulates endothelial nitric
oxide synthase expression and nitric oxide synthesis and upregulates the expression of
cellular adhesion molecules. It may also directly modulate the oxidation of LDL (81).
Furthermore, smooth muscle cells and macrophages in arterial tissue have been shown
to produce CRP. a process that is substantially upregulated in the atherosclerotic
plaque (22). Elevated CRP levels may be a marker of the hyper-responsiveness of the
inflammatory system even to small stimuli (82). CRP was shown to be a stronger
predictor of future CVD events than LDL and can identify at-risk individuals with low
LDL levels (81.82).
Homocysteine: Increased levels of homocysteine, also called hyperhomo-
cysteinaemia, is an independent risk factor for CVD and all-cause mortality (85) In
addition, high levels increase the risk of fatal and non-fatal coronary events (86). Some
studies found an association between hyperhomocysteinaemia and intima -media
thickness (87-90), a surrogate marker of atherosclerosis, but other studies failed to
show such associations (90,91). Furthermore, hyperhomocysteinaemia is associated
with impairment of endothelial regulatory functions, characterised by decreased nitric
oxide synthesis or availability, and prothrombotic changes (92). It is unclear however
whether homocysteine itself is causal in the pathogenesis of CVD, nor has it been fully
elucidated yet by which mechanism(s) hyperhomocysteinaemia exerts its adverse
effects on the vascular wall.
1.2.2: Risk assessment scores
Risk factors by itself and in combination with each other can be used in the risk
assessment of CVD. and risk assessment as well as risk factor modification has
become essential tools in the management of CVD (107). Among the first to develop a
risk assessment score were the researchers of the Framingham Heart Study. The
Framingham risk score can be used by physicians to assess the cardiovascular risk of
individuals. The Framingham risk score is based on age, gender, total, HDL-, and LDL-
cholesterol, smoking, presence of diabetes and blood pressure (107). Other studies
that have developed risk scores for the assessment of cardiovascular risk include the
Systematic Coronary Risk Evaluation (SCORE) project (108), the PRECARD® study
(109), the Prospective Cardiovascular Munster Study (PROCAM) (110) and the UKPDS
study (111).
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SCORE: The SCORE risk assessment system is derived from a large dataset of
prospective European studies and predicts any kind of fatal atherosclerotic end-point,
such as fatal CVD events, over a 10-year period (108). Variables included in the
SCORE project are age, gender, total cholesterol, systolic blood pressure and smoking.
Different charts are developed for European regions at high risk and at low risk for
CVD. However, glucose tolerance is not a risk factor that is included in the SCORE risk
function which makes the risk assessment inappropriate for subjects with diabetes.
Therefore, the European Society of Cardiology has recommended that subjects with
diabetes are considered as subjects with "established CVD" and need to change
lifestyle when relevant, receive aspirin and a statin, and consider hypertension
treatment (26). Subjects without diabetes need to have their risk score assessed before
therapy is implicated or existing therapy is adjusted.
PRECARD®: The PRECARD® study is a European risk calculation program developed
in Denmark which calculates the absolute and relative risks for coronary heart disease
as well as the expected efficacy of any intervention (109). The PRECARD® program
uses the Copenhagen Risk Score to calculate absolute risk for coronary heart disease
and generates an individualized patient-focused health advice It is based on non-
modifiable and modifiable risk factors, i.e. age, gender, presence of diabetes, genetic
predisposition, previous coronary heart disease, and smoking, total cholesterol, HDL-
cholesterol. body mass index, systolic blood pressure.
PROCAM: The PROCAM study is a prospective study for cardiovascular isk factors
(110). Their scoring scheme was based on the follow-up results of middle-aged men in
Germany and included the variables age, LDL-cholesterol, smoking. HDL-cholesterol,
systolic blood pressure, family history of premature myocardial infarction, presence of
diabetes mellitus, and triglycerides (www.chd-taskforce.com). The risk however cannot
be extrapolated to women.
UKPDS Risk Engine: A diabetes-specific risk engine was recently created by the UK
Prospective Diabetes Study (UKPDS) team, including the variables age, sex, ethnicity,
smoking status, presence or absence of atrial fibrillation and levels of HbA1c, systolic
blood pressure, total cholesterol and HDL-cholesterol (111). This risk engine is
developed specifically for calculating the risk of CHD in ten years in individuals with
type 2 diabetes not known to have a heart disease
(www.dtu.ox.ac.uk/index.html?maindoc=riskengine).
When comparing the different risk scores, very different percentages are calculated.
For example, a Caucasian non-smoking male of 60.7 years of age, with a type 2
diabetes duration of 1 year, with HbA1c 6.9%, systolic blood pressure 147 mmHg, total
cholesterol 5.2 mmol/l (198 mg/dl), HDL-cholesterol 1.0 mmol/l (38 mg/dl), LDL-
cholesterol 3.1 mmol/l (118 mg/dl), triglycerides 1.8 mmol/l (178 mg/dl), no previous
history of CHD and no family history of CHD, has a 22.8% risk of CHD in 10 years
according to the UKPDS Risk Engine, 18% risk of acute coronary events in 10 years
according to the PROCAM risk score and only 5% risk of CVD in 10 years according to
the SCORE risk for populations at high risk. More research is therefore needed
considering the applicability of the these risk scores in different populations.
The contribution of risk factors to the risk of developing cardiovascular disease is
not fully known yet. but recently it was shown that 80% to 90% of patients who
developed clinically significant CHD, and more than 95% of patients who experienced a
fatal CHD event, had at least one of the conventional risk factors, i.e. cigarette smoking,
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diabetes, hyperlipidemia. or hypertension (112,113) In addition, a literature study about
4 emerging, non-classical risk factors, i.e. C-reactive protein, lipoprotem(a), fibnnogen
and homocysteine, could not determine what their optimal use was in routine screening
and risk stratification of CVD (114) These reports challenge the frequent claim that only
50% of CHD is attributable to the conventional risk factors of smoking, diabetes,
hypertension and hyperlipidemia and point out that additional research is needed to
establish the role of other novel CVD risk markers.
1.3: Atherosclerosis
The lesions of atherosclerosis principally occur in large and medium-sized elastic and
muscular arteries and may be present throughout a persons lifetime in a relatively
benign form (115) The earliest type of atherosclerotic lesion, the so-called fatty streak,
is commonly present in infants and young children (116) However, these lesions can
also result in ischemia of the heart, brain, or extremities, resulting in infarction It is not
yet clear which process is the key event in the initiation and development of early
atherosclerosis Presently, two hypothesis about the early processes of atherosclerosis
exist, namely the 'response-to-injury' hypothesis and the 'response-to-retention'
hypothesis The response-to-injury hypothesis states that atherosclerosis is a process
of endothelial injury or activation (117-120). and recently, of inflammation (115) In this
hypothesis, hyperlipidemia, endothelial dysfunction and permeability, blood flow, and
lipoprotein oxidation are thought to be causes of the early atherosclerosis process
Williams and Tabas disagreed with the response-to-injury hypothesis and modified it to
the response-to-retention hypothesis (96). This theory states that lipid retention in the
arterial wall is the key pathogenic event that is necessary for the formation of an
atherosclerotic lesion in an otherwise-normal artery, and that hyperlipidemia, lipoprotein
modification, turbulent blood flow and alterations in endothelium. smooth muscle cells
and the matrix only contribute to the atherosclerosis process (Figure 2).
After the formation of an early atherosclerotic lesion, accumulation of
mononuclear cells, migration and proliferation of smooth muscle cells, and formation of
foam cells and fibrous tissue takes place (115). This will lead to further enlargement
and restructuring of the lesion, so that it becomes covered by a fibrous cap that overlies
a core of lipid and necrotic tissue, a so-called advanced, complicated lesion (97). The
artery wall thickens, which is compensated by gradual dilation, so that the lumen
remains unaltered (121). This process is also known as arterial remodelling. At some
point, the artery can no longer compensate and the lesion may than intrude into the
lumen and alter the blood flow. In most patients, myocardial infarction results of erosion
or uneven thinning of the fibrous cap with subsequent rupture, often at the shoulders of
the lesion where the macrophages enter, accumulate, and are activated (122). The
continuing influx and activation of macrophages results in release of metalloproteinases
and other proteolytic enzymes. These enzymes cause degradation of the matrix, which
can lead to haemorrhage from the vasa vasorum or from the lumen of the artery and
can result in thrombus formation and occlusion of the artery
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Figure 2: Schematic of the response-to-retention model of early atherosclerosis. Mild to moderate
hyperlipidemia causes lesion development only in specific sites within the arterial tree, implying the existence
of predisposing stimuli, such as shear stress, that make these sites particularly lesion-prone by stimulating
local synthesis of apoB-retentive molecules (B). Predisposing stimuli in the absence of abundant atherogenic
lipoproteins (i.e. <2 mmol LDL cholesterol/L) are insufficient to cause atherosclerosis. Predisposing stimuli in
the presence of abundant atherogenic lipoproteins result in Itpoprotein retention (C). Evidence suggests that
aggregation promptly follows or may be part of the retentive process. Once significant retention has occurred,
a cascade of early responses, including lipoprotein oxidation and cellular chemotaxis, leads to lesion
development (D). ECs indicate endothelial cells; PGs proteoglycans; IEL internal elastic lamina; SMCs
smooth muscle cells; LpL lipoprotein lipase; SMase sphingomyelinase; LPs lipoproteins (96).
1.3.1: Plaque vulnerability
Three major factors determine the vulnerability of the fibrous cap: circumferential wall
stress or cap fatigue', lesion characteristics (location, size, and consistency), and blood
flow characteristics (123). A plaque is considered vulnerable when the lipid core
accounts for more than 40% of the whole core (123). This may explain the beneficial
effects of lipid-lowering therapy in reducing coronary events. It is of interest that the
culprit lesions leading to acute coronary syndromes are often mildly stenotic and are
therefore, as a rule, not detectible by angiography (123). These rupture-prone lesions
usually have a large lipid core, a thin fibrous cap. and a high density of inflammatory
cells, particularly at the shoulder region. Furthermore, one third of acute coronary
syndromes occur without plaque disruption but in plaques with a superficial erosion
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(123). Thrombus formation depends under such conditions on the prothrombogenic
state triggered by systemic factors, such as elevated LDL and decreased HDL-
cholesterol. cigarette smoking, diabetes, and yet unidentified factors.
1.3.2: Role of endothelial dysfunction and permeability in early atherosclerosis
Endothelial injuries are thought to play a key role in early atherogenesis in the
response-to-injury hypothesis if they are severe enough to cause functional
modifications (117-120,124) such as increased permeability, particularly to atherogenic
lipoproteins (125,126). Possible causes of endothelial dysfunction in the injury theory
include 1) elevated and modified LDL; 2) free radicals caused by cigarette smoking,
hypertension, and diabetes mellitus; 3) genetic alterations; 4) elevated plasma
homocysteine concentrations, 5) infectious micro-organisms such as herpesvirus, and
6) combinations of these or other factors (53). However, research showed that normal,
healthy endothelium transports, or leaks' many molecules, including lipoproteins, and
that the rate of LDL transport into the normal, healthy arterial wall exceeds the LDL
accumulation rate (96). Most importantly, several studies showed in vivo that the rates
of lipoprotein entry into prelesional susceptible sites, i.e. sites of low shear stress such
as non-branch points, were not different from resistant sites for the development of
atheromata, i.e. sites of high shear stress. Therefore, Williams and Tabas stated that
enhanced endothelial permeability to lipoprotein influx appears not to be the key
pathological event in atherosclerosis (96). However, because prelesional susceptible
arterial sites show enhanced retention of apoB-rich atherogenic lipoproteins, Williams
and Tabas argued that endothelial permeability can play a contributory role in
conditions such as smoking, dyslipidemia, and hypertension, but only if some of the
infiltrated material is retained (96). Retention of lipoproteins may be caused by
advanced glycosylation end-products (AGEs) which are shown to trap soluble plasma
proteins (127). Covalent trapping of low-density lipoproteins by AGE on collagen may
promote excessive lipid accumulation in the arterial walls of diabetics. Furthermore,
LDL particles isolated from patients with CHD have higher affinity for proteoglycans
glycosaminoglycans in the vessel wall than LDL from control patients (128,129).
1.3.3: Role of cell adhesion molecules in early atherosclerosis
Other functional modifications that have been documented in the endothelial layer in
vivo during the atherosclerotic process are the expression of cell adhesion molecules
by endothelial cells that overlie lesions, such as vascular adhesion molecule-1 (VCAM-
1) (96). However, this seems to be a consequence of initial retention of lipoproteins
within the arterial wall rather than a cause of endothelial changes, because expression
of cell adhesion molecules was shown after more than four days of severe
hypercholesterolemia and resultant foam cell formation, while lipoprotein retention and
aggregation was detectable within minutes to hours after the onset of
hypercholesterolemia (96). Furthermore, it was shown that atherogenic lipoproteins
regulate the endothelial expression of cell adhesion molecules (96).
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1.3.4: Role of blood flow in early atherosclerosis
Turbulent blood flow also may have an early effect on atherosclerosis (96). However,
lesion development at sites of turbulent flow in vivo show an absolute requirement of
high plasma concentrations of atherogenic lipoproteins. The plasma concentration of
LDL must exceed 2 mmol/L for atherogenesis, even at sites of high shear stress such
as at branch points (96). Furthermore, at sufficiently high plasma concentrations of
lipoproteins, lesions develop at sites of low shear stress, such as at non-branch points.
Williams and Tabas hypothesized that the role of shear stress in early atherogenesis is
primarily through the stimulation of intramural synthesis of molecules, such as
proteoglycans, that promote lipoprotein retention (96). Later, once retained lipoproteins
are accumulated within the arterial wall, the threshold for injury and activation from
continued shear stress may be lowered. Because many stimuli are known to activate
endothelial cells, synergy is likely between shear stress and, for example, oxidative
breakdown products of retained lipoproteins.
1.3.5: Lipoprotein oxidation in early atherosclerosis
In the response-to-injury hypothesis, lipoprotein oxidation plays an important role (130-
132). However, in vitro lipoprotein oxidation by cells or transition metal is blocked by
low concentrations of plasma or plasma proteins such as albumin, and in vivo oxidized
lipoproteins in the plasma would be rapidly removed by the liver. Furthermore, it was
shown that adherence of LDL to arterial proteoglycans increased LDL's susceptibility to
oxidation in vitro, but that prior oxidation of LDL does not enhance its retention in
arteries (96). Moreover, once lipoproteins are sequestered from the protective elements
of plasma in vitro, nearby healthy arterial cells will cause oxidation (96). Therefore,
oxidation can be seen as a normal, expected consequence of intramural sequestration
of sufficient quantities of atherogenic lipoproteins within an otherwise healthy artery.
Therefore, Williams and Tabas think that pathophysiologically important oxidation can
occur only after the retention of lipoproteins within the microenvironment of the arterial
wall (96).
Although factors responsible for retention of lipoproteins and subsequent lesion
development are not clear yet, it is known that, after retention by proteoglycans in the
arterial wall, LDL undergoes several modifications with important biological
consequences (96). Retained and modified lipoproteins and nearby macrophages can
stimulate chemotaxis and transformation of smooth muscle cells from the contractile to
the proliferative state (115). This causes increased synthesis of proteoglycans in
smooth muscle cells, including LDL-binding proteoglycans which may result in an
increased retention of lipoproteins. In vitro, proteoglycan-bound LDL forms aggregates
and vesicular structures and shows increased susceptibility to oxidation. Minimally
oxidized LDL induces endothelial and smooth muscle cells to express monocyte
chemotactic activity, and more extensively oxidized LDL is directly chemoattractive to
monocytes, macrophages, smooth muscle cells, and T-lymphocytes (96,116). Recently,
a report showed that lipid retention in the vascular wall of two mouse strains with
different atherosclerosis susceptibility is not sufficient to promote progression to an
atherosclerotic plaque after the first lesion has formed, but points to the more important
role of endothelial cells in this regard (133). The conversion of macrophages to foam
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cells stimulates the release of more lipoprotein lipase and other atherogenic factors.
Also, it has been shown to alter proteoglycan metabolism which may result in more lipid
retention.
1.3.6: Conclusion
Atherosclerosis is a complex and multifactorial process Today, two theories exist about
the early process of atherosclerosis, i.e. the response-to-injury hypothesis and the
response-to-retention hypothesis. Both theories have their merit Recent findings favour
the response-to-retention hypothesis for its role in the process which results in the
formation of an early atherosclerotic lesion Factors such as hyperlipidemia. smoking,
hypertension, turbulent blood flow and lipoprotein oxidation can increase the harmful
effects of lipid retention in fie arterial wall and contribute to the development of an
atherosclerotic lesion into an atherosclerotic plaque The response-to-injury hypothesis
may be more appropriate to describe the development to an unstable vulnerable
plaque After the first formation of an atherosclerotic lesion, foam cells and fibrous
tissue are formed, which leads to enlargement of the lesion This will eventually result in
intrusion of the atherosclerotic plaque in the vascular lumen. Different factors determine
the vulnerability of the plaque, and when thinning of the fibrous cap occurs, rupture of
the plaque can take place. This can result in thrombus formation and occlusion of the
artery leading to myocardial infarction or stroke.
1.4: Surrogate markers for atherosclerosis
The atherosclerosis process is slow and often remains silent' until the first clinical
manifestation presents itself. Frequently, this first manifestation is a major
cardiovascular event such as myocardial infarction, stroke, or sudden death (134).
Epidemiological studies and intervention trials with such clinical endpoints require long
time follow-up and participation of large populations. These studies are, by necessity,
costly and long-term. There is however an urgent need for data from which valid
conclusions can be drawn about the determinants of the disease or the effectiveness
and safety of a therapeutic intervention (135). Therefore, surrogate markers are
continuously sought, which can be used to investigate determinants of atherosclerosis
at early stages of the process. Also, at a later stage, they can be used to assess
disease modifiers of atherosclerosis progression, such as lifestyle and pharmacological
interventions.
1.4.1: Intima-media thickness
Early surrogate markers for atherosclerosis have aiginated from techniques available
for the clinical assessment of patients with vascular disease, such as angiography and
Doppler ultrasound. However, these techniques do not provide useful information on
the early stages of arterial wall thickening prior to lesion formation (121,136,137). In
contrast, ultrasound techniques have evolved to such extent that the walls of superficial
arteries can be imaged non-invasively in real-time and at high resolution. Ultrasound
imaging can visualize the arterial wall Iself in every stage of atherosclerosis, from a
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normal lumen to a plaque or complete arterial occlusion. The distance between the
ultrasound interfaces of the lumen-intima and media-adventitia ultrasound on the far
wall have been proven to reflect the intima-media complex by histological and
pathological studies (138-140) and is widely known as intima-media thickness or IMT.
Because ultrasound imaging is non-invasive, IMT measurements can be used in
observational studies in healthy populations as well as in trials on atherosclerosis
progression.
IMT can be measured at the femoral and brachial arteries, but is mostly
measured at the carotid artery. Different segments of the carotid artery can be used for
IMT measurements, i.e. common carotid artery, bulbus and internal carotid artery
(Figure 3), but reproducibility is higher in the common carotid artery segment (141).
Atherosclerosis in the carotid arteries is correlated with coronary artery calcium
detected on electron beam CT scans, which is a marker of atherosclerotic disease
(142). Furthermore, larger IMT of the carotid artery has been shown to be associated
with elevated levels of risk factors for coronary heart disease (CHD) in a number of
prospective studies (134), as well as in numerous population- and hospital-based
studies (143-146). In addition, the relationship between carotid IMT and future CHD
events have been confirmed many times (147-152). Furthermore, it has been shown
that lipid-lowering treatment can slow the progression rate of carotid IMT (134,153).
Therefore, IMT can be considered a marker of change in atherosclerosis elsewhere in
the arterial system and should reflect generalized vascular damage or atherosclerosis
as a surrogate marker, and thus cardiovascular risk.
The majority of cross-sectional studies indicated that elevated levels of
established risk factors of CVD such as age, sex, total cholesterol, LDL-cholesterol,
systolic blood pressure, body mass index (BMI), and a decrease in HDL-cholesterol are
associated with an increased carotid IMT in a graded manner (154). In addition,
subjects with a certain lifestyle or predisposing condition, such as smoking,
hypertension, diabetes mellitus, previous CHD or intermittent claudication, have a 5 to
12% increased carotid IMT relative to subjects without these conditions (154).
Moreover, Greactive protein has been associated with increased carotid IMT which
indicates the potential of C-reactive protein as a risk factor for CVD (155,156).
A variety of IMT measurement protocols, based on different ultrasound methods,
have been developed and improved in order to obtain reliable and reproducible results
(137-142,157). Both B- and M-mode ultrasonographic techniques are used to measure
IMT and there is an acceptable agreement with no important systematic difference
between these two methods (158). With the B-mode technique, proposed by Bond and
Ball (159), Pignoli et al. (136) and further developed by Wendelhag et al. (140), a
twodimensional ultrasound image is made of the carotid artery, and the anterior wall,
lumen and posterior wall can be distinguished (150). Another technique, using M-mode
images, has been proposed by Roman et al. (160). Two-dimensionally guided M-mode
tracings of the common carotid artery are performed and stored for off-line analysis.
The B-mode technique represents the average IMT of an arterial segment whereas M-
mode IMT is the IMT at a discrete arterial position. Most research has been published
using the B-mode technique, because it was the first ultrasound technique developed to
image the vascular wall. However, the M-mode technique is more time efficient than the
B-mode, is more user-independent, and has an adequate reproducibility (157). In
addition, with the M-mode technique it is easier to assess local pulse pressure, wall
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thickness, diameter and distensibility (relative increase in cross-sectional area per
change in blood pressure) (157). These parameters can be used to calculate vascular
charactenstics such as the distensibility and compliance coefficient and Young's elastic
modulus (50). The reproducibility of these arterial stiffness measurements has been
sufficiently studied to be applied in epidemiological studies (161.162). and can be used
to non-invasively study early functional and structural wall changes caused by
atherosclerosis Distensibility is the ability of the artery to expand as a response to
pulse pressure, i.e. the relative change in arterial diameter during the cardiac cycle, and
distensibility decreases with age and hypertension (50). Compliance is defined as the
ratio of change of volume to change in pressure, or the slope of the pressure volume
curve, and is related to the distensibility and diameter of the artery. Young's elastic
modulus provides information on the mechanical properties of the wall material
independent of the geometry (50) and can be considered a marker of arterial stiffness.
Formulas to calculate these parameters are given in Chapter 5.
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Figure 3: Illustration of the carotid artery with intima-media thickness and the 3 segments division, based on
the arterial anatomy and geometry. The 3 segments are the distal common carotid artery, the carotid
bifurcation or bulbus, and the proximal internal carotid artery.
1.4.2: Arterial stiffness
Arterial stiffness relates to the cushioning function of the arteries and is determined by
the visco-elastic properties of the artery wall (147). These properties are determined by
smooth muscles cells and the elastin to collagen ratio, whereas the subendothelial
matrix also affects arterial stiffness. One of the clearest consequences of increased
arterial stiffness of the large arteries is increased pulsatile blood pressure. Increased
pulse pressure leads to an increased left ventricular workload in combination with a
reduced perfusion of the coronary arteries in diastole (50). However, the
pathophysiological mechanisms of stiffening of the arteries are not fully understood.
The most prominent factor is age: with increasing age, arteries become stiffer (50). With
ageing, the increase in large artery stiffness is related to the degree of mechanical
stress that results in fragmentation and disruption of elastic lamellae and in
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derangement of the orderly structure of the elastic laminae of the vessel wall, changing
the collagen to elastin ratio (50). Furthermore, sustained hypertension can result in
accelerated arterial degeneration and to prematurely occurring structural changes
similar to those seen in ageing. Other causes of altered structural arterial wall
properties may be plaques (163) or hemodynamic factors (164). Moreover, structural
changes can be caused by formation of advanced glycosylation end products (AGEs),
secondary to hyperglycemia in diabetes or IGT subjects (165). AGEs induce collagen
cross-linking due to non-enzymatic glycation of arterial wall matrix proteins and can trap
atherogenic lipoproteins as well (128,166). The endothelial stress caused by the actions
of AGEs may induce secretion of specific proteins that will be deposited in the matrix
(167,168) and this process may lead to structural changes and remodelling (169). In
addition to the above mentioned factors, smoking, elevated lipid levels, and indicators
of glucose intolerance were also found to be related to arterial stiffness (161,162,170,171).
Arterial stiffness can be assessed using ultrasound as was described in section
1.4.1. Stiffness measured by this method is local and of superficial arteries. Another
non-invasive method to measure arterial stiffness is the aortic pulse wave velocity
technique, although this technique does not measure local but regional or segmental
arterial stiffness. The aortic pulse wave velocity can also be measured by the wall
tracking system, and is calculated from measurements of pulse transit time and the
distance travelled by the pulse between the common carotid artery and one of the
common femoral arteries (172). The propagation speed of the pulse wave along the
arteries is related to the elastic properties of the arterial wall and depends on current
distending blood pressure. Arterial stiffness measurements described in this thesis are
all done by means of M-mode ultrasound imaging wall track techniques.
1.4.3: Prospective studies
Several prospective cohort studies have examined the relationship between carotid IMT
and CHD events (Table 2). In the Kuopio Ischemic Heart Disease (KIHD) risk factor
study (151), it was found that for every 0.1 mm increase in carotid IMT in middle-aged
men, the risk of myocardial infarction (Ml) increased by 11%. Similar results were found
for this age group in the Atherosclerosis Risk In Communities (ARIC) study (148). In
this study, a 0.19 mm increment in mean carotid IMT increased the risk of Ml or
coronary death in middle-aged men by 36% (Table 2). CHD risk was almost twofold
higher in those men with a carotid IMT of > 1.0 mm compared with a carotid IMT <1.0
mm (OR 1.85; Cl: 1.28-2.69). In women, the incidence of Ml or coronary death
increased by 69% for every 0.19 mm increase in carotid IMT (Table 2). A mean carotid
IMT of > 1.0 mm was associated with a fivefold increase in CHD risk (OR 5.07; Cl:
3.08-8.36). In the Cardiovascular Health Study (CHS) (152), the relative risk of Ml or
stroke increased for every 0.2 mm increase in carotid IMT (Table 2), and the relative
risk of Ml increased by 46%. Subjects in the highest quintile of carotid IMT had an
almost fourfold increase in risk compared with subjects in the lowest quintile (OR 4.22;
Cl: 3.02-5.91). Similarly, in the Rotterdam Study (149), the risk of Ml increased by 43%
for every 0.16 mm increase in carotid IMT of the common carotid artery (Table 2).
Following exclusion of subjects with a history of Ml or stroke, a 0.16 mm increment in
carotid IMT was associated with a 51% increase in the risk of Ml (Table 2). However, in
contrast with ARIC, the strength of the association between carotid IMT and the
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incidence of coronary events was similar in men and women. In a long-term follow up of
male CHD patients who participated in the Cholesterol Lowering Atherosclerosis Study
(CLAS) (150). the risk of Ml or coronary death increased by 40% for every 0.13 mm
increment in carotid IMT (Table 2) and the risk was almost eightfold increased in the
highest quartile of carotid IMT relative to the lowest quartile (OR 7.7; Cl: 1.7-34.7).
Furthermore, for every 0.03 mm/y increase in carotid IMT progression over the follow-
up penod. the nsk of Ml or coronary death doubled (OR 2.2; Cl: 1.4-3.6) whereas the
risk of Ml. coronary death or revascularisation tripled (OR 3.1: Cl: 2.1-4.5).
Longitudinal prospective data on the relation of arterial stiffness, measured by
ultrasound, with future CVD are limited (147). Only three studies have been published
in which common carotid distensibility measured by ultrasound imaging was used as
marker for arterial stiffness (173-175). One of these studies also used Young's elastic
modulus (175). an index of arterial stiffness, and was found to be an even stronger
predictor for future CVD than distensibility or diameter. In subjects after renal
transplantation, the distensibility of the common carotid artery was an independent
predictor of CVD (174). In end-stage renal disease (ESRD) patients. Young's elastic
modulus was associated with a 6.4 fold (Cl 1 8-23.3) increased risk of all-cause
mortality, independent of other prognostic factors (175). Only one study has been
published in subjects with impaired glucose tolerance (175). In this study, the
distensibility coefficient appeared not to be related to increased mortality. Common
carotid artery diameter however, was independently associated with mortality risk and
most likely reflects arterial remodelling.
In summary, prospective studies on the potential relationships between carotid IMT
and CHD events have been done in a variety of populations, healthy and symptomatic,
and across various geographical areas (Table 2). These studies unequivocally show
that IMT increments of 0.1 mm are associated with an increased odds ratio of various
cardiovascular events in the range of 1.06 to 1.80 over a follow up period of 1 month to
8.8 years. However, only one prospective study (150) related change in carotid IMT
over time to subsequent events. Therefore, more longitudinal data are needed on the
change of carotid IMT as a predictor of CHD events. In contrast with carotid IMT,
information en the relation of arterial stiffness and the risk of CVD among a large
number of high-risk patients or among the general population is still lacking.
Furthermore, direct comparisons between carotid IMT and indicators of arterial stiffness
in their ability to predict future CVD has not yet been done. Both measurements
however appear to be a useful as indicators of CVD risk although more data are
needed to potentially distinguish subjects into those with a high and a low absolute risk
of CVD.
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1.5: Risk factors for both type 2 diabetes and cardiovascular
diseases
Subjects with type 2 diabetes have an increased risk of CVD and it has been shown
that they have increased risk rates of all cardiovascular disorders affecting heart, brain
and peripheral vessels (176) Specifically, all manifestations of CHD (myocardial
infarction, sudden death and angina pectoris) are at least twice as common in patients
with type 2 diabetes as in nondiabetic individuals (177). The risk for fatal and non-fatal
CHD events is relatively higher in female type 2 diabetic patients than in male type 2
diabetic patients, and is largely independent of age. The Framingham study reported a
relative risk for CHD mortality of 1.7 in diabetic men relative to non-diabetic men, and a
relative risk of 3.3 in diabetic women compared with their non-diabetic counterparts
(178) Moreover, subjects with type 2 diabetes without previous myocardial infarction
(Ml) have a risk of Ml as high as non-diabetic subjects with previous Ml (179) Ml is
more often silent in type 2 diabetes patients and this may hamper adequate diagnosis
and treatment. They also suffer from higher rates of complications or even higher
mortality rates after suffering cardiovascular events than subjects without diabetes (180).
In addition to CHD, the occurrence of stroke and peripheral vascular disease is at
least twofold higher in type 2 diabetes than in control subjects in all age groups. Higher
mortality rates after stroke in diabetes have been found in several studies (181) and
population-based studies have indicated that the risk for stroke is considerably elevated
in type 2 diabetes (181). Furthermore, several epidemiological studies have shown a
higher prevalence of absent peripheral leg and foot pulses in type 2 diabetes (181,182),
which is an indication of peripheral vascular disease. In the Framingham Heart Study,
the 34-year age-adjusted incidence of intermittent claudication was 2.7 times higher in
male diabetic patients and 3.4 times higher in female diabetic patients than in men and
women without diabetes (183).
1.5.1: Risk factors
It is known that several predisposing factors simultaneously affect the development of
CVD and diabetes. Among these concomitant factors are obesity, physical inactivity
and unhealthy diet, heredity, gender, and advancing age (57). Other potential
pathogenic processes in the development of both atherosclerosis and diabetes include
elevated blood pressure, increased glycosylation of proteins, and oxidative stress (176).
Prospective studies have shown that classical risk factors for CVD (high total/LDL-
cholesterol, elevated blood pressure, smoking) contribute in a similar way in diabetic
patients as in non-diabetic individuals (57,184). As risk factors for CVD are already
present amongst those subjects with marked insulin resistance, even without any
significant disturbance in glucose tolerance, the pre-diabetic state itself has to play a
role in the pathogenesis of atherosclerosis in type 2 diabetes. Several prospective
studies from different populations including a large number of subjects with type 2
diabetes have shown that glycaemic control is important for cardiovascular risk (13).
However, cardiovascular disease in type 2 diabetes cannot be explained by major risk
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factors alone, because they predispose to chronic diseases with complex and often
overlapping mechanisms, also called clustering
1.5.2: Metabolic syndrome
Clustering of several cardiovascular risk factors has been the subject of debate since
the introduction of the concept known as Syndrome X in 1988 (185). However, Kylin
already described clustering of the risk factors hypertension, hyperglycemia and
hyperuricemia as early as in 1923 (5). Reaven suggested that Syndrome X was an
important risk factor for cardiovascular disease and that insulin resistance and
compensatory hyperinsulinemia underlie the clustering of the metabolic disturbances
(185). Nowadays, metabolic syndrome seems to be the most appropriate and widely
accepted term for clustering of cardiovascular risk factors. These risk factors are
common in individuals with insulin resistance and include dyslipidemia, glucose
intolerance, obesity and especially abdominal obesity, elevated blood pressure, and
prothrombotic and proinflammatory factors (e.g. plasminogen activator inhibitor-1,
fibrinogen, and inflammatory cytokines) (175) In addition, some investigators hold the
opinion that hyperinsulinemia and insulin resistance are major determinants of
atherosclerotic vascular disease. The most common combinations of components cf
the metabolic syndrome however, are obesity with hypertension or dyslipidemia, which
are seen in about 50% of patients with type 2 diabetes and in 10-20% of subjects with
normal glucose tolerance (186). The metabolic syndrome commonly precedes the
onset of diabetes by several years and it has been shown that the metabolic syndrome
predicts CHD (104)
The appearance of hyperglycemia in patients with the metabolic syndrome appears
to accelerate atherosclerosis, possibly by enhanced formation of glycosylated proteins
and advanced glycation products (130,166) which can increase endothelial dysfunction
(116). These direct consequences of hyperglycemia probably contribute to the
microvascular disease underlying nephropathy and retinopathy, and they may promote
macrovascular disease as well. Thus, detection of insulin resistance relatively early in
life offers the opportunity to identify at an early stage those subjects at risk of
developing dyslipidemia, hypertension, and ultimately type 2 diabetes. Type 2 diabetes
can therefore be viewed as the end product of years of metabolic stress against a
background of insulin resistance. It is important to understand and intervene early in the
continuum of events that lead to CVD, starting with the metabolic syndrome as t
progresses to impaired fasting glucose and/or impaired glucose tolerance, and
ultimately type 2 diabetes.
1.5.3: Obesity
Epidemiological studies have demonstrated that increased central obesity is associated
with insulin resistance, early vascular stiffness' and poor endothelial function (176).
Because increased central obesity is accompanied by increased plasma free fatty acid
levels and increased triglycerides storage in liver and muscle, this may drive insulin
resistance further (176). Increased central obesity is also associated with higher levels
of inflammatory markers such as Creactive protein, interleukin-6, and tumor necrosis
factor-u, which all have been related to increased risk of diabetes, myocardial
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infarction, and stroke in subjects with and without type 2 diabetes (167). Therefore,
increased central obesity may be a precursor for both atherosclerosis and diabetes.
1.6: Conclusion
Type 2 diabetes mellitus is the most common form of diabetes and it is estimated to
increase in a pandemic manner over the next 10 to 20 years (4). Although the early
symptoms are often not severe, the long-term effects of hyperglycemia result in. or are
associated with, micro- and macrovascular diseases like retinopathy. nephropathy, and
atherosclerosis (1.187). Ultimately, this can lead to blindness, renal failure and CVD
events such as myocardial infarction and stroke.
The atherosclerosis process is often slow and principally occurs in large and
medium-sized arteries Two theories exist nowadays to explain the early process of
atherosclerosis, i.e. the response-to-injury hypothesis and the response-to-retention
hypothesis (96). Although it is not clear yet which of the hypotheses are true, research
seems to be more favourable to the response-to-retention hypothesis which states that
lipid retention in the arterial wall is the key to the development of an early
atherosclerotic lesion. Factors such as hyperlipidemia. smoking, hypertension, turbulent
blood flow and lipoprotein oxidation may increase the harmful effects of lipid retention in
the arterial wall and contribute to the development of an atherosclerotic lesion into an
atherosclerotic plaque When the fibrous cap of the plaque ruptures, thrombus
formation and occlusion of the artery can result which can lead to myocardial infarction
or stroke (123). Because of the slow nature of the atherosclerosis process, surrogate
markers like intima-media thickness and arterial stiffness measurements have been
used to investigate determinants of atherosclerosis at early stages of the process and
to assess disease modifiers of the progression of atherosclerosis (135). Prospective
studies have shown that both IMT and arterial stiffness can be used as good indicators
of risk of CVD (147).
Both type 2 diabetes mellitus and CVD have common risk factors. Because the
presence of type 2 diabetes increases the risk of CVD two to four times, it is crucial to
understand how atherosclerosis develops and progresses in subjects with type 2
diabetes. Insulin resistance precedes other risk factors of the metabolic syndrome, and
although the exact pathogenesis of CVD in type 2 diabetes is yet unknown, there is
evidence that subjects in the pre-diabetic state, i.e. impaired glucose tolerance,
impaired fasting glucose, or metabolic syndrome, are already at high risk for CVD
events. Moreover, insulin resistance accelerates atherosclerosis long before the onset
of hyperglycemia (188). Thus, early detection of insulin resistance is likely to identify
those persons who are at risk of developing dyslipidemia, hypertension, impaired
glucose tolerance, and ultimately diabetes.
1.7: Outline of the thesis
To study the effects of glucose tolerance on atherosclerosis, a prospective, population
based study was created. The subjects for the present study, named the Cohort study
Diabetes and Atherosclerosis Maastricht (CODAM), are participants of two large
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ongoing cohorts of the National Institute for Public Health and the Environment in the
Maastricht area (Monitoring Project for Cardiovascular Diseases (189) and its
predecessor (190)). In Chapter 2, the subjects, methods and design of the CODAM
study are described. Also, a description of the differences between subjects with type 2
diabetes, impaired and normal glucose tolerance is given. A description of the design of
the screening for the present study and the SLIM study, Study on Lifestyle-intervention
and Impaired Glucose Tolerance Maastricht (21), as well as the screening results are
given in Chapter 3.
To diagnose type 2 diabetes, an OGTT is recommended by the WHO (1). However,
in the screening phase of large epidemiological studies, it may not be feasible to use
venous blood sampling. As capillary blood sampling is easier, less expensive and less
invasive to obtain, we validated capillary plasma glucose samples with venous plasma
glucose samples for the diagnosis of type 2 diabetes and IGT according to the 1999
WHO criteria (1) in Chapter 4.
Intima-media thickness and arterial stiffness (reflected by Young's elastic modulus)
are both surrogate markers of atherosclerosis in the large arteries. Few data exist
however, on these markers combined in recently diagnosed type 2 diabetes or glucose
Intolerance. Therefore, we investigated in Chapter 5, 1) whether the vessel wall
properties differed between subjects with recently diagnosed type 2 diabetes, impaired
glucose tolerance, and normal glucose tolerance, and 2) which variables predict the
variance of these properties.
Hypertension is a very important risk factor for both type 2 diabetes and CVD. In
Chapter 5, we report that hypertension predicts Young's elastic modulus and that pulse
pressure, the difference between systolic and diastolic blood pressure, predicts intima-
media thickness. Because pulse pressure has been recognized as an independent
predictor of CVD, we evaluated whether a high pulse pressure was associated with
increased prevalence of metabolic and/or cardiovascular disorders, target organ
damage, or abnormal vessel wall properties in Chapter 6.
In Chapter 7, the main results of this thesis are discussed. It contains general
conclusions about the development of atherosclerosis in type 2 diabetes as well as a
discussion on public health implications. Furthermore, methodological aspects are
addressed as well as suggestions for future research.
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Subjects, methods and design of the CODAM study
2.1: Subjects: screening and inclusion
Participants of two large ongoing cohorts of the National Institute for Public Health and
the Environment (RIVM) in the Maastricht area (Monitoring Project br Cardiovascular
Diseases (1) and its predecessor (2)), that were > 40 years of age. had a BMI > 25
k g W or one or more of the other risk factor(s) (Table 1). had been invited to participate
in a screening for the Cohort study of Diabetes and Atherosclerosis Maastricht
(CODAM) The invitation letter and participation form are given in Appendix 2.6 and 2.7.
The CODAM study is a prospective, population based, cohort study in the Netherlands.
The study is carried out in cooperation with the Hoorn study in the Netherlands and
both studies combined are called the DIALOG study (DIAbetes. Lipids. Obesity,
Genetics). The local Medical Ethical Committee of the University of Maastricht and
University Hospital Maastricht approved the study, including screening, inclusion and
follow-up stages. All participants gave written informed consent.
Table 1: Inclusion and exclusion criteria for CODAM.
Inclusion criteria
And
Or
a
Or
Or
Or
Or
Exclusion criteria:
Age > 40 years
BMI > 25 kgW,
Positive family history of type 2 diabetes mellitus.
History of gestational diabetes,
Use of antihypertensive medication.
Postprandial Wood glucose > 6.0 mmol/L (108 mg/dl),
Glucosuna.
combinations of the separate inclusion criteria
Medication known to affects glucose metabolism
Non-Caucasian ethnicity
From March 1999 until May 2000, 2715 subjects participated in the screening
phase, and subjects reported in the morning between 08.00 and 09.30 a.m. after an
overnight fast (10-12 hours) for an oral glucose tolerance test (OGTT). Capillary
glucose concentrations were measured at baseline and two hours after ingestion of a
75-g oral glucose load (Glucometer Elite®, Bayer, USA). According to the 1999 WHO
criteria (see Chapter 1, Table 1), 226 of the 2715 subjects (8.3%) were newly
diagnosed DM, 385 (14.2%) were IGT, 215 (7.9%) had impaired fasting glucose (IFG)
and 1889 (69.6%) were classified as NGT. The results of this screening are presented
in Chapter 3. Subjects were included in either the CODAM study or in the Study on
Lifestyle-intervention and Impaired Glucose Tolerance Maastricht (SLIM), a lifestyle
intervention study directed at a healthy diet and increased physical activity. All 226
newly diagnosed DM subjects and 728 randomly selected NGT subjects were invited to
the inclusion phase of the CODAM study. Moreover, 49 participants of the monitoring
cohorts who were known to have type 2 diabetes of recent onset, i.e. more than 1 year,
but less than 4 years diagnosed with type 2 diabetes, were invited. The 385 subjects
diagnosed with IGT either participated in the SLIM study (N=114), as described by
Mensink et al. (3), or in the present study (N=129), while the remainder did not wish to
47
Chapter 2
participate. An example of the letters of invitation for subjects with NGT and with IGT a
DM, as well as the enclosed information package, are given in Appendices 2.8, 2.9 and
2.10. Participants underwent a second OGTT with venous plasma glucose
measurements in order to re-establish their glucose tolerance status. Eventually, a total
of 574 subjects were included in the CODAM cohort study, of whom 147 (25.6%) had
type 2 diabetes (86 newly diagnosed by screening, 14 diagnosed less than 1 year and
47 recent onset, i.e. diabetes more than 1 year but less than 4 years), 129 (22.5%) had
IGT (104 IGT and 25 IFG), and 298 (51.9%) were NGT subjects. All DM subjects
combined are defined as "recently diagnosed" throughout this thesis.
2.2: Description of the visits for the CODAM study
Study participants reported at the metabolic unit at two occasions (time interval
between 2 weeks to 10 months). The metabolic unit is a climate controlled clinical
research room. During the first visit, inclusion in the study was formalized. Subjects had
to report between 08.00 and 0.900 a.m. Informed consent forms were signed. At home,
subjects have had to fill in a general questionnaire to determine lifestyle factors (4-9) as
well as a questionnaire about quality of health care. Furthermore, subjects had been
asked to bring a morning urine sample for the determination of urinary albumin
concentration. Body weight was measured and systolic and diastolic blood pressures
were measured using a Maxi Stable 3 (Speider & Keller, Germany). Subsequently, an
OGTT was done to determine glucose tolerance status during which additional blood
samples were taken to determine HbA1c, blood lipids, insulin and anti-oxidants. Buffy
coats were also collected. During the OGTT, a food frequency questionnaire (10) was
filled in.
For the second visit, subjects were asked to bing another morning urine sample.
During this visit, systolic and diastolic blood pressures were measured in the same way
as during the first visit. Subsequently, carotid artery wall ultrasound measurements
were carried out as a surrogate marker of atherosclerosis. During these measurements,
systolic and diastolic blood pressures were measured with an automatic device, the
OMRON 705CP (Nieuwegein, the Netherlands), to calculate vessel wall characteristics.
Thereafter, Ankle/Brachial Index was measured as a marker of peripheral vascular
disease. Furthermore, body height, body composition (skin fold thicknesses), and body
fat distribution (waist and hip circumferences, sagittal and transversal diameters) were
measured, as well as a 12-lead rest electrocardiogram.
2.3: Materials and methods
Medication Subjects were asked to report all presently used medication. Lipid lowering
medication was stopped 10 days before the first visit and 2 days before the second
visit. The half-life of the inhibitory effect of most statins on HMG-CoA-reductase is 2 to 3
hours, with the longest half-life of 20-30 h for atorvastatin (www.lipitor.com). Common
knowledge from pharmacokinetic theory indicates that after 5 half-lives a new
equilibrium is reached. With atorvastatin, no inhibitory effect on HMG-CoA-reductase
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should be present after 6.25 days (about one week), which means that there was no
effect of atorvastatin during the first visit. However, dunng the second visit an effect of
atorvastatin could still exist. During this visit however, no blood samples were taken
and. as far as we know, lipid lowering medication has no direct effects on ultrasound
measurements. All other medication was stopped the day before both visits, including
antihypertensive medication.
Glucose tolerance Glucose tolerance was measured by a standard 75-g oral glucose
tolerance test (OGTT) and defined according to the 1999 WHO criteria (11). Subjects
arrived at the metabolic unit after an overnight fast At first, a Venflon catheter (Becton-
Dickinson, Sweden) was inserted into an antecubital vein and a blood sample was
taken for measurement of fasting plasma glucose concentrations. Subsequently, a 75-g
glucose load (82.5 g Dextrose monohydrate, Avebe, the Netherlands) in 250 ml plain
water was given. A few drops of lemon juice were added for taste. Another blood
sample was taken after 30, 60 and 120 minutes for the measurement of plasma
glucose concentrations. Plasma glucose was measured with the hexokinase glucose-6-
phosphate dehydrogenase method (HK-G6PD method. ABX Diagnostics Glucose HK
125, Montpellier, France). In addition to venous plasma glucose measurements,
capillary plasma glucose concentrations were measured at fasting and 2h post-load in a
subset of 350 subjects using a Glucometer Elite® (Bayer, USA) to validate capillary
measurements as a screening tool The results of this study are described in Chapter 4.
Blood parameters In addition to fasting plasma glucose concentrations, fasting plasma
insulin concentration, HbA1c, total cholesterol, HDL- and LDL-cholesterol, triglycerides,
non-esterified fatty acids (NEFA's or FFA, free fatty acids), apolipoprotein B (apoB), C-
reactive protein (CRP), complement factor 3 (C3), creatinine, and soluble intercellular
adhesion molecule (ICAM) were measured from the fasting blood sample. Insulin was
determined using a two-sided immunoradiometric test by the Endocrinological
Laboratory at the University Hospital Free University Amsterdam (the Netherlands),
using paired monoclonal antibodies (Medgenix Diagnostics, Fleurus, Belgium). This test
is insulin specific and does not show cross reactivity with pro-insulin and split products.
Intra- and inter-assay coefficients of variation were 5% and 6%, respectively. HbA1C
was determined by HPLC (reference value 4.4 - 6.2%) by the Department of Clinical
Chemistry of the Academic Hospital Maastricht (the Netherlands). Total cholesterol,
HDL-cholesterol and triglycerides were measured by enzymatic methods (Roche,
Mannheim, Germany) by the Department of Clinical Chemistry of the University
Hospital Free University Amsterdam (The Netherlands). LDL-cholesterol was calculated
according to Friedewald et al. (12). Non-HDL cholesterol was calculated by subtracting
the plasma HDL-cholesterol from total cholesterol concentration. An enzymatic
colorimetric method (Wako NEFA C, Richmond, USA) was used for the quantitation of
NEFA's (or FFA) at the Department of Clinical Chemistry of the Erasmus Medical
Centre (Rotterdam, The Netherlands). Coefficients of variance ranged between 1.1%
and 2.7%. CRP was measured with a high-sensitive kit (Latex, Roche Diagnostics
Nederland BV, Almere, the Netherlands). Plasma creatinine was determined with a
Roche kit (Roche Diagnostics Nederland BV, Almere, the Netherlands). Soluble ICAM
was measured by Elisa (Biosource, USA). ApoB and C3 were determined in serum by
an autoanalyzer (Hitachi 912) with a Roche kit (Roche Diagnositics Nederland BV).
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CRP, creatinine, soluble ICAM, C3 and apoB were all determined at the Laboratory of
Toxicology, Pathology and Genetics of the National Institute for Public Health and the
Environment (Bilthoven, the Netherlands).
Anthropometry Height (in cm) was measured upright against a stadiometer. Body
weight to the nearest 100 grams was measured after an overnight fast, without shoes
and wearing light indoor clothing. Body Mass Index (BMI) was calculated by dividing
weight by height in kg/m'. Waist circumference (in cm) was measured at the level
midway between the lateral lower rib margin and the spina iliaca anterior superior. Hip
circumference (in cm) was measured at the level of both trochanter majors. Both waist
and hip circumferences were measured with the subject in standing position and
Waist/Hip Ratio (WHR) was calculated. Sagittal and transversal diameter (in mm) were
measured at the level of the spina iliaca anterior superior by a slide gauge with the
subject in supine position on a hard couch with the subjects hands folded under the
head. Skin fold measurements were repeated three times using a skin fold caliper at
the biceps, triceps, subscapular and suprailiacal region on the non-dominant side of the
body. The average value for every skin fold and sum of the average skin folds were
calculated. The sum of the average skin folds was converted to a fat percentage by the
table of Ournin and Womersley (13).
Blood pressure Hypertension is one of the major risk factors for the development of
carotid atherosclerosis and peripheral arterial disease (14). Therefore, blood pressure
was measured twice on each visit after 5 minutes of rest with a precision blood
pressure instrument (Maxi Stable 3, Speider & Keller, Germany) on the right arm in
supine position. Cuff size was adjusted to the circumference of the arm. Systolic and
diastolic blood pressures were defined according to the Korotkoff sounds I and V. The
average of both the systolic and diastolic blood pressure (SBP and DBP)
measurements of both visits was calculated and pulse pressure (PP) was defined as
average SBP minus average DBP. Mean arterial pressure (MAP) was calculated as
DBP + (PP / 3). Hypertension was defined as SBP/DBP >140/90 (14), or use of
antihypertensive medication. Furthermore, during the second visit, SBP was measured
with a standard Doppler device on both arms and ankles (a. tibialis posterior and a.
dorsalis pedis) to calculate Ankle/Brachial Index: ABI a. tibialis posterior = highest SBP
a. tibialis posterior / highest SBP arms; ABI a. dorsalis pedis = highest SBP a. dorsalis
pedis / highest SBP arms. An ABI < 0.90 is considered to be an indication for peripheral
vascular disease (15,16).
Electrocardiogram A standard 12-lead electrocardiogram (ECG) was made after 5
minutes rest with the subject in supine position, using a Marquette 12 SL ECG (GE
Marquette Medical Systems, Milwaukee, Ml, USA) or a Cardiette® daedalus view (H&C
Medical Devices Spa, Italy). Heart rate, QRS duration and QT-interval were
automatically registered. Heart rate adjusted QTc-interval was calculated with a
modified Bazett formula, using heart rate instead of RR interval for adjustment. A
prolonged QTc-interval predicts all cause and cardiovascular mortality in DM patients
(17) and the elderly (18,19). QRS duration is considered a marker of metabolic stress
(20) and represents conduction disturbances. The ECG was coded according to the
Minnesota Code System (21) by the head of the ECG Service of Leiden University
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Medical Center, mr. AC Maan (PhD) (SEAL, the Netherlands). Left ventricular
hypertrophy was considered to be present either as Sokolow-Lyons index without the
presence of a bundle branch block (SV1 • RV5 or 6 > 38 mm) (data missing N=286), or
Cornell voltage QRS duration product > 2440 mm'ms (50.51) (data missing N=329), or
when the ECG was coded 3.1 or 3.3 (data missing N=15) (total data missing N=12).
Urine sample The morning urine samples of both visits were checked for glucose.
proteins, pH and blood by a multiple reagent strip (Bayer Corporation, USA) and was
frozen at -80° C. The albumin concentration of the first sample was determined by rate
nephelometry (Array Protein System. Beckman. PaloAlto, USA) at the Department of
Clinical Chemistry of the University Hospital Free University Amsterdam (the
Netherlands). Microalbuminuria. an early marker of renal damage, is an indicator of
increased cardiovascular risk, and the presence of microalbuminuria is considered an
indication for antihypertensive treatment by the European Society of Hypertension (22).
Microalbuminuria was considered to be present when albumin concentration > 20 mg/L
(23).
Carotid artery Ultrasound Procedures Intima-media thickness (IMT) reflect structural
vessel wall properties and distensibility and Young's elastic modulus of the common
carotid artery (CCA) reflect both structural and functional vessel wall properties IMT Is
frequently used in epidemiological studies as a quantitative measure since it has been
validated as marker of vascular damage and of future cardiovascular risk (24). The
reproducibility of distensibility and Young's elastic modulus measurements is sufficient
for application in epidemiological studies (25,26) and both measures have shown a
relationship to cardiovascular risk factors (27).
Carotid intima-media thickness (IMT) was measured on both sides with ultrasound in
M-mode (Ultramark 4+, ATL, Bothel, Washington, USA) by a linear array transducer of
7.5 MHz positioned perpendicular to the common carotid artery (CCA), as described
before (28). The head was tilted at an angle of approximately 45° to the contra-lateral
side and both a. carotis communis were measured approximately 10-20 mm proximal to
the bulbus after 15 minutes rest. Measurements were repeated seven times at both left
and right CCA. The median value of the seven measurements was determined for the
left and right side. Since no difference existed between right and left IMT median in the
presently studied subjects, the average of the left and right median was used as a
representative IMT value. When less than five measurements could be done, the
measurement was considered missing. When measurements were obtained from one
side only, the median value of that side was used in the analysis. The inter-observer
coefficient of variation was 3.9 %, determined in 7 subjects on two occasions. The intra-
observer coefficient of variation was 3.7 % with observer 1, determined in 5 subjects
and 4.0 % with observer 2, determined in 7 subjects. Systolic and diastolic blood
pressures were measured with a validated automatic oscillometric blood pressure
device (OMRON 705CP, Nieuwegein, the Netherlands) on the right arm before the
procedure, and after the third and seventh measurement. The average of all systolic
and diastolic measurements during the procedure was calculated. Brachial pulse
pressure (PP) was defined as average systolic blood pressure minus average diastolic
blood pressure and was used only to calculate distensibility. compliance and Young's
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elastic modulus. Brachial mean arterial pressure (MAP) was calculated as diastolic
pressure + (pulse pressure / 3).
Vessel wall properties were assessed with an Ultramark 4+ (Ultramark 4+, ATL,
Bothel, Washington, USA) and by using an echo wall tracking system at the same
position in the common carotid artery (CCA) as used in IMT. The wall tracking system
measures, non-invasively, the diastolic diameter d and distension Ad, the change in
diameter as function of time (29,30). Distensibility (DIS), compliance (COM) and
Young's elastic modulus (YEM) are defined as follows:
Distensibility DIS = (AA/A) / PP (1/MPa)
Compliance COM = AA / PP (mm2/kPa)
Young's elastic modulus YEM = d / (IMT * D) (MPa),
where A is the diastolic lumen area (calculated by p*(0.5*d)^), AA the change in cross-
sectional area from diastole to systole (calculated by p*((d + Ad)* - d*) / 4), and IMT is
the IMT value resulting from the IMT measurement (29). All measurements were
repeated seven times at both the left and right CCA. Measurements were repeated
when the diameter showed a standard deviation of more than 1 % or distension showed
a standard deviation of more than 10%. In calculations, we used the average of the left
CCA diameter and distension because of the small number of missing values on this
side, and because few subjects had the left hand side as the dominant side (6.3%).
A complete ultrasound measurement protocol was obtained in 86.9% (499 of 574) of
the subjects. IMT and distensibility measurements combined were available in 65.9%
(378 of 574) subjects. Most common reasons for missing data, or subjects, were
cardiac arrhythmia, longitudinal or oscillating movements of the carotid artery, (neck)
obesity, or logistic problems. These factors had more impact in the DM group, because
vessel wall properties were assessed successfully in 56.5% (83 of 147) of all DM
subjects in the CODAM cohort compared to 62.8% of IGT subjects (81 of 129) and
71.8% (214 of 298) NGT subjects in the CODAM cohort. Variables that differed
between subjects who did have an ultrasound and subjects who failed an ultrasound
are shown in Table 2, 3 and 4. Subjects with DM who failed an ultrasound
measurement were more obese than subjects who completed the measurement. IGT
and NGT subjects who failed an ultrasound measurement were older, more obese and
had a higher HbA1c than subjects who had a complete ultrasound protocol.
Furthermore, NGT subjects with incomplete measurements also had a higher blood
pressure and insulin level than subjects who had complete measurements.
Questionnaires Subjects filled in a questionnaire about physical activity (4), use of
medication, medical history of themselves and their first-degree family members, family
history of cardiovascular diseases and type 2 diabetes mellitus, smoking habits,
ischaemic heart pain and intermittent claudication (5,6), diabetes symptoms (diabetes
checklist-2) (7), quality of life (RAND-36) (8), and depressive symptoms (CES-D, Dutch
version) (9). The results are used to determine the impact of lifestyle factors. Subjects
filled in a questionnaire about quality of health care and a validated semi-quantitative
food frequency questionnaire (RIVM, Bilthoven, the Netherlands) as well (10).
82
Subjects, methods and design of the COOAM study
DM-I
(N-63)
61.1
31.6
1074
106.8
± 5 8
±5 1
±12.7
±11.0
0.999 ± 0.069
239 7
2872
35.4
148.9
851
638
±36.2
±25 3
±6.8
±19.8
± 9 8
±16 2
1.15 ±0 20
70 ±1.0
Tabte 2: Variables different between subjects with type 2 diabetes meMus (DM) who had a complete
lAraaound measurement (C) and who had an incomplete ultrasound measurement (I) and thus were not used
in statistical analyses
DM-C
(N-83)
Age (years) 60 3 1 6 4
BMI (kg/m') 29 3 ± 3.9*
Waist (cm) 103 0 ± 10.4*
Hip (cm) 104 5 1 8 1 '
WHR 0 98610 067
Sag Diam (mm) 223 4 130 9*
Trans Cham (mm) 282 4 1 25 1
Fat perc (%) 34 1 1 6.2
Systole BP (mmHg) 147 7 t 18 7
Diastolic BP (mmHg) 84 2 1 9 7
PP (mmHg) 63 5 1 16 0
ABIatibtalis 109 ±0.12
HbA1c(%) 6 . 8 l 12
Insulin Oh' (pmot/L) 75_5 9 1 ^
Data are mean i SD; ' unadjusted median value shown in table: " slgnMcantly OMwwil from subjects who
failed ultrasound measurements: BMI = body mass index: WHR = waist/hip ratio: sag • sagittal, dtam •
diameter, trans = transversal: perc = percentage: BP = blood pressure: PP • pulse pressure: ABI •
anMe/brachial index
Table 3: Variables different between subjects with impaired glucose tolerance (IGT) who had a complete
ultrasound measurement (C) and who had an incomplete ultrasound measurement (I) and thus were not used
in statistical analyses.
IGT-C IGT-I
(N=81) (N-48)
Age (years) 58.3 ±6 .1* 61.217.4
BMI (kg/m*) 28.4 1 3.8 29.7 ± 4.7
Waist (cm) 99.1 110.3 102.81 13.5
Hip (cm) 104.618.2 107.1 ± 10 3
WHR 0.94710.071 0 96010.082
Sag. Diam. (mm) 215.0 134.5* 231.9 137.1
Trans. Diam. (mm) 277.9 ± 29.2 283.5 1 32.8
Fat perc. (%) 33.017.1 31.817.8
Systolic BP (mmHg) 142.7 1 20.4 147 6 1 18.4
Diastolic BP (mmHg) 83.7 19.3 85.4 ±10 5
PP(mmHg) 59.0115.7 62.2113.1
ABIatibialis 1.1610.15* 1.1110.09
HbA1c(%) 5.8 10.4* 6.010.4
Insulin Oh' (pmol/L) 67_5 65J5
Data are mean ± SD: * unadjusted median value shown in table: * significantly different from subjects who
failed ultrasound measurements: BMI = body mass index: WHR = waist/hip ratio; sag = sagittal; diam «
diameter; trans = transversal; perc = percentage; BP = blood pressure; PP = pulse pressure; ABI =
ankle/brachial index.
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Table 4: Variables different between subjects with normal glucose tolerance (NGT) who had a complete
ultrasound measurement (C) and who had an incomplete ultrasound measurement (I) and thus were not used
in statistical analyses.
Age (years)
BMI (kg/rrf)
Waist (cm)
Hip (cm)
WHR
Sag Diam. (mm)
Trans Diam (mm)
Fat perc. (%)
Systolic BP (mmHg)
Dlastollc BP (mmHg)
PP (mmHg)
ABI a tibiahs
HbA1c(%)
Insulin Oh' (pmol/L)
NGT-C
(N=214)
57.4 ± 7.3'
26.9 ± 3.3*
94.1 ±9.8#
101.316.9*
0.930 ± 0.075*
196.6 ±26.8*
269.4 ± 27.5*
29 5 ± 7.5*
133.1 ±17.9*
79.3 ± 8.5'
53.8 ± 13.7"
1.15±0.11
5.6 ± 0 4*
490*
NGT-I
(N=84)
60.5 ±6.9
29.3 ±4.8
101.6 ±12.3
106.1 ±10.0
0.958 ± 0.076
220.3 ± 34 6
279.0 ± 29.2
31 6 ±7.8
142.0 ±17.1
82.4 ± 7.8
59.7 ±13.4
1.14±0.13
5.7 ±0.4
590
Oats art imm ± SD:' unadjusted median value shown in table. * significantly different from subjects who
failed ultrasound measurements; BMI = body mass index; WHR = waist/hip ratio; sag = sagittal; diam =
diameter; trans • transversal; perc • percentage; BP = blood pressure; PP = pulse pressure; ABI =
ankle/brachial index.
2.4: Description of subjects according to glucose tolerance
status
In total, 352 men and 222 women (combined N=574), who had a mean age of 59.1 ±
7.0 years and BMI of 28.6 ± 4.3 kg/m^, participated in the CODAM study. All variables
were adjusted for age and gender in statistical analyses. The variables urinary albumin
concentration, triglycerides, insulin concentration, distensibility, compliance, Young's
elastic modulus, and C-reactive protein had a skewed distribution and were log-
transformed to satisfy conditions of normality. In tables however, their untransformed
median values have been used for clarity.
DM subjects were significantly older than IGT or NGT subjects (Table 5). HbA1c,
fasting and 2h post-load venous plasma glucose concentration were significantly higher
in DM subjects compared to IGT and NGT subjects. These results are inherent to the
definition of DM, IGT and NGT. Total and non-HDL cholesterol were not different
between the groups. HDL-cholesterol was lower in subjects with DM compared to IGT
and NGT subjects, both in men and women, and triglycerides were significantly higher.
Both low HDL-cholesterol and high triglycerides are characteristic lipoprotein
abnormalities of diabetes as well as normal or high LDL-cholesterol (31). In the present
study however, LDL-cholesterol was significantly lower in DM subjects compared to IGT
and NGT subjects (Table 5). ApoB was not significantly different between the glucose
tolerance groups. This metabolic phenotype (lower LDL cholesterol, higher
triglycerides. but similar apoB) suggests the presence of small, dense LDL particles in
DM subjects Both FFA and insulin concentration were significantly higher in DM
subjects compared to IGT and NGT subjects. In conclusion, DM subjects show
54
Sublets, imthod* and d*Hgn of tht CODAM ttudy
abnormalities in HDL- and LDL-cholesterol, triglycerides. FFA and insulin in association
with hyperglycemia, or. alternatively, these abnormalities precede hyperglycemia in the
progression from IGT to DM. particularly the increased levels of FFA and triglycerides.
Except for height, all body composition variables were different between the
glucose tolerance groups, i.e. weight. BMI, waist and hip circumference. WHR. sagittal
and transversal diameter, sum of skin fold measurements, and fat percentage (Table
6). A remarkable incremental gradient for these measurements of bodycomposition was
found from NGT to IGT and to DM. Therefore, increased body fatness, more abdominal
obesity, and increased subcutaneous fat was a characteristic of recently diagnosed
type 2 diabetes. This supports the concept that DM appears against a background of
obesity (3,32.33).
Systolic and diastolic blood pressure, pulse pressure and mean arterial pressure
were significantly different between the groups, with the highest value in DM and the
lowest in NGT subjects, regardless of whether the subjects used antihypertensive
medication or not (Table 7) Ankle/Brachial Indexes of both arteries were significantly
lower in DM compared to IGT and NGT subjects, which suggests more peripheral
vascular disease (15,16). Furthermore, urinary albumin concentration was significantly
higher in DM subjects compared to the IGT and NGT subjects, which suggests that
more early renal damage is present in subjects with DM than in subjects with IGT or
NGT (22). A more detailed analysis and description of blood pressure variables is
presented in Chapter 6.
Heart rate and QRS duration were significantly higher in DM subjects compared to
IGT and NGT subjects (Table 8). This indicated disturbances in conduction of the heart,
suggesting higher metabolic stress for DM subjects than for IGT and NGT subjects
(20). However, heart rate corrected QT-time was not different between DM, IGT and
NGT subjects. As prolonged QTc-time is associated with a higher risk of all cause or
CVD mortality (17-19), this suggests that recently diagnosed DM subjects may not be at
increased risk of CVD events compared to IGT and NGT subjects.
Although in previous reports an increased IMT was found in subjects with DM
(34,35), no differences were found in the present study in IMT or distension on both
sides between the glucose tolerance groups (Table 9). Diameter of the left CCA
however, was significantly higher in DM subjects. Distensibility coefficient was
significantly lower and Young's elastic modulus was significantly higher in DM subjects,
which indicates a higher arterial vessel wall stiffness in DM subjects compared to IGT
and NGT subjects. Compliance coefficient at the right side, but not the left side, was
significantly lower in DM subjects, which also indicated higher stiffness. These data will
be presented and discussed in more detail in Chapter 5.
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Table 5: Age and venous blood
Age (years)
HbA1c(%)
Fasting glucose (mmol/L)
Glucose cone 0.5h (mmol/L)
Glucose cone 1h (mmol/L)
Glucose cone 2h (mmol/L)
Total cholesterol (mmol/L)
Non-HDL cholesterol
(mmol/L)
HDL cholesterol all
(mmol/L)
men
women
Triglycerldes* (mmol/L)
LDL cholesterol (mmol/L)
Apolipoprotein B (g/L)
Free fatty acids (mmol/L)
Fasting Insulin' (pmol/L)
parameters
N
574
567
573
524
524
526
574
574
574
352
222
572
568
573
573
568
according to glucose tolerance
DM
(N=147)
60.7
(59 6-61.8)
6.9
(6.7-7.0)
7 9
(7.8-8.1)
12.7
(12.4-13.1)
15.3
(149-157)
133
(12.9-13.6)
5.16
(5.00-5.32)
4.10
(3.94-4.27)
1.06
(101-1.11)
1.00
(0 94-1 05)
1 16
(106-1.27)
1.80
(0.60-6.70)
3.13
(299-3.28)
1.14
(1.10-1.18)
0.60
(0.57-0.63)
865
(22.0-395.0)
IGT
(N=129)
59.4
(58.2-60.6)
5.8
(5.7-6.0)
5 9
(5.7-6.1)
103
(10.0-10.6)
11.2
(10.8-116)
8.5
(8 2-8 9)
5.30
(5.13-5.47)
4 14
(3.97-4.32)
1.16
(1.10-1.21)
105
(0.99-1 12)
1.33
(1 22-143)
1.65
(0.50-4.10)
3.38
(3.23-3.53)
1.15
(1.11-1.20)
0.55
(0.52-0.58)
67.0
(18.0-279.0)
status in the CODAM study.
NGT
(N=298)
582
(57.4-59.0)
5.6
(5.6-5.7)
5.3
(5.2-5.4)
8 8
(8.6-9.0)
8 4
(8.1-8.6)
5.6
(5.4-5.8)
521
(5 10-5.33)
3.95
(3.83-4.06)
1.27
(1.23-1.30)
1.17
(1.13-1.21)
1.41
(1.35-1.48)
1.20
(0.40-4.70)
3.35
(3.25-3.45)
1.11
(1.08-1.14)
048
(0.46-0.50)
52.0
(20.0-213.0)
p-value
(trend)
0001
<0.001
<0.001
<0.001
<0.001
<0.001
NS
NS
<0.001
<0.001
<0 001
<0.001
0.026
NS
<0.001
<0.001
Data are mean (95% confidence interval) and are corrected for age and gender (except for age. that is
corrected for gender only); * unadjusted median value (min-max) shown in table, but p-value trend calculated
with log-transformed values, adjusted for age and gender; NS = non significantly different.
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Table 6: Body composition variables according to glucose tolerance status in the COOAM
Height (cm)
Weight (kg)
BMI (kg/rrf)
Waist (cm) all
mm
women
Hip (cm) aM
man
women
WHR afl
men
women
Sagittal diameter
(mm)
Transversal diameter
(mm)
Sum of skin folds
(mm)
Fat percentage (%)
N
574
573
573
568
347
221
565
347
218
564
347
217
565
565
423
421
DM
(N=147)
170.0
(169.1-171.0)
87.9
(85.8-90.0)
30.4
(29.7-31.0)
104.4
(102.6-106.2)
1071
(105.0-109.1)
100.0
(96 7-103.3)
1066
(105.2-108.0)
105.2
(103.7-106.8)
1088
(105.9-111.6)
0980
(0.971-0.990)
1.017
(1.00-1.027)
0.922
(0.903-0.940)
229.3
(223.9-234.7)
283.7
(279.2-288.2)
81.8
(77.7-86.0)
35.1
(34.2-36.0)
IGT
(N=129)
171 7
(170.7-172.7)
853
(83.0-87.6)
289
(282-29.6)
100.5
(98 6-102 4)
103.4
(101.1-105.7)
958
(92.7-99.0)
105.5
(104.0-107.0)
104.1
(102.3-105.8)
107.6
(104.9-110.3)
0.953
(0.943-0963)
0993
(0.981-1.005)
0.890
(0.873-0.907)
221.4
(215.7-227.1)
280.2
(275.4-285.0)
70.0
(65.4-74.6)
32.4
(31.4-33.4)
NGT
(N=298)
171.0
(170.4-1717)
80.7
(79.3-82.2)
27.6
(27.1-28.0)
96.4
(98 8-1030)
98.9
(97.3-100.4)
927
(90.6-94.8)
102.6
(101.6-103.6)
101.2
(1001-1024)
1049
(103.1-106.7)
0.941
(0.934-0.947)
0976
(0.968-0.984)
0.885
(0.873-0.896)
203.8
(200.1-207.5)
272.4
(269.2-275.5)
595
(56.7-62.4)
30.0
(29.3-30.6)
study.
p-value (trend)
NS
<0.001
<0.001 ^
<0.001 -K
<Q,001 .
<0.001
<0.001 ; ,
<0.001
0.017
<0.001
<0.001
0.002
<0.001
<0.001
<0.001
<0.001
Data are mean (95% confidence interval) and corrected for age; N = number of measurements.
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Table 7: Blood pressure measurements according to glucose tolerance status in the CODAM
Systolic BP (mmHg)
Diastolic BP (mmHg)
PP(mmHg)
MAP (mmHg)
ABI a. dorsalis
ABI a. tiUalts
Urinary albumin
concentration' (mg/l)
Use of antlhyp,
medication (%)
M
573
573
574
573
568
572
574
573
DM
(N=147)
146.7
(143.9-149.6)
84.3
(82.8-85.8)
62.4
(60.3-64.6)
105.1
(103.3-106.9)
1.08
(1.06-1.10)
1.11
(1.09-1.13)
4.40
(2.00-23100)
544
IGT
(N=129)
144.2
(141.2-147.3)
84.3
(82.8-85.9)
59.9
(57.6-62.2)
104.3
(102.4-106.2)
1.11
(1.09-1.13)
1.14
(1.12-1.16)
3.40
(2.00-388.00)
40.3
NGT
(N=298)
136.4
(134.4-138.5)
80.2
(79.2-81.3)
56.2
(54.7-57.7)
99.0
(97.7-100.2)
1.13
(1.12-1.15)
1.15
(1.14-1.16)
3.50
(2.00-227.00)
25.5
study.
p-value
(trend)
<0.001
<0.001
<0.001
<0.001
<0.001
0.007
O.001
<0.05
M * are mean (95% conf idence interval) and are corrected for age and gender;' unadjusted median value
(min-max) shown in table, but p-value trend calculated with log-transformed values, adjusted for age and
gender; N • number of measurements; BP = blood pressure; PP = pulse pressure; MAP = mean arterial
pressure; ABI • ankle/brachial Index; a. = artery.
Table 8: Electrocardiogram (ECG) characteristics in the CODAM study.
Heart rate ECG
(beats/min)
QRS-time (ms)
QTc-tlme (ms)
N
553
553
552
DM
(N=147)
66.1
(64.4-67.8)
91.3
(89.2-93.4)
415.2
(412.3-418.1)
IGT
(N=129)
61.3
(59.5-63.1)
91.4
(89.2-93.7)
409.3
(406.2-412.4)
NGT
(N=298)
59.9
(58.7-61.1)
94.6
(93.1-96.1)
411.8
(409.8-413.8)
p-value
(trend)
<0.001
0.006
NS
Data are mean (95% confidence interval) and are corrected for age and gender; N = number of
measurements.
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TaMe 9: Carotid artery waU characteristics according to glucose tolerance status in the CODAM study.
IMT right (mm)
IMT left (mm)
IMT mean (mm)
Diameter right CCA (mm)
Diameter left CCA (mm)
Distensibility coefficient right
CCA' (MPa')
Distensibility coefficient left CCA*
(MPa')
Compliance coefficient light
CCA* (mm'/kPa)
Compliance coefficient left CCA*
(mm'/kPa)
Young's modulus right CCA*
(MPa)
Youngs modulus left CCA*
(MPa)
N
469
478
488
476
462
411
408
411
408
411
408
DM
(N-147)
0.70
(0.66-0.73)
071
(0.68-075)
0.71
(0.68-O.73)
7.80
(7.62-7.98)
775'
(7.59-7.92)
15.1
(5.8-29.7)
14.3
(5 4-33 8)
0.59
(0 18-146)
0.55
(0.23-1.43)
0.74
(0.28-5.88)
083
(0.29-348)
IGT
(N-129)
0.70
(0.66-0.73)
071
(0.67-0.75)
0.71
(0.68-074)
7.79
(7.61-7.96)
7.69
(7.53-7.86)
16.3
(5.7-39.7)
156
(5.3-43.3)
0.66
(023-1 51)
061
(0.24-1.34)
0 70
(0 28-184)
065
(020-300)
NGT
(N-298)
0.69
(0.67-0.71)
0.70
(0.67-0.72)
069
(0.68-0.71)
7.63
(7.52-7.74)
745*
(7.34-7.55)
183
(6.5-509)
17.7
(5.6-51.5)
0.68
(0.23-1.85)
0.61
(0.22-2.24)
057
(0.21-449)
060
(0.19-3.76)
p-value
(trend)
NS
NS
NS
NS
0.001
<0.001
<0.001
0009
NS
0002
0.004
Data are mean (95% confidence interval) and are corrected for age and gender; * unadjusted median value
(min-max) shown in table, but p-value trend calculated with log-transformed values, adjusted for age and
gender; * significantly different from the right side; N = number of measurements, IMT » intima-media
thickness; NS = non significantly different; CCA = common carotid artery.
In addition to blood parameters like glucose, insulin and lipid parameters, selected
inflammatory variables were determined. Soluble ICAM, C3, CRP, and creatinine were
all significantly different between the DM, IGT and NGT subjects (Table 10). C3 is an
acute phase reactant and increased synthesis of C3 is induced during acute
inflammation (www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120700). The liver is the
main site of synthesis, although small amounts are also produced by activated
monocytes and macrophages. Soluble ICAM was significantly higher in subjects with
DM, which suggest an increased risk on CVD (36-38). Also, C3 concentration was
higher, which suggests a higher level of inflammation in DM subjects. The median value
of CRP was highest in DM and lowest in NGT subjects. Although the effect of CRP is
confounded by the effect of obesity (39,40), CRP indicates increased risk on future Ml
and stroke in DM subjects (41,42). Creatinine concentration was significantly lower in
DM subjects than in IGT and NGT subjects. Because the albumin concentration in DM
subjects in the present study was significantly higher than in IGT or NGT subjects and
microalbuminuria precedes the appearance of higher creatinine levels (43), the reason
for the lower creatinine concentration in DM subjects is presently unexplained. It may
reflect a reduced mass of skeletal muscle in DM, most likely a long-term adaptation to a
sedentary lifestyle. An alternative, more speculative, explanation is that the reduced
muscle mass is governed by genetic factors, reflecting susceptibility to diabetes, as
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muscle is the most important contributor to glucose uptake from plasma and
subsequent oxidation.
Table 10: Selected inflammatofy variables according to glucose tolerance status in the CODAM study.
N DM IGT NGT p-value
(N=147) (N=104) (N=298) (trend)
Soluble intercellular adhesion 573 372.3 358.8 339.7 0.002
molecule (ng/mL) (356.6-387.8) (342.3-375.3) (328.8-350.6)
Complement factor 3 (g/L) 571 1.921 1.874 1.705 <0.001
(1.869-1.973) (1.819-1.929) (1.669-1.741)
C-reactive protein* (mg/L) 572 3.42 2.76 2.19 <0.001
(0.54-51.85) (0.60-30.50) (0.42-53.82)
Creatinine (umol/L) 573 69.7 71.9 73.0 0.011
(67.6-71.8) (69.7-74.1) (71.6-74.5)
Data are mean (95% confidence interval) and are corrected for age and gender;' unadjusted median value
(min-max) shown in table, but p-value trend calculated with logtransformed values, adjusted for age and
gender; N = number of measurements.
There were no differences in gender or smoking habits among the glucose
tolerance groups (Table 11). Besides lifestyle factors like smoking and exercise, it is
known that DM also has a genetic component and part of this genetic component is
transmitted maternally, although the underlying mechanism has not been clarified (44-
46). Significantly more parents with DM were present in DM subjects compared to IGT
or NGT subjects (Table 11). Furthermore, significantly more hypertension was present
in subjects with DM compared to IGT and NGT subjects. Data from several
epidemiologic studies have suggested that the prevalence of hypertension in patients
with diabetes mellitus is approximately one-and-a-half to two times greater than in an
appropriately matched nondiabetic population (47). Use of antihypertensive medication
such as ACE inhibitors, |}-blockers. and diuretics as well as lipid lowering medication
was also significantly higher in DM subjects compared to IGT and NGT subjects (Table
12).
Glucose intolerance is one of the risk factors that can contribute to the metabolic
syndrome according to both the WHO (11) and the Adult Treatment Panel (ATP) III of
the National Cholesterol Education Program (NCEP) (48). Indeed, 78.2% of the
subjects with DM also had the metabolic syndrome according to the definition of the
NCEP (48), which was significantly more frequent than in subjects with IGT or NGT, i.e.
52.7% and 19.1% respectively (Table 11). Subjects with metabolic syndrome are at
increased risk of CVD and CHD (2,49). No differences however, existed in self-reported
CVD and CHD or in the different disorders that make up CVD and CHD (Table 13). This
is in contrast to the well-known increased prevalence of CHD and CVD. by a factor 2 to
4, in type 2 diabetes and IGT (49). These findings indicate that, in theory, it should be
possible to prevent medical suffering from cardiovascular events in IGT and DM
subjects, when detected in time and treated for the correct risk factors.
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Table 11: Percentage are1 Odds Ratio (OR) with confidence interval (Cl) m parentheses of males, smokers of
cigarettes and cigars, hypertension, parents with diabetes and satisfaction to exercise guidelines according to
phfrfMfo tolerance status in the CODAM study, adjusted for age and gender (except for pen
Male
Smoking, cigarettes
Ex-smoker
Cigar smoker
Parents with diabetes
Hypertension (> 140/90 or
hypertension medication)
Metabolic Syndrome
NCEP ATPIII (%)
(%)
OR(CI)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR(CI)
(%)
OR (Cl)
<%)
OR (Cl)
(%)
OR (Cl)
NGT
(N=298)
59 7
1
16.5
1
48.8
1
4.1
1
30.3
1
51.5
1
19.1
1
IGT
(N«104)
59.7
1.0(0.7-1.5)
17.8
1.2(0.7-2.1)
52.7
1.2(0.8-18)
3 1
0.8 (0.2-2.5)
35.7
1.3(0.8-2.0)
69.0
2.0* (1.3-3.2)
52.7
5.0* (3.1-7.8)
DM
(N-147)
66.0
0 8(0.5-1.1)
14.3
1.0(0.6-1.8)
59.9
1.5(0.9-2.3)
4.9
1.2(0.4-3.1)
46.9
2.1* (14-3.2)
81.0
3.5* (2.1-5.6)
78.2
15.8* (9.6-26.1)
antage males).
N
874
en
ws
863
873
573
874
* OR significantly different from NGT; Data are given as percentages and as OR (Cl); N • number of
measurements.
Table 12: Percentage and Odds Ratio (OR), with confidence interval (Cl) in parentheses, wlthfn groups of
antihypertensives and use of lipid lowering medication according to glucose tolerance status in the CODAM
study, adjusted for age and gender.
Use of ACE inhibitor
Use of alpha-blocker
Use of beta-blocker
Use of calcium antagonist
Use of central working
antihypertensive drugs
Use of nitrates
Use of diuretics
Use of angiotensin
antagonists
Use of lipid lowering
medication
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
NGT
(N=298)
6.7
1
1.0
1
14.8
1
7.7
1
0.3
1
7.7
1
6.1
1
4.0
1
14.1
1
IGT
(N=104)
11.6
1.8(0.9-3.6)
0.8
0.7(0.1-7.4)
24.0
1.8* (1.1-3.0)
13.2
1.8(0.9-3.5)
0.8
2.1 (0.1-33.9)
7.8
1.0(0.4-2.1)
13.2
2.2* (1.1-4.6)
6.2
1.5(0.6-3.9)
17.8
1.3(0.7-2.2)
DM
(N=147)
21.8
3.6* (2.0-6.5)
1.4
0.8(0.1-5.4)
29.3
2.2' (1.4-3.6)
13.6
1.6(0.8-3.1)
0.7
1.8(0.1-29.2)
6.1
0.7(0.3-1.5)
170
3.0* (1.5-5.7)
6.6
1.7(0.7-4.0)
259
1.9* (1.2-3.1)
N
573
873
573
573
873
673
573
573
874
* OR significantly different from NGT; Data are given as percentages and as OR (Cl).
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Table 13: Percentage and Odds Ratio (OR) with confidence interval (Cl) in parentheses of cardiovascular
cMiooio. cardiovascular events and preventive surgery according to glucose tolerance status in the CODAM
study, adjusted tor age and gender.
Coronary heart disease
Cardiovascular disease
Prior myocardial infarction
Serious heart disease
other than Ml
Stroke or brain hemorrhage
Documented peripheral
artery disease
Narrowed blood vessels
of the viscera or legs
Bypass surgery
Percutaneous translumlnal
balloon dilation (PTCA)
Operation of blood vessels
History of coronary
angiography
Pacemaker
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
NGT
(N=298)
16.9
1
20.1
1
75
1
9.2
1
34
1
6.9
1
34
1
3.7
1
64
1
1.3
1
8.1
1
0
-
IGT
(N=104)
22.2
1.4(0.8-2.3)
26.6
1.4(0.8-2.3)
9 3
1.2(0.6-2.6)
10.2
1.1 (0.5-2.2)
4.8
1.4(0.5-3.8)
11.3
1.6(0 8-3 6)
4 7
1.3(0.5-3.7)
3.9
1.0(0.4-3.0)
55
0.8 (0.3-2.0)
3.1
2.3 (0 6-9.4)
11.8
1.5(0.7-3.0)
0
-
DM
(N=147)
20.0
1.0(0.6-1.8)
25.7
1.2(0.7-1.9)
75
0.8(0.4-1.8)
9.7
0.9(0.5-18)
5.5
1.4(0.5-3.7)
13.9
1 8(0.9-3.6)
6.9
1.7(0.7-4.3)
4.8
1.0(0.4-2.8)
4 8
0.6(0.3-1.6)
4 1
2.9 (0.8-10.6)
13.6
1.5(0.8-2.9)
0
-
N
566
557
570
564
561
557
565
571
571
571
571
570
* OR significantly different from NGT; Data are given as percentages and as OR (Cl); Ml = myocardial
Infarction
The European Society of Hypertension recently recognized that secondary organ
involvement, i.e. target organ damage, could act as a risk factor for cardiovascular risk
on its own (22). Target Organ Damage (TOD) was defined as follows: intima-media
thickness (IMT) > 0.90 mm, microalbuminuria > 20 mg/L (23), left ventricular
hypertrophy either as Sokolow-Lyons index without the presence of a bundle branch
block (SV1 + RV5 or 6 > 38 mm), or Cornell voltage QRS duration product > 2440
mm'ms (50,51), or when the ECG was coded 3.1 or 3.3 according to Minnesota, and
serum creatinine in men > 115 nmol/l and in women > 107 (imol/l (22). We extended
the criteria for vessel wall damage (IMT) by adding criteria for endothelial dysfunction
and peripheral vascular disease (PVD). Endothelial dysfunction, of which plasma
soluble intercellular adhesion molecule (sICAM) concentrations is a marker (37,38),
was considered present when plasma sICAM concentrations exceeded the 90th
percentile determined in NGT subjects, i.e. 450 ng/mL. PVD was considered present
when the ABI was below 0.90 (15,16). Significantly more target organ damage of
peripheral vascular disease and microalbuminuria was found in DM subjects, i.e more
damage of the large vessels and kidneys was present in DM subjects compared to IGT
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and NGT subjects (Table 14). A more detailed description of these results will be given
in Chapter 6.
Table 14: Percentage and Odds Rabo (OR) with confidence interval (Cl) in parentheses of glucose tolerance
of Target Organ Damages defined by the European Society of Hypertension (27). adjusted for age and
gender
Vessel wall
TOD-IMT
TOD-PVD
TOO-SICAM
Heart
TOD-LVH
Kidneys
TOD-CREAT
TOD-MA
(%)
OR(CI)
(%)
OR(CI)
(%)
OR(CI)
(%)
OR(CI)
(%)
OR(CI)
(%)
OR(CI)
NGT
(N=298)
10.9
1
2.0
1
10.1
1
20.5
1
0.3
1
5.8
1
IGT
(N=104)
124
1.1(0.5-2.2)
3.1
18(0.5-6.5)
11.6
1.2(0.6-2.4)
224
1.1 (0.5-2.3)
0
-
6.7
1.2(0.4-3.2)
DM
(N=147)
118
0.9(0.5-1.8)
9.0
4.3* (1.6-11.7)
17.1
2.0* (1.1-3.6)
255
1.2(0.6-2.6)
2.1
4.5 (0 5-45 0)
21.0
4.2* (2.1-8.7)
N
499
568
573
245
573
432
* OR significantly different from NGT; Data are given as percentages and as OR (Cl); TOD- IMT = target
organ damage defined according to intima-media thickness (IMT > 0.90 mm); TOD-PVD = target organ
damage defined according to the presence of peripheral vascular disease (ABI < 0.90); TOD-SICAM = target
organ damage defined according to the concentration of plasma soluble intercellular adhesion molecule (cone
< 450 ng/mL); TOD-LVH = target organ damage defined according to the presence of left ventricular
hypertrophy (Minnesota code 3.1 or 3.3, or Sokolow -Lyons index without the presence of a bundle branch
block (SV1 + RV5 or 6 > 38 mm), or Cornell voltage QRS duration product > 2440 mm'ms); TOD-CREAT =
target organ damage defined according to concentration of plasma creatinine (concentration creatinine men:
> 115 nmol/l; women > 107 ^mol/l); TOD-MA = target organ damage defined according to the presence of
microalbuminuna (concentration albumin > 20 mg/L).
These results combined indicate that hyperglycemia is preceded by abnormalities in
cholesterol, triglycerides, FFA and insulin, as well as increased body fatness, more
abdominal obesity, and increased subcutaneous fat. Furthermore, blood pressure was
significantly higher and peripheral vascular disease and early renal damage, indicated
by Ankle/Brachial Index and microalbuminuria, is found in DM subjects. In agreement
with these results, target organ damage as defined by the European Society of
Hypertension (22) was already significantly more present in DM subjects, i.e. on the
level of the large vessels and kidneys. Other indicators of cardiovascular disease that
we found in DM subjects were conduction disturbances of the heart and metabolic
stress, indicated by increased heart rate and QRS duration, but not heart rate corrected
QT time. Also, increased arterial stiffness was found in DM subjects, as well as
increased soluble ICAM and CRP. Although corrected QT-time and a similar IMT
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suggest that subjects with recently diagnosed DM are not at increased risk for CVD, the
other variables certainly indicate that they are, and that even some form of CVD is
already present, such as peripheral vascular disease and renal damage. A possible
explanation for normal QTc time and IMT may be that these variables appear abnormal
only when diabetes is of longer duration. Therefore, we conclude that subjects recently
diagnosed with DM are already at increased risk for CVD and even show some
vascular damage which is mostly due to, or associated with, metabolic abnormalities.
2.5: Description of Impaired Glucose Tolerance (IGT) and
Impaired Fasting Glucose (IFG)
In total, 104 subjects with IGT and 25 subjects with IFG participated in the CODAM
study. In the IGT group, 58 men and 46 women were included with mean age of 59.5 ±
6.7 years and BMI of 28.9 ±4.1 kg/m^. In the IFG group, 19 men and 6 women with a
mean age of 59.1 ± 7.3 years and BMI of 28.9 + 4.5 kg/m* were included. In most
populations, IGT is considerably more prevalent than IFG (52,53). In agreement with
this, we found that, in the screening phase of the present study, the prevalence of IGT
was almost twice that of IFG, 14.2 versus 7.9% respectively (3). The prevalence of IGT
is reported to be higher in women than men in all age groups except over the age of 60
in Asian populations and over the age of 80 in European (53). However, we found more
men than women with IGT in the CODAM study (55.8%), although the percentage men
was lower in the screening phase (49.1%). One possibility is that this is caused by
selection bias, because subjects who were defined IFG in the screening phase were
not invited for the CODAM study. However, IFG is reported to be more common in men
than women in virtually all age groups, typically one-and-a-half to three times higher,
but up to seven or eight times higher in Europeans aged 50-70 years (53). In both the
screening phase and in the CODAM study, most subjects with IFG were male (61.2%
and 76.0% respectively).
Both impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are very
strong risk markers for the development of diabetes (53). In type 2 diabetes, impaired
insulin action, insulin secretory dysfunction, and increased endogenous glucose output
are present. IGT is particularly associated with peripheral insulin resistance, mostly at
the level of the skeletal muscle, which is characterized by elevated post-load glucose
(53). During an OGTT, the normal response to the absorption of the carbohydrate load
is both to suppress hepatic glucose output and to enhance glucose uptake in the
muscle and liver. This requires a prompt increase in insulin secretion, and adequate
hepatic and muscle sensitivity to insulin. Therefore, impaired insulin action and insulin
secretory dysfunction are already present in IGT. IFG on the contrary, is predominantly
characterized by abnormalities of the metabolic functions that control fasting glucose
(53). Normal control of fasting glucose depends on the ability to maintain adequate
basal insulin secretion, as well as on an appropriate degree of insulin sensitivity in the
liver to control hepatic glucose output. Increased hepatic glucose output thus probably
contributes to the mildly elevated fasting glucose concentrations in IFG. Therefore, IGT
and IFG have a different etiology.
There is still some controversy whether subjects with IGT and IFG differ in
anthropometric or other metabolic characteristics. A study in non-diabetic Pima Indians
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showed that subjects with IFG were heavier, had a larger percent body fat, fat mass
and fat-free mass than those with IGT (54). The Botnia Study from Finland showed that
subjects with IFG had a higher WHR. triglycendes. and total cholesterol, and a lower
HDL cholesterol than subjects with IGT (55). The RIAD study (56) and the Pahs
Prospective Study (57) found lower FFA levels in IFG subjects but did not find other
metabolic differences. In contrast to the study of the Pima Indians and the Botnia study,
the present study found, after adjustment for age and gender, a significantly lower WHR
and concentration triglycerides and no differences in cholesterol in IFG compared to
IGT subjects (Table 15) We also found significantly lower free fatty acids and fasting
plasma insulin concentrations in IFG subjects compared to IGT subjects which was in
agreement with the RIAD study (56) and the Paris Prospective Study (57) In addition,
we found one of the inflammation sensitive proteins, C3, to be significantly lower in IFG
subjects compared to IGT subjects.
Although some data suggest that IGT is more strongly associated with hypertension
and dyslipidemia than IFG (53), no differences were found in the presence of
hypertension between IGT and IFG in the present study (Table 15). However, the use
of antihypertensive medication was significantly higher in IGT subjects (Table 13) Beta-
blockers were significantly more used by subjects with IGT (28.8% versus 4.0%
respectively in subjects with IFG). There were no differences in the use of lipid lowering
medication. Furthermore, significantly more CHD and CVD was reported by IGT
subjects, 26.5% and 32 0% respectively versus 4 2% and 4.2% respectively by IFG
subjects, which was caused by the fact that only prior myocardial infarction and PTCA
were reported by IFG subjects while all disorders that were included in the definition of
CHD and CVD were reported by IGT subjects. Little data are available about the
relationship between IGT and IFG with CVD, but in unadjusted analyses both IFG and
IGT were found to be associated with CVD and total mortality (53). When considering
target organ damage (22), no differences were found (data not shown).
In conclusion, the differences that exist between IGT and IFG are not fully
elucidated yet. IGT subjects appear to have higher levels of risk factors for CVD and
type 2 diabetes and have more self-reported CVD and CHD compared to IFG subjects.
However, our cross-sectional data can not fully explain what this means. Therefore,
more prospective research is needed to elucidate the possible different roles that IGT
and IFG play in the development of both type 2 diabetes and CVD. The number of IFG
subjects was rather small in comparison with the number of IGT subjects in the present
CODAM study, and differences were only present in a small number of variables. This
may have been caused by the fact that the IFG subjects in the CODAM study were
diagnosed as IGT subjects in the preceding screening Therefore, we decided to treat
both groups as one in all analyses presented in this thesis.
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Table 15: Variables different between impaired glucose tolerance (IGT) and
the CODAM study, adjusted for age and gender.
Age (years)
Body Mass Index (kg/rrf)
Waist-to-Hip Ratio
Fasting glucose (mmol/L)
Glucose cone 2h
(mmol/L)
Triglycerides" (mmol/L)
Total cholesterol
(mmol/L)
HDL-chotesterol (mmol/L)
Free fatty acids (mmol/L)
Fasting insulin' (pmol/L)
Complement factor 3
(fl/L)
Hypertension (%)
Antlhypertensive
medication (%)
Use of lipid lowering
medication (%)
CHD (%)
CVD (%)
IFG
(N = 25)
59.2
(56.5-61.9)
29.0
(27 3-30.6)
0.934
(0.911-0.956)
6.3
(6.1-6.5)
5.9
(5.4-6.3)
1.20
(0.50-3.00)
5.20
(4.81-5.59)
1.24
(1.12-1.37)
046
(0.39-0.53)
49.0
(25 0-1530)
1.69
(1.57-1.82)
64.0
20.0
8.0
4.2
4.2
IGT
(N = 104)
59.4
(58.1-60.8)
28.9
(28 1-29.7)
0958
(0.947-0.969)
5.8
(5.7-5.9)
9.2
(9.0-9.4)
1.65
(0.50-4.10)
5.33
(5.14-5.52)
1.14
(1.08-2.10)
0.57
(0.54-0.61)
70.0
(18.0-279.0)
1.92
(1.86-1.98)
69.2
45.2
20.2
26.5
32.0
impaired fasting glucose (IFG) in
p- value
NS
NS
0.041
<0.001
<0.001
0.036
NS
NB
0.013
0.006
0.001
Odds ratio IGT to IFG
1.4(0.6-3.7)
3.4* (1.2-9.9)
2.9 (0.6-13.3)
10.2* (1.3-81.5)
12.9* (1.6-101.4)
Data in the upper table are mean (95% confidence interval); * unadjusted median value (mirt-max) shown in
table, but p-value trend calculated with log-transformed values; * OR significantly different from IFG; Data are
given as percentages and as OR (Cl); NS = non significantly different; CHD = coronary heart disease; CVD =
cardiovascular disease.
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2.6: Appendix 'Letter of invitation for the screening of the SLIM and CODAM
studies'
Onderzoek naar faktoren die een rol spelen bij het ontstaan van suikerziekte
Aan geadresseerde,
; - " • > Datum poststempel
Geachte mevrouw, meneer,
In het voorjaar van 1998 heeft u meegewerkt aan een onderzoek van de GGD en het
RIVM Hiervoor heeft u een korte vragenlijst ingevuld en een test gedaan met een
urinestrip. U gaf verder aan accoord te gaan in de toekomst benaderd te worden voor
aanvullend onderzoek. Voor aanvullend onderzoek op het gebied van diabetes mellitus
(suikerziekte) willen wij nu graag uw medewerking vragen.
Diabetes mellitus type 2 (ouderdoms-suikerziekte) is een veel voorkomende
aandoening. Naar schatting lijden zo'n 300.000 Nederlanders hieraan. De ziekte gaat
gepaard met een verhoogd risico op allerlei complicaties, zoals aandoeningen van hart
en vaten, ogen en nieren. Overgewicht is een van de belangrijke oorzaken, maar
daarnaast spelen nog een groot aantal andere risicofactoren een rol, waaronder het
voorkomen van suikerziekte in de familie en te weinig beweging. Om diabetes en
bijbehorende complicaties te bestrijden is echter meer kennis nodig over hoe deze
factoren precies werken en op wat voor manier we het optreden van diabetes kunnen
uitstellen of voorkomen.
In samenwerking met de Universiteit Maastricht en het Academisch Ziekenhuis
Maastricht zijn wij onlangs gestart met een grootschalig onderzoek op dit gebied, onder
andere gesteund door het Diabetes Fonds Nederland. In 1999 nodigen we een deel
van de mensen uit die, net als u, al eerder aan het onderzoek van de GGD en RIVM
hebben meegedaan. Wij hopen van harte dat u meedoet.
Ook als uw gezondheid niets te wensen overlaat, is uw deelname belangrijk!
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Wat houdt het onderzoek voor u in?
Op de dag van het onderzoek brengt u op een afgesproken bjdstip ("s ochtends) een
bezoek aan het Academisch Ziekenhuis Maastricht Het is de bedoeling dat u nuchter
naar het ziekenhuis komt. Dit houdt in dat u de dag voor het onderzoek vanaf 22.00 uur
niets meer mag eten en niets anders mag dnnken dan water.
Er zal aan u gevraagd worden een korte vragenhjst in te vullen en er zal een glucose
tolerantie test bij u worden afgenomen Aan het begin van de test wordt met behulp van
een vingerprik uw nuchtere bloedsuikergehalte bepaald Daarna krijgt u een
suikerdrank te dnnken Vervolgens wordt nog 2 keer uw bloedsuikergehalte bepaald (1
uur en 2 uur na het dnnken van de suikerdrank).
De glucose tolerantie test geeft aan in hoeverre uw bloedsuiker te hoog is en of er
mogelijk sprake is van diabetes. Aan de hand van de uitslag kunt u mogelijk gevraagd
worden om mee te doen aan een vervolgonderzoek U hoeft op dit moment echter nog
met te beslissen of u daar aan mee zou widen doen.
Op bijgevoegd antwoordkaartje kunt u aangeven of u bereid bent om mee te werken
aan het onderzoek. Als u aangeeft mee te willen werken. wordt u binnen een maand
gebeld door iemand van de Universiteit Maastricht voor een afspraak.
Belangrijk om te weten is dat het onderzoek zal lopen tot het einde van dit jaar. Indien
u op dit moment verhinderd bent tot deelname -door vakantie of ziekte- is het dus ook
mogelijk in de loop van de komende maanden deel te nemen. In dat geval willen we u
vragen op het kaartje aan te geven wanneer we met u contact kunnen opnemen voor
het maken van een afspraak. Wilt u het antwoordkaartje liefst binnen twee weken
ingevuld retourneren? (U hoeft geen postzegel te plakken).
Mocht u nu al vragen hebben, dan kunt u nadere informatie krijgen bij
Mw. T. Hermans en Mw. I. Nijs van de Universiteit Maastricht, tel 043-3881638.
Met vriendelijke groet,
Drs H. de Munter, GGD Maastricht
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2.7: Appendix 'Participation form for the screening of the SLIM and CODAM
studies'
Ik ben wel / niet bereid om mee te doen aan het onderzoek (svp doorstrepen wat niet
van toepassing is)
Ik ben telefonisch bereikbaar (s.v.p. bij alle dagen doorstrepen wat niet van toepassing
• )
Maandag ochtend/middag
Dinsdag ochtend/middag
Woensdag ochtend/middag
Oonderdag ochtend/middag
Vrijdag ochtend/middag
op het werk / thuis
op het werk / thuis
op het werk / thuis
op het werk / thuis
op het werk / thuis
Mijn telefoonnummer op het werk is
Mijn telefoonnummer thuis is : ..
Indien u telefonisch niet bereikbaar bent, wilt u dan zelf 's ochtends bellen naar:
van het Onderzoeksteam Diabetes aan de Universiteit Maastricht.
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2.8: 'Letter of invitation for participation in the CODAM study for NGT subjects'
Aan geadresseerde,
Geachte heer/mevrouw,
Enige tijd geleden heeft u de uitslag ontvangen van het Diabetes Onderzoek Maastricht
van het Academisch Ziekenhuis Maastricht in samenwerking met het RIVM en de GGD.
Uit de uitslagen van de vingerprik nuchter en de vingerprik na de suikerdrank bleek dat
u geen suikerziekte heeft Verder heeft u aangegeven geen bezwaar te hebben voor
deelname aan een vervolgonderzoek.
Een van de vervolgonderzoeken die door het Academisch Ziekenhuis Maastricht hi
samenwerking met de Universiteit Maastricht wordt uitgevoerd is een zogenaamde
'vokj'- of cohortstudie. Bij dit onderzoek worden een aantal metingen herhaald om zo te
bepalen welke risicofactoren van diabetes (suikerziekte) en atherosclerose
(aderverkalking) in de loop van de tijd veranderen. Hieruit kan afgeleid worden welke
factoren voorspellend zouden kunnen zijn voor het ontstaan van diabetes en
atherosclerose en welke factoren juist beschermen. Voor deze cohortstudie widen wij
nu graag uw medewerking vragen.
Bij deze brief is een informatiebrochure gevoegd Wij willen u vragen deze aandachtig
door te lezen. Indien u aan het onderzoek wilt deelnemen willen wij u vragen ons zo
spoedig mogelijk te bellen op tel. nr: (043) 388 1638 om een afspraak te maken. Ook
wanneer u nog vragen heeft bent u vrij ons te bellen op dit telefoonnummer.
Bij voorbaat dank,
Drs. M. Kruijshoop
mede namens de overige leden van het Onderzoeksteam Diabetes:
Drs. M.R. Mensink
Mw. T.J.F. MB. Hermans
Mw. I. Nijs
Dr. E.E. Blaak
Prof. Dr. T.W.A. de Bruin
75
2.9: Appendix 'Letter of invitation for participation in the CODAM study for IGT S i
and DM subjects'
Aan geadresseerde,
Geachte heer/mevrouw,
Enige tijd geleden heeft u de uitslag ontvangen van het Diabetes Onderzoek Maastricht
van het Academisch Ziekenhuis Maastricht in samenwerking met het RIVM en de GGD.
Uit de uitslagen van de vingerprik nuchter en de vingerprik na de suikerdrank bleek dat
u een verhoogde bloedsuikerspiegel heeft. Verder heeft u aangegeven geen bezwaar
te hebben voor deelname aan een vervolgonderzoek.
EAn van de vervolgonderzoeken die door het Academisch Ziekenhuis Maastricht in
•amenwerking met de Universiteit Maastricht wordt uitgevoerd is een zogenaamde
'volg'- of cohortstudie. Bij dit onderzoek worden een aantal metingen herhaald om zo te
bepalen welke risicofactoren van diabetes (suikerziekte) en atherosclerose
(aderverkalking) in de loop van de tijd veranderen. Hieruit kan afgeleid worden welke
factoren voorspellend zouden kunnen zijn voor het ontstaan van diabetes en
atherosclerose en welke factoren juist beschermen. Voor deze cohortstudie willen wij
nu graag uw medewerking vragen.
Bij deze brief is een informatiebrochure gevoegd. Wij willen u vragen deze aandachtig
door te lezen. Indien u aan het onderzoek wilt deelnemen willen wj u vragen ons zo
spoedig mogelijk te bellen op tel. nr: (043) 388 1638 om een afspraak te maken. Ook
wanneer u nog vragen heeft bent u vrij ons te bellen op dit telefoonnummer.
Bij voorbaat dank,
Drs. M. Kruijshoop
mede namens de overige leden van het Onderzoeksteam Diabetes:
Drs. M.R. Mensink
Mw. T.J.F. MB. Hermans
Mw. I. Nijs
Dr. E.E. Blaak
Prof. Dr. TWA. de Bruin
76
Appendices with Chapter 2
2.10: Appendix 'Information package'
Informatiebrochure voor deelnemers aan
ffl
c
o
Cohortstudie Diabetes en
Atherosclerose Maastricht(MEC 99-112)
Contactpersonen: - Drs. M. Kruijshoop 8 043 3881638
- Drs MR. Mensink S 043 3881638
- Dr. E.E. Blaak « 043 3881639
- Prof. Dr. T.W.A. de Bruin 8 043 3877019
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Een onderzoelr naar de b/ydrage van omgew'ngsfacforen en erfe//y/ce fiacforen b//
hef onfsfaan van ouderdo/ns-su/frerz/eKfe en nart- en vaafz/e/cfen
Doel van het onderzoek
Er zijn sterke aanwijzingen dat, naast roken, weinig lichamelijke inspanning, voedings-
en leefgewoonten, ook erfelijke gevoeligheid een rol speelt bij het ontstaan van hart- en
vaatziekten. De wijze waarop hart- en vaatziekten bij suikerziekte ontstaan is echter
nog niet goed bekend. Wei is bekend dat er in het algemeen een 2 tot 4 keer verhoogd
risico kan zijn op het ontstaan van hart- en vaatziekten bij ouderdoms-suikerziekte (in
medische termen type 2 diabetes mellitus).
Het doel van dit onderzoek is na te gaan wat de invloed van een aantal erfelijke
factoren is op het ontstaan van hart- en vaatziekten bij mensen met en mensen zonder
een verhoogd risico op de ontwikkeling van suikerziekte in Maastricht. Ook zal de
invloed van een aantal bekende risicofactoren, zoals roken, lichamelijke activiteit,
voeding en cholesterolgehalte bekeken worden. Het is voor het onderzoek niet
belangrijk of u momenteel onder behandeling van uw huisarts en/of dietiste staat in
verband met een verhoogde bloedsuikerspiegel.
Opzet van het onderzoek
Het onderzoek zal 5 jaar gaan duren waarin u gevraagd wordt naar het Academisch
Ziekenhuis Maastricht of de Universiteit Maastricht te komen. In deze 5 jaar zullen de
metingen in totaal drie keer uitgevoerd worden. De metingen bestaan uit'baseline- of
nulmetingen die na drie en vijf jaar herhaald worden waarbij de verschillende
onderdelen verdeeld worden over drie bezoeken. U wordt dus gevraagd om in totaal 9
keer naar het ziekenhuis of de universiteit te komen, verspreid over 5 jaar.
De metingen die verricht worden dienen om de bloedsuikerspiegel te bepalen, een
aantal risicofactoren in het bloed en in de urine te meten, verschillende erfelijke
factoren met betrekking tot ouderdoms-suikerziekte en hart- en vaatziekten te bepalen,
de lichaamssamenstelling te meten (de verdeling tussen de hoeveelheid vet en spieren
in het lichaam) en de vaatwanddikte te bepalen. Daarnaast wordt u gevraagd een
aantal vragenlijsten in te vullen om een goede indruk te krijgen van uw
voedingsgewoonten, lichamelijke activiteiten en een aantal zaken betreffende de
gezondheid en gezondheidszorg.
Naast de meting van de bloedsuikerspiegel worden er nog een aantal andere
factoren in het bloed bepaald zoals het cholesterolgehalte en factoren die een rol
spelen bij de bloedstolling. Ook de erfelijke factoren die mogelijk een rol spelen bij het
ontstaan van ouderdoms-suikerziekte en hart- en vaatziekten worden uit het
afgenomen bloed bepaald.
De erfelijke factoren die worden bepaald spelen een rol bij:
-een verhoogd cholesterol, vetgehalte en aderverkalking.
-overgewicht. Overgewicht is een belangrijke risicofactor voor het ontwikkelen van
diabetes.
-hypertensie. Verhoogde bloeddruk gaat vaak samen met suikerziekte.
-stoornissen in de suiker- en vetstofwisseling. Deze komen beide voor bij suikerziekte.
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-de afgifte van het hormoon insuline. Bij ouderdoms-suikerziekte heeft het lichaam
meer insuline nodig dan het lichaam zelf (door middel van de alvleesklier) kan
aanmaken.
Wat houdt het onderzoek voor u in?
Hieronder wordt uitgelegd wat er precies gaat gebeuren bij de metingen die gedaan
zullen worden tijdens beide bezoeken.
Hef eersfe bezoefc:
U wordt gevraagd s morgens nuchter naar het ziekenhuis of de universiteit te komen
(de dag voor het onderzoek na 22:00 uur niets meer eten, niets anders dan water
drinken en niet roken) Voor bloeddonoren bij de bloedbank is het belangnjk te weten
dat er tussen de laatste bloeddonatie en het eerste bezoek van dit onderzoek minimaal
4 weken tijd moet zitten Verder widen wij u vragen om met de auto of het openbaar
vervoer te komen aangezien fietsen de bloedsuikerspiegel kan beinvloeden Gemaakte
reiskosten kunnen worden vergoed.
8/oedsu/fcersp/ege/.
Na uitleg van het onderzoek wordt eerst het gewicht en de bloeddruk gemeten. Hlerna
zal een infuus ingebracht worden in een ader van de onderarm. Na ongeveer 15 min
zal wat bloed worden afgenomen. Uit deze eerste bloedafname zullen, naast de
bloedsuikerspiegel, ook een aantal andere factoren bepaald worden, zoals
cholesterolgehalte en stollingsfactoren. Hierna wordt de bloedsuikerspiegel direct
bepaald met de vingerprik. Vervolgens krijgt u een suikerdrankje te drinken en na 30
minuten wordt voor de tweede maal via het reeds ingebrachte infuus wat bloed
afgenomen. Een uur en twee uur na het drinken van het suikerdrankje zal er nogmaals
via het infuus wat bloed worden afgenomen. Tevens wordt na twee uur de
bloedsuikerspiegel nogmaals direct gemeten middels db vingerprik. In totaal wordt er
dus vier keer via het infuus bloed bij u afgenomen en twee keer een vingerprik
uitgevoerd om (onder andere) het verloop van de bloedsuikerspiegel na het
suikerdrankje te kunnen bepalen. De eerste keer wordt ongeveer 85 ml bloed
afgenomen. De tweede, derde en vierde keer wordt 10 ml bloed afgenomen. U wordt in
totaal echter maar 1 keer in de arm geprikt (aan het begin van het onderzoek) en 2 keer
in de vinger (aan het begin en aan het eind van het onderzoek). In totaal zullen er 21
buisjes bloed afgenomen worden, hetgeen overeenkomt met 125 ml bloed (= 0,125
liter; u heeft zelf ongeveer 5,0 liter bloed).
L/rine.
De urine wordt onderzocht op mogelijke eiwit-uitscheiding. Hiervoor dient u de eerste
ochtendurine op de eerste ochtend van het onderzoek op te vangen in bv. een oud
jampotje dat u eerst goed heeft afgewassen, nagespoeld en afgedroogd. U kunt hier
ook een urinepotje bij uw apotheek voor kopen. Na afloop van uw bezoek krijgt u van
ons een tweede potje mee om de ochtendurine op te vangen op de ochtend van uw
tweede bezoek.
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VragenArysten.
Om de invloed van levensgewoonten na te gaan wordt u gevraagd een algemene
vragenlijst en een gezondheidszorg-vragenlijst in te vullen wat ongeveer een half uur
duurt. Deze vragenlijsten zullen door ons opgestuurd worden. U wordt gevraagd deze
volledig ingevuld mee te nemen naar het eerste bezoek. De vragenlijst bevat vragen
met betrekking tot de volgende onderwerpen: lichamelijke inspanning, rookgewoonten,
symptomen van suikerziekte, mogelijk geneesmiddelen gebruik en uw lichamelijke
gezondheid. Tijdens de pauzes tijdens de bloedafnames krijgt u een
voedingsvragenlijst en een erfelijkheidsformulier. De voedingsvragenlijst kan direct ter
plaatse worden ingevuld en het erfelijkheidsformulier worden mee naar huis gegeven.
Het ttveede toezoefr:
U wordt gevraagd naar het ziekenhuis of de universiteit te komen. Deze keer hoeft u
niet nuchter te zijn en kunnen de metingen ook 's middags plaatsvinden, maar u wordt
wel gevraagd geen alcohol, koffie en thee te gebruiken en niet te roken vanaf 22:00 uur
de dag voor het onderzoek. Ook wordt u gevraagd in de twee uur voorafgaande aan de
metingen niet te eten en de avond voor de metingen geen zware inspanningen te
verrichten.
Ha/ss/agacter-onderzoe/c.
Er zullen metingen van de dikte van de wand van een bloedvat in de hals gedaan
worden met behulp van een echo-apparaat dat zonder druk op de huid van de hals
geplaatst wordt. Voor deze laatste meting wordt u gevraagd gedurende 45 minuten
rustig op een bed liggen. Dit onderzoek geeft geen extra risico voor de gezondheid.
Tevens zal de bloeddruk gemeten worden en er zal een hartfilmpje (ECG of
electrocardiogram) gemaakt worden.
/./c/jaamssamensfe///ng.
De lichaamssamenstelling wordt volgens vijf methoden gemeten. Bij de eerste methode
wordt uw lengte en uw gewicht bepaald De tweede methode bestaat uit het meten van
de omtrek van uw taille en heupen met behulp van een meetlint. Bij de derde methode
wordt gebruik gemaakt van een schuifmaat om de doorsnede van de buik van links
naar rechts en van voor naar achter te meten. De vierde methode bestaat uit het meten
van de huidplooidikte van de arm, schouderblad en bekken. Dit wordt gedaan met
behulp van een soort tang en is geheel pijnloos. Uit deze metingen kan het
vetpercentage berekent worden. Bij de vijfde en laatste methode zal met een
bioimpedantiemeter de weerstand van uw lichaam worden gemeten op een eveneens
pijnloze wijze. Wij berekenen hieruit de lichaamssamenstelling.
L/rine.
U wordt opnieuw gevraagd de eerste ochtendurine op te vangen in het potje dat u bij
uw vorige bezoek hebt meegekregen en dit mee te brengen naar uw tweede bezoek.
Vragen/z/sf.
U wordt gevraagd het erfelijkheidsformulier ingevuld mee te brengen naar het tweede
bezoek. Het invullen hiervan zal ongeveer een half uur tot een uur duren.
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Risico's.
De bovengenoemde metingen en procedures vormen geen extra risico voor uw
gezondheid. Mocht u toch nadelige medische gevolgen ondervinden ten gevolge van
een van de onderzoeken of procedures dan is de Lhiversiteit Maastricht, als instituut,
hiervoor verzekerd. evenals het Academisch Ziekenhuis Maastricht. U vindt, ten
bewijze hiervan, een afschrift toegevoegd. Deze verzekering bestond overigens altijd
al. Nadat u schriftelijk en mondeling van informatie bent voorzien over dit onderzoek
door de onderzoekers. kan het voorkomen dat er bij u behoefte bestaat aan nadere
inlichtingen over dit onderzoek of over de procedures Het is mogelijk om deze zaken
ook met een onafhankelijk (i.e. niet bij het onderzoek betrokken) arts te bespreken,
namelijk de heer P. de Leeuw, internist, of de heer A. Kroon. internist, werkzaam in het
Academisch Ziekenhuis Maastricht, afdeling Interne Geneeskunde, telefoon: 043-38
77005.
' "-•- ••".. J. f i
Privacy
Al uw gegevens worden vertrouwelijk behandeld. Om de privacy te waarborgen wordt
er op onderzoeksdocumenten geen naam, maar een deelnemersnummer vermeld.
Resultaten van de lichamelijke onderzoeken zullen altijd aan u medegedeeld worden.
Wanneer u de uitkomsten niet wenst te vernemen kan daartegen bezwaar gemaakt
worden. De uitslagen van het DNA-onderzoek zullen niet medegedeeld worden in
verband met de anonieme verwerking ervan.
Toestemming tot deelname
Deelname aan deze studie is geheel vrijwillig. U kunt op ieder moment uw
medewerking, ook zonder opgaaf van redenen, opzeggen. Voor de start van de studie
zullen wij u vragen een verklaring te tekenen waarin u aangeeft voldoende
gemformeerd te zijn over het onderzoek en toestemming geeft tot deelname. Na
toestemming tot deelname zullen uw adresgegevens door het RIVM worden
overgedragen aan de Universiteit Maastricht.
U kunt uiteraard ook gedurende het onderzoek te alien tijde om nadere inlichtingen
vragen. Mocht u ooit, in het kader van een verzekering of keuring, gevraagd worden of
u bent onderzocht op erfelijke afwijkingen, dan geldt uw medewerking aan dit
onderzoek niet als een erfelijkheidsonderzoek, en kunt u de vraag met 'nee'
beantwoorden.
Voor vragen kunt u terecht bij:
Drs M. Kruijshoop, onderzoeker, tel: 043 3881638
Drs. MR. Mensink, arts-onderzoeker, tel: 043 3881638
Dr. E.E. Blaak, senior-onderzoeker en voedingsdeskundige, tel: 043 388139
Prof. Dr. T.W.A. de Bruin, projectleider en internist-endocrinoloog, tel: 043 3877019
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Abstract
The study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM) is a 3 years randomised
clinical trial designed to evaluate the effect of a combined diet and physical activity intervention program on
glucose tolerance in a Dutch population at increased risk for developing type 2 diabetes. Here the design of
the lifestyle-intervention study is described and results are presented from the preliminary population
screening, conducted between March 1999 and June 2000. In total, 2820 subjects with an increased risk of
having disturbances in glucose homeostasis (i.e. age >40 years and BMI>25 kg/m* or a family history of
diabetes) underwent a first oral glucose tolerance test (OGTT). Abnormal glucose homeostasis was detected
in 826 subjects (30 4%) 226 type 2 diabetes (type 2DM, 8.3%), 215 impaired fasting glucose (IFG, 7.9%) and
385 impaired glucose tolerance (IGT, 14.2%). Both increasing age and BMI were strongly related to the
prevalence of IGT and diabetes. After a second OGTT, 114 subjects with glucose intolerance and in
otherwise good health were eligible for participation in the intervention study (SLIM). The high prevalence of
disturbances in glucose homeostasis observed in the preliminary screening underscore the importance of
•arty (lifestyle) interventions in those at risk for developing diabetes. SLIM will address this topic in the Dutch
population.
Study design and preliminary screening
1. Introduction
Type 2 diabetes mellitus is rapidly becoming one of the main health issues in the 21*'
century. Prevalence has increased explosively in the last two decades, and global
estimates indicate a further rise from a current 150 million people with diabetes, to 300
million in 2025 (1.2). Impaired glucose tolerance (IGT) is the obligatory transition state
preceding type 2 diabetes. Prevalence of IGT varies widely between populations, from
as low as 2.0% in rural populations to more than 20% in high-risk populations (3) The
cumulative incidence of type 2 diabetes in subjects with IGT ranged from 3.6 to 8.7%
per year in six prospective studies (4), and is strongly related to the fasting and the 2h
plasma glucose concentrations at the time of IGT recognition (4.5) The most important
modifiable risk factor for progression from IGT to diabetes is obesity. Body mass index
(BMI) at the time of IGT recognition is a strong predictor of progression, independently
of fasting and 2-h blood glucose concentrations (4) Dietary factors, especially a high fat
intake, are also related to the risk of conversion from IGT to diabetes (6).
Several recent studies have reported the feasibility and efficacy of interventions to
prevent or delay the progression to type 2 diabetes in subjects with IGT (7-13).
Acarbose, (13). as well as metformin (12), have been shown to reduce the incidence of
diabetes in a population with IGT. Other studies have focused on the potential of
lifestyle changes t> reduce the progression rate from IGT to type 2 diabetes. The
Finnish diabetes prevention study (DPS) (11) and the US diabetes prevention program
(DPP) (12) reported that weight-loss, changes in dietary intake, and increased physical
activity resulted in a 58% reduction in the incidence of diabetes after a mean follow-up
of only 3 years. Moreover, lifestyle-intervention was much more effective in reducing
the incidence of diabetes than pharmacological intervention (i.e. metformin) (12). It is
important to confirm these observations in different populations, with a different dietary
and physical activity background, and a different attitude towards changing lifestyle-
habits.
The study on lifestyle-intervention and impaired glucose tolerance Maastricht
(SLIM) is a 3 years randomised clinical trial designed to evaluate the effect of a
combined diet and physical activity intervention program on glucose tolerance in a
Dutch population at increased risk for developing type 2 diabetes. Furthermore, we will
consider changes in anthropometric measurements, aerobic capacity and
cardiovascular risk factors. Additional measurements will be performed in subgroups of
the study population in a search for underlying mechanisms.
The objective of this report is to describe the design of the lifestyle-intervention
study and to evaluate the results of the preliminary population screening, from which
the subjects were recruited for the intervention study. Data are presented about the
prevalence of disturbances in glucose homeostasis in a middle-aged Dutch population.
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2. Study design and methods
SLIM is designed to study whether a diet/physical activity intervention program can
improve glucose tolerance in subjects with a high risk for developing type 2 diabetes
mellitus. The total duration of the study is 3 years. The medical ethical review
committee of Maastricht University approved the study protocol, and all subjects gave
their written informed consent before the start of the study.
2.1. Recruitment of subjects
The recruitment period started in March 1999 and was completed at the end of May
2000. :-.-: r
2.7. t. Pre//m/nary screen/ng
Subjects with an increased risk for glucose intolerance, i.e. those of age >40 years and
a family history of diabetes or a BMI>25 kg/rn^, were selected from a large existing
cohort, monitoring health and disease in the general population (14), and invited to
undergo a standard oral glucose tolerance test (OGTT) (glucose load 75 g) (15). Blood
glucose was measured in capillary blood using the Glucometer Elite Bayer, Zurich,
Schweiz). Furthermore, body weight was measured, without wearing shoes and
jackets. Subjects with known diabetes, or those with fasting glucose values >8.5
mmol/L did not participate in the OGTT.
2.f.2. Second OG 7T
Those subjects with a 2h blood glucose concentration >7.8 mmol/L at the preliminary
screening and which were otherwise in good health (i.e. no history of cardiovascular
disease, or any (chronic) disease or medication use that makes participation in a
lifestyle intervention program impossible) were invited for a second OGTT During this
second OGTT, glucose tolerance was measured in venous plasma. Furthermore a
medical history was taken, a physical examination was performed and several
additional measurements were performed (see Section 2.3, below).
2.13. F/na/ recru/fmenf
For definitive inclusion in the lifestyle-intervention study, mean 2h glucose
concentration of both OGTTs had to be between 7.8 and 12.5 mmol/L, together with a
fasting glucose concentration of less than 7.8 mmolL. Other inclusion and exclusion
criteria for participation in the intervention study are indicated in Table 1. To follow
changes in glucose tolerance over time, data obtained by the second (venous) OGTT
were used as baseline values.
Study design and preliminary screening
Tabte 1 Indusion and exclusion crrtena for the lifestyle-intervention study (SLIM).
Inclusion criteria Mean 2-h blood glucose > 7.8 and < 12.5 mmoVL
Mean fasting blood glucose < 7.8 mmoVL
Caucasian
Age 40-70 yeare
Exclusion cntena Known diabetes mellitus
Mean 2-h blood glucose > 12 5 mmol/l
Mean fasting blood glucose > 7 8 mmolLI
Any chronic illness that makes 5-years survival improbable, or that interferes with
glucose tolerance, or that makes participation in a lifestyle-intervention imposttbtt
Mediation known to interfere with glucose tolerance
Participation in a vigorous exercise and/or diet program
After final recruitment, subjects were randomised to two study groups, the lifestyle
intervention group or the control group. Randomisation was carried out with
stratification for sex and mean 2h plasma glucose concentration.
Based on the preliminary results after 1 year of the Finnish DPS (16), we calculated
that 50-60 subjects per group would be sufficient to detect a 1,0 mmol/L difference in
the 2h glucose concentration between groups.
2.2. Lifestyle-intervention program
The intervention program consists of a dietary and physical activity part.
2.2. f. D/efary /nfervenf/on
Dietary recommendations are based on the Dutch guidelines for a healthy diet (Dutch
Nutrition Council, 1992, see Table 2). Participants are encouraged to stop smoking and,
if necessary, to reduce alcohol intake. Dietary advice is given at regular intervals by a
skilled dietician on an individual basis after consideration of a 3 days food record (see
Table 2). A body weight loss of 5-7% is the objective. If subjects do not loose weight on
this regimen during the first year, mild energy restriction is prescribed during the second
year. No very-low calorie diet or dietary products are used to encourage weight loss.
2.2.2. £xerc/se /ntervenf/on
Subjects are encouraged to increase their level of physical activity to at least 30 min of
moderate physical activity a day for at least 5 days a week (17). Individual advice is
given on how to increase daily physical activity (walking, cycling, swimming), and goals
are set. Furthermore, subjects are encouraged to participate in an exercise program,
especially designed for this study, including components of aerobic exercise training
and components of resistance training (18). Subjects have free access to these training
sessions, and are stimulated to participate for at least 1 h a week. Participation in the
exercise sessions is recorded.
2.2.3. Conrro/ group
Subjects in the control group are given oral and written information, about the beneficial
effects of a healthy diet, weight loss and increased physical activity, whereas no
individual advice or programs are provided. No additional appointments are scheduled,
apart from the annual visits for follow-up measurements.
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Table 2: Details of the dietary intervention.
Dietary guidelines
Carbohydrates:
Fat:
Proteins:
Fiber
± 55% energy
Maximum 15 - 25% energy mono- and
disaccharides
3 0 - 3 5 %energy
S 10% energy saturated fatty acids
< 33 mg/MJ cholesterol, maximal 300 mg a day
1 0 - 15% energy
± 0.8 g/kg bodyweight
>3g/MJaday
Visit Tim* Visit and Topic
1
2
3
4
S
6
7
S
9
10
11
12
13
14
0
4-6 weeks
3 months
6 months
9 months
12 months
15 months
18 months
21 months
24 months
27 months
30 months
33 months
36 months
Baseline visit
Discussion baseline food-record
Faf
'Carbohydrates'
Group-session: 'label-reading' and 'novel foods'
1-year meeting
'Artificial sweeteners'
'Special occasions, e.g. a party'
Group-session: a dietary game'
2-year meeting
'Vegetarian food'
Vitamins and minerals'
Group-session: lifestyle and diabetes'
3-year meeting
2.3. Measurements
At the start of the study, and every year thereafter several measurements are
performed, in both the intervention and control group.
2.3. f. Laboratory assessmen/s
A standard OGTT is performed every year, according to the guidelines described by the
WHO (15). Venous blood samples are immediately centrifuged and plasma is frozen at
-80 °C until analysis. Plasma glucose and FFA concentrations are measured using
standard enzymatic techniques (Glucose HK 125, ABX diagnostics, Montpellier,
France; FFA-C test kit, Wako Chemicals, Neuss, Germany, respectively). Plasma
insulin concentration is measured with an ELISA assay (Mercodia, Uppsala, Sweden)
which shows no cross-reactivity with pro-insulin. Glycated haemoglobin (HbA1c) is
determined with the HPLC technique (reference value for our laboratory 4.4-6.2%).
Insulin sensitivity is estimated with the HOMA-index and insulin secretion with the
insulinogenic index 30' (Insulin30-lnsulin0)/(glucose 30-glucose0) (19). Blood lipids are
measured with standard enzymatic techniques in fasting serum samples (triglycendes:
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Sigma. St Louis, USA; cholesterol: cholesterol 100. ABX diagnostics; HDL: HDL-C
Roche, Indianapolis, USA). LDL cholesterol is calculated according to the formula of
Friedewald (20). -1
2.3.2. dnfhropomefry
Body weight is measured on an electronical scale BMI is calculated as the ratio of
weight and height squared (kg/m\ Skinfold measurements are performed to calculate
fat mass, fat free mass and body fat percentage (21) Waist circumference (waist) is
measured at the level midway between the lowest rib and the iliacal crest. Hip
circumference is measured as the maximum circumference over the buttocks Sagittal
and transverse abdominal diameter are measured with the subject in a recumbent
position, at the level of the iliacal crest using a sliding beam calliper.
2.3.3. Max/ma/ aerob/c capac/ry
To evaluate changes in aerobic fitness, an incremental exhaustive exercise test is
performed on an electronically braked bicycle ergometer (Lode Excalibur, Groningen,
Netherlands) The test starts at a workload of 0 75 W/kg FFM for 3 mm, followed by 3
min at 1.5 W/kg FFM. Subsequently, workload is increased every 3 min by 0 5 W/kg
FFM until exhaustion. 02 consumption and CO2 production are measured with an
Oxycon-Beta (Mijnhardt, Breda, Netherlands) to define maximal peak VO2.
2 3.4. Orrter measuremenfs
At every (annual) visit a physical examination is performed, including recording a 12-
lead resting ECG. Blood pressure is measured twice on the right arm with a standard
sphygmomanometer, after at least 10 min of rest Subjects taking any blood pressure-
lowering medication are asked not to take these on the morning of the measurements.
A 3 days food record (2 weekdays and 1 weekend day) is kept at the start of the study
and every year thereafter. Food records are checked by a dietician and intake of
nutrients is calculated with a computer program according to the Dutch food table.
2.3.5. Oufcome
Primary outcome measure is the change in glucose tolerance (i.e. 2h plasma glucose),
one of the most important risk factors for progression to diabetes (4). Secondary
outcome measures are changes in fasting plasma glucose concentration, plasma
insulin concentration, insulin resistance, HbA1c, and changes in body weight, body
composition and V02max. Furthermore changes in cardiovascular risk factors are
assessed (blood pressure and blood lipid profile).
2.4. Statistical analysis
Data from the intervention study are analysed according to the intention-to-treat
principle. Differences between groups (over time) are analysed by unpaired t-tests or
ANOVA (repeated measures). The level of significance is set at 0.05.
Results of the preliminary screening were analysed with ANOVA (differences
between categories) and Chi-square-testing (frequency distribution of disturbances in
glucose homeostasis).
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3. Results
In total 6108 subjects were invited to participate in the preliminary screening. Of those,
2820 subjects were willing to participate in this first OGTT. Non-response was observed
in 3288 cases (53.8%). Mean age of the non-responders was 55.7±0.1 years, which
was significantly lower than the responders (N=2820; age 56.8±0.1; p-value <0.001).
No difference was seen in gender between responders and non-responders (50.6 male
vs. 50.9% male, respectively, p=NS). After considering the selection criteria, 379 men
and women were invited for the second OGTT, of whom 177 were willing to participate.
Finally, 114 subjects, 64 men and 50 women, were included in the lifestyle intervention
study (SLIM).
From the 2820 subjects participating in the screening OGTT, 105 were excluded
from the analysis: 48 because of recently diagnosed diabetes; 57 because of non-
Caucasian ethnicity, non-fasting state, or incomplete data. Results from the remaining
2715 subjects are depicted in Table 3. WHO criteria of 1999 for capillary plasma were
applied, as the Glucometer Elite measures glucose levels equivalent to capillary plasma
(15). Abnormal glucose homeostasis was detected in 826 subjects (30.4%): 226
subjects with type 2 diabetes (type 2DM, 8.3%), 215 with impaired fasting glucose (IFG,
7.9%) and 385 with impaired glucose tolerance (IGT, 14.2%). Of the latter group,
almost two-thirds (N=244) had normal fasting glucose (NFG/IGT) and one-third (N=141)
impaired fasting glucose (IFG/IGT). The prevalence of type 2 DM and IFG was higher
among men than women. A strong upward trend for age and BMI was seen from NGT
to type 2 DM, with IGT and IFG in between (Table 3).
In Table 4 the prevalence of NGT, IFG, IGT and type 2 DM is given for age and BMI
groups, for men and women separately. In both men and women, prevalence of
disturbed glucose homeostasis increased with age, except for IFG which reached the
highest prevalence in the age group of 55-59 years. In the population of 65 years and
j or' »flir ,mnr a?rtr' Jl>?J"/%' v/i' if It* *v\jirieii i lau' uuimai '
homeostasis. In men and women with a BMI above 30 kg/m*, diabetes was three times
more prevalent and IFG and IGT were two times more prevalent, compared with those
with a BMI below 27 kg/rn^. The prevalence of newly diagnosed diabetes was almost
two times higher in men than in women in each BMI and age group. Likewise, IFG was
1.5 times more frequent in men than in women, especially in the age groups below 55
years. Additionally, more women were normoglycaemic than men (p<0.001).
Table 3: Results of the preliminary screening (N=2715).
NGT IFG IGT type 2 DM P-value'
number (%(N)) 69 9(1889) 7.9(215) 14.2(385) 8.3 (226)
sex
age
BMI
FBG
2hBG
(% male)
(year)
(kg/nV)
(mmol/L)
(mmol/L)
47.5
55.9
28.0
5.2 t
6.5 t
±0.2
±0.1
0.1
0.1
61.2
58.8
29.7
6.3 ±
6.8 ±
±0.4
±0.3
0.1
0.1
49.1
57.1 ±0.5
29.5 ± 0.2
5.8 ±
10.1
0.1
±0.1
67.8
59.8 ± 0.4
30.6 ± 0.3
7.4 ±0.1
13.0 ±0.2*
< 0.0001
O.0001
<0.0001
<0.0001
<0.0001
Data are mean t sem; FBG = Fasting Blood Glucose, 2h BG = 2-hour Blood Glucose:' ANOVA. comparison
of frequencies was done by a Chi-square tes t; * subjects with fasting glucose > 8.5 mmot/1 did not undergo an
OGTT (N=28).
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Table 4: Prevalence of cSsturbance* in glucose ha
women separately (N=2715).
Age
<50
50-54
55-59
60-64
- 6 5
BMt
<27
27-30
= 30
Total
MEN
N
289
256
289
301
238
477
484
412
1373
DM
6 6
7.8
11.1
14.0
168
6.7
8.9
18.9
11.1
IGT
8.0
10.2
14.5
16.3
206
10.5
10.5
21.4
13.8
IFG
6.2
13.7
12.5
9.0
7.1
6.1
9.7
13.8
9.7
moostsbs
NGT
79.2
684
61.9
60.8
55.5
76.7
70.9
45.9
654
according to age and BMI groups
WOMEN
N
254
252
281
322
233
515
415
412
1342
DM
0.8
2.4
6.8
8.6
10.3
3.1
4.1
9.7
5.4"
IGT
9.1
13.9
14.6
15.8
19.7
10.1
15.7
19.2
14.6
.for men and
IFG
24
6.7
7.8
6.8
64
4.1
5.5
9.2
6.1"
NGT
87.8
77.0
70.8
70.5
63.5
82.7
74.7
61 9
73.8"
** p<0.001 between sexes (Chi-square test).
4. Discussion
4.1. Lifestyle-intervention
The justification of lifestyle-intervention studies is that they may prevent or postpone the
onset of type 2 diabetes and related complications. Both the Finnish DPS and the US
DPP reported that changing dietary and physical activity habits reduce the incidence of
diabetes by about 58% (11.12). Confirmation of these results in different populations is
important. SLIM will consider this in a middle-aged Dutch population at increased risk
for diabetes. The Dutch population has a low prevalence of obesity (22), and Dutch
subjects are known for their relatively high level of physical activity. In 1997 slightly
more than one-half of the population was, on average, moderately active for more than
half an hour per day (23), compared with about one-third of US adults (24). As obesity
and physical activity are important factors associated with diabetes, it is important to
know whether lifestyle changes result in a comparable risk reduction in the Dutch
population as in the Finnish and American population.
Dietary and physical activity intervention strategies are combined, as earlier reports
indicated that the combination is most effective (25,26). The intervention strategy in this
randomised study is based on general public health recommendations for nutritional
intake and physical activity. A regimen, based on general recommendations, is much
more suitable to prevent diabetes, as it is less time consuming and much better
tolerated than very intensive intervention programmes. Furthermore, we will perform
additional measurements in small subgroups of the intervention and control population
(N=10 per group) using stable isotopes, indirect calorimetry and muscle biopsies. Since
type 2 diabetes and IGT are characterised by disturbances in skeletal muscle fatty acid
uptake and oxidation (27-29), the question will be addressed whether changes in
glucose tolerance are accompanied by changes in skeletal muscle fatty acid
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metabolism. These additional measurements could identify some of the mechanisms
underlying the development of insulin resistance and type 2 diabetes mellitus. ?..
4.2. Methodological considerations
Participation rate was relatively low in the present study, approximately 50%. As
subjects were selected from an ongoing monitoring project for health and disease,
some research-fatigue' could not be excluded, and this could have led to some
selection bias. Classification of the subjects was based on a single OGTT (with the
Glucometer Elite), and was not confirmed by repeated testing as recommended. Some
misclassification might have occurred because of the known high intra-individual
variability in glucose levels. However, a previous Dutch study showed that the
prevalence of IGT and diabetes was not different between the first and the second test
(30). Only when the diagnosis was based on meeting classification criteria at both
OGTT's, did the prevalence decrease. Finally, we tested the consistency in
classification between measurements made with the Glucometer Elite and
measurements made with a standard enzymatic technique in venous plasma.
Consistency in classification according to the WHO criteria was good (69%, kappa 0.55,
p-value<0.001; N=245; (31)).
4.3. Preliminary screening
The results of the preliminary screening confirm the high-risk profile of the population
under study. Three out of every ten subjects had disturbed glucose homeostasis, which
is quite comparable with the results reported in the STOP-NIDDM trial, which also
screened in a high-risk population (32). The prevalence of IGT and newly diagnosed
diabetes in the screening population was higher than reported in the Dutch Hoorn Study
over the period 1989-1992 (10.3% for IGT and 4.8% for newly diagnosed diabetes
(33)). This may reflect the world-wide increasing prevalence of disturbances in glucose
homeostasis (1), and parallels the increasing prevalence of obesity reported in the
Dutch population (22). However, in the Hoorn study the old WHO criteria (1985) were
used. Since the fasting glucose level for the diagnosis of diabetes has now been
reduced, this could partly explain the higher prevalence of diabetes in our study, but not
the higher prevalence of IGT.
In line with other populations, the present study confirmed that IGT is considerably
more prevalent than IFG, and that overlap between the two categories is limited (3).
This limited overlap points towards the difference in metabolic background: IGT is
primarily associated with insulin resistance while IFG is associated with a more
pronounced defect in insulin secretion and endogenous glucose output (34).
A strong positive relation was observed between increasing age and prevalence of
IGT and diabetes. For IFG, the highest prevalence was seen in middle-aged subjects
(aged 55-59 years). This is a consistent finding in European populations, particularly
among men (3). The prevalence of disturbances in glucose homeostasis was almost 2-
fold higher in the group with a BMI>30 kg/m^ compared with those with a BMI<30
kg/m*. This underscores earlier reports, showing dramatic increases in the relative risk
of diabetes in the highest BMI groups, compared with the lowest BMI group (35).
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Type 2 diabetes is generally more prevalent in women compared with men (1). In
contrast, we observed a prevalence of diabetes being two times higher in males than in
females, in all BMI and age groups. In the Ftnnmark study (36), BMI was reported to be
a dominant risk factor for both sexes. In women, however, the relationship was
confounded by other factors such as blood pressure, height. HDL. glucose, smoking
and physical activity. Furthermore, in addition to over-all adiposity, body fat distribution
is an important risk factor for diabetes (35). Thus, differences in other risk factors,
beside age and BMI, can underlie the observed higher prevalence of diabetes in men in
the present study. ^ ^
4.4. Conclusion
The high prevalence of disturbances in glucose homeostasis observed in the
preliminary screening underscores the importance of early interventions in those at risk
for developing diabetes. Changes in dietary habits and physical activity have shown to
reduce the incidence of diabetes. Additional studies are required to confirm these
results in different populations with a dfferent dietary and physical activity background.
SLIM will address this question in the Dutch population.
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Background: The use of an oral glucose tolerance test (OGTT) has been recommended to diagnose type 2
diabetes, but an OGTT with venous bkxxj sampling may not be feasible in the screening phase preceding
large epidemiological studies. We have conducted a population-based screening in 2715 men and women
and evaluated the diagnostic validity of capillary plasma glucose concentration measurements versus venous
plasma glucose concentration measurements in a subset of 350 subjects.
Method: During a single OGTT, glucose concentrations were measured in venous plasma as well as in
capillary plasma.
Results: Based on the 1999 WHO criteria for venous glucose concentrations, the study population (N=350)
yielded 97 subjects with type 2 diabetes mellitus, 77 subjects with impaired glucose tolerance and 176
subjects with normal glucose tolerance. Sensitivity and specificity to diagnose type 2 diabetes mellitus by
capillary plasma were 84% and 98%, respectively Consistent classification by either venous or capillary
plasma glucose measurements was 78% (k = 0.65, p<0.001).
Conclusion: Capillary glucose measurements are suitable for use in epidemiological studies to diagnose and
detect type 2 diabetes and normal glucose tolerance. Use of capillary measurements can result in cost-
effective Inclusion schemes in epidemiological studies.
Validation of capillary glucose measurements
1. Introduction
The standard 75-g oral glucose tolerance test (OGTT) has been recommended by the
World Health Organization (WHO) in population studies of glucose intolerance and
diabetes (1). Capillary blood glucose measurements may constitute an alternative for
venous blood glucose measurements in population studies, specifically during the
screening phase, because they are easier, less expensive and less invasive to obtain.
Capillary blood sampling requires less skills, but resulting glucose measurements may
be more dependent on the properties of the materials used and may have a different
time course of glucose concentrations. Recent studies have shown that modern hand-
held glucose measuring devices have excellent technical characteristics and yield
similar results as for reference laboratory methods (2.3). However, very few studies
have addressed the performance of hand-held glucose measuring devices in the setting
of a large-scale epidemiological study.
Several reports have evaluated differences between capillary and venous blood
samples in whole blood and plasma (4-13). Most reports indicate that there is no
difference in measured glucose concentrations in capillary and venous blood samples
in the fasting state (4-7,12). They also reported that capillary blood glucose
concentrations are higher than venous blood glucose concentrations in the non-fasting
state, both in subjects with and without diabetes. Recently, new criteria have been
published by the American Diabetes Association (ADA) (14) and the WHO (1) to
diagnose type 2 dabetes based on glucose levels in venous plasma and whole blood,
as well as in capillary plasma and whole blood. This has led to further evaluation of
these criteria in recent literature (15-18). It was the objective of the present study to
evaluate whether capillary blood glucose measurements are a valid method to screen
populations for type 2 diabetes in comparison to the standard venous OGTT using the
1999 WHO criteria. We therefore examined: (a) diagnostic properties of capillary blood
glucose measurements; (b) differences between capillary and venous blood glucose
measurements, both in the fasting and non-fasting state; and (c) the impact of the
degree of glucose tolerance on capillary and venous glucose concentrations after an
OGTT.
2. Materials and Methods
2.1 Subjects
The Cohort study Diabetes and Atherosclerosis Maastricht (CoDAM) is a prospective
population-based cohort study in the Netherlands directed at the effects of glucose, i.e.
normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes
mellitus (DM), and at the effects of lipids, lifestyle and genetics on cardiovascular
complications. Inclusion criteria were: age 40-70 years and either a BMI > 25 kg/m , a
positive family history for type 2 diabetes mellitus, a history of gestational diabetes, the
use of antihypertensive medication, a postprandial blood glucose larger than 6.0
mmol/L or glucosuria. Combinations of these separate inclusion criteria were allowed.
Exclusion criteria were the use of medication that affects glucose metabolism and non-
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Caucasian ethnicity. From February 1999 until March 2000, 2715 subjects participated
in the screening phase of the CoDAM study which was carried out with capillary plasma
glucose measurements. According to the 1999 WHO criteria for capillary glucose (1),
226 of 2715 subjects (8.3%) had newly diagnosed DM, 385 (14.2%) were IGT, 215
(7.9%) had impaired fasting glucose (IFG) and 1889 (69.6%) were classified as NGT.
All newly diagnosed DM subjects, as well as 291 IGT and 728 NGT (randomly
selected) subjects were invited to the inclusion phase of the CoDAM study. Moreover,
49 subjects who were known to have had DM for more than 1 year but no longer than 4
years were invited. Participants underwent a second OGTT with venous plasma
glucose measurements (see below) in order to establish their glucose tolerance status.
Eventually, 100 newly diagnosed DM, 47 known DM, 103 IGT, 25 IFG and 299 NGT
subjects were included in the CoDAM study (N = 574, response 46%). Of these 574
subjects, 350 were consecutively included in the present study. All subjects gave
written informed consent. The study was approved by the local Medical Ethical
Committee of the University of Maastricht and University Hospital Maastricht.
2.2 Measurements
Glucose tolerance was defined according to the 1999 WHO criteria (1) and was
measured by a standard 75-g oral glucose tolerance test as follows: after an overnight
fast, a Venflon catheter (Becton-Dickinson, Sweden) was inserted into an antecubital
vein and a blood sample was taken (NaF containing tube) for measurement of fasting
glucose concentration in venous plasma. Immediately thereafter, the glucose
concentration was measured in capillary whole blood from the third or fourth fingertip of
the non-dominant hand, using Glucometer Elite® (Bayer, USA). Notably, Glucometer
Elite® converts capillary whole blood values to capillary plasma values (technical data
supplied by the manufacturer, Bayer, Mijdrecht, the Netherlands). Inter-coefficients of
variation at fasting and 2h after the glucose load were 4.5% and 9.3%, respectively
(19). Subsequently, a 75-g glucose load (analogous to 82.5 g dextrose monohydrate,
Avebe, the Netherlands) in 250 ml plain water was given. A few drops lemon juice were
added for taste adjustment. Two hours after the glucose load, a venous blood sample
was taken. Immediately thereafter, a capillary whole blood sample was taken from the
same fingertip as with the fasting measurement. Plasma glucose was measured with
the hexokinase glucose-6-phosphate dehydrogenase method (HK-G6PD method, ABX
Diagnostics Glucose HK125, Montpellier, France). To measure accuracy of the capillary
measurement, 39 subjects underwent two successive measurements on two different
fingers, both at fasting and 2h after the glucose load. Intra- and inter-coefficients of
variation were 2.1% and 1.8%, respectively (19). Height (in cm) and body mass to the
nearest 100 g were measured without shoes and wearing light indoor clothing. BMI was
calculated in kg/rn^.
2.3 Statistical Methods
Statistical analyses were performed by SPSS 6.1.1 for Macintosh. Data are presented
as mean ± S.D. The statistical significance of differences between the glucose
tolerance groups was evaluated using analysis of variance (ANOVA) and Bonferroni
post hoc test A two-sided p value of less than 0.05 was considered significant.
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Correlation and linear regression analyses were performed. Results obtained using
venous and capillary plasma glucose measurements were compared using the method
of Bland and Altman (20) in which differences between paired measurements are
plotted against the mean of each pair. To examine the agreement between capillary
and venous blood glucose measurements, a cross table was made The overall
indicator kappa (k), which measures the agreement across all categories of glucose
tolerance, was calculated. A value of 1 indicates perfect agreement, while a value of 0
indicates that agreement is no better than chance (21). Values larger than 0.75 may be
taken to represent excellent agreement, values smaller than 0.40 may be taken to
represent poor agreement and values between 0.40 and 0.75 may be taken to
represent fair to good agreement.
3. Results
We included 207 men and 143 women (total N = 350) with a mean age of 58.9 ± 7.2
years (Table 1). Age, BMI, fasting venous glucose and 2h venous glucose
measurements for this subgroup did not differ from those of the total population of the
CoOAM study (data not shown). Capillary plasma glucose values in all subjects
combined were significantly higher than venous plasma glucose values both during the
fasting state (difference = delta (A) = 0.18 mmol/L; 95% Cl 0.10-0.26) and 2h after
glucose ingestion (A = 1.09 mmol/L; 95% Cl 0.87-1.32) (Table 1). The differences
between fasting capillary and venous plasma glucose levels were not significantly
different between the groups (DM A=0.21 mmol/L, IGT A=0.20 mmol/L, NGT A = 0.16
mmol/L) (Table 1). The capillary-venous difference at 2h post load glucose levels in
NGT subjects (A = 1.42 mmol/L) was significantly different from the difference in IGT
and DM subjects (A = 0.66 mmol/L and A = 0.58 mmol/L, respectively).
3.1 Capillary versus venous glucose measurements
A high correlation between capillary and venous plasma glucose values was found
during fasting (r = 0.92; p < 0.0001) and at 2h post load (r = 0.83; p < 0.0001).
Regression analysis of capillary glucose measurements on venous glucose
measurements in the entire group showed an intercept of 0.05 (p = 0.70) and a
regression coefficient of 1.02 (p < 0.0001) for the fasting state. At 2 h post load, the
intercept was 2.08 (p < 0.0001) and the regression coefficient was 0.87 (p < 0.00001).
Because a high correlation coefficient does not necessarily mean that two methods
agree satisfactorily, a Bland-Altman plot (20) was calculated at fasting and at 2h after
the glucose load (Figs. 1 and 2). Differences between paired measurements have been
plotted against the mean of each pair and the horizontal top and bottom lines represent
the mean ± 2 S.D., respectively.
In the fasting state, discrepancies were observed in the lower range of blood
glucose values (< 4.0 mmol/L), whereas at 2h post load, discrepancies were found over
the entire range of blood glucose values. Subjects with IGT and NGT had significantly
higher capillary glucose concentrations than venous glucose levels, both fasting and 2h
post load (p < 0.05) (Table 1). In DM, fasting, but not 2h post load, capillary glucose
values were significantly higher than venous glucose values.
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Table 1: Characteristics of the entire study group (N=350) and the three glucose tolerance categories
according to classification by venous blood glucose concentrations.
Number (N)
Men (%)
Age (years)
BMI (kg/m*)
Fasting glucose C (mmol/L)
Fasting glucose V (mmol/L)
2h Glucose C (mmol/L)
2h Glucose V (mmol/L)
Delta C-V fasting (mmol/L)
(95% Cl)
Delta C-V 2h (mmol/L)
(95% Cl)
Total 350
59
58.9 ± 7.2
28.6 ±4.1
6.0±1.3t
5.8 ±1.0
8.7 ± 3.4t
7.6 ± 3.3
0.18
(0.10-0.26)
1.09
(0.87-1.32)
DM97
69
58.3 ± 5.8
30.2 ±4.1*
7.7±1.7*t*
7.5 ±1.3'*
13.7±3.9*±
13.1 ±3.2't
0.21
(-0.08-0.51)
0.58
(-0.19-1.34)
IGT 77
60
59.8 ± 6.9
29.1 ±4.1
6.1 ±0.8'f
5.9 ± 0.5*
9.4 ± 2.6*t
8.7 ±1.6*
0.20
(0.04 - 0.36)
0.66
(0.14-1.18)
NGT 176
53
58.7 ± 7.6
27.9 ±4.0
5.4 ± 0.7f
5.3 ±0.4
7.0±1.9t
5.6 ±1.2
0.16
(0.07 - 0.25)
1.42*§
(1.20-1.65)
Data are mean ± S.D.
C • capillary plasma glucose concentrations; V = venous plasma glucose concentrations
* significantly different from NGT (p<0.05)
f significantly different from venous glucose (p<0.05)
$ significantly different from IGT (p<0.05)
§ significantly different from DM (p<0 05)
3.2 Classification of glucose tolerance status
The 350 participating subjects were stratified by glucose tolerance status as NGT, IGT
or DM, according to the 1999 WHO criteria using either venous (V) plasma glucose or
capillary (C) plasma glucose concentrations (Table 2). After application of the 1999
WHO criteria for venous plasma glucose concentrations (1), the proportion of DM was
97 of 350 (27.7%) subjects and that of IGT 77 of 350 (22.0%) subjects. The consistency
in classification between capillary and venous glucose measurements was 78% (k =
0.65, p<0.001). Sensitivity and specificity to diagnose DM by capillary glucose
measurements were 84% and 98%, respectively. Among DM subjects, 17 out of 111
subjects (15.3%) were classified as IGT by capillary glucose criteria compared with
classification by venous glucose criteria (Table 2) and thus remained glucose intolerant.
Only 1 subject was classified as NGT. In subjects with NGT, 12 out of 143 subjects
(8.4%) were classified as IGT. In subjects with IGT, 48 out of 96 subjects (50.0%) were
differently categorised of which 44 were diagnosed as NGT according to capillary
levels.
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TaMe 2: Resulting classification of glucose tolerance status in study subjects according to the 1999 WHO
criteria tor venous (V) and capiMary (C) ptesma concentrations.
Normal glucose
toterance (V)
Impaired glucose
tolerance (V)
Type 2 diabetes
mellitus (V)
Total (C)
Normal glucose
tolerance (C)
Impaired glucose
tolerance (C)
Type 2 diabetes
mellitus (C)
Total (V)
131
44
1
176
12
48
17
77
0
4
9*
97
143
96
111
350
Fig. 1: Bland and Altman plot of capillary (C) and venous (V) plasma glucose measurements in the fasting
state. The horizontal top and bottom line represent ± 2 S.D.
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Fig. 2: Bland and Altman plot of capillary (C) and venous (V) plasma glucose measurements, 2h post load.
The horizontal top and bottom line represent ± 2 S.D. . J ; J *
10 r
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• * +t ' 1-
0 10 20
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4. Discussion
The OGTT has been used in the diagnosis of diabetes or glucose intolerance when
blood glucose levels are equivocal, during pregnancy, or in epidemiological studies (1).
The OGTT in the present study had been done according to guidelines of the WHO.
Nowadays, reflectance meter measurements of glucose correspond well with reference
laboratory glucose measurements (2,3). This report presents evidence that capillary
plasma glucose measurements obtained by Glucometer Elite® are suitable for use in
the screening phase of epidemiological studies to detect type 2 diabetes mellitus. A
high correlation has been found between capillary and venous plasma glucose
concentrations (fasting r = 0.92; 2h post load r = 0.83). Moreover, the Bland-Altman plot
showed minor discrepancies in the fasting state (<4 mmol/L) between capillary and
venous plasma glucose measurements, and only in the lower glucose range. In the 2h
post load state, discrepancies occurred over the entire range of glucose levels.
The present study found capillary plasma glucose levels to be systematically higher
in the fasting state. This finding seems to contrast with those of other studies, which did
not find a difference between capillary and venous glucose measurements in the fasting
state (4-7,12). Most of these studies however did not use a commercially available
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glucose meter and had a considerably smaller number of subjects, leaving open the
possibility that significant differences may have been missed due to logistic problems or
lack of statistical power. Other studies which compared and evaluated capillary and
venous blood glucose measurements differed from the present study in their design
(i.e. in the study of specific age groups, gender, pregnant women, in the use of self-
monitoring blood glucose devices, laboratory methods and randomly taken samples
(4,6,9,10,12)). Therefore, their data may not be fully comparable with our results. The
only study in which a comparable number of subjects was used as in the present study
(N = 207) (7) also found a tendency towards higher capillary plasma glucose values in
the fasting state, although this did not reach statistical significance.
No significant difference existed between capillary and venous plasma glucose
measurements in subjects with DM in the 2h post load state. This is in contrast to
findings in IGT and NGT subjects, although the delta of DM is approximately the same
as for IGT After the ingestion of glucose, insulin secretion by the pancreas is
stimulated (22). Defects in insulin secretion at the level of the [) cell, and insulin
resistance in muscle, can lead to the development of glucose intolerance or overt
diabetes. In DM, muscle tissue is more insulin resistant than IGT and NGT (22) Such
insulin resistance results in lower glucose uptake and extraction from blood and a
smaller difference between venous and capillary plasma glucose measurements will
therefore be measured, explaining the findings in the present study in DM subjects.
Larsson-Cohn et al. (4) and West (23) already reported different relationships
between glucose concentrations in capillary and venous blood at the different time
points during an oral glucose tolerance test. This information has been incorporated in
the classification according to the 1999 WHO criteria, which take the differences
between capillary and venous plasma glucose measurements for the different glucose
tolerance groups into account. In the present study, this is shown by little disagreement
found in classification according to capillary and venous plasma glucose measurements
among NGT subjects, i.e. 12 of 143 (8.4%). In the DM category, 18 of 111 (16.2%)
were potentially misclassified, but 17 of the 18 subjects were classified as IGT and thus
remained glucose intolerant. Our findings were in agreement with Farrer et al. (11), who
found no effect of the choice of blood sampling, venous whole blood or venous plasma,
on the subsequent classification of type 2 diabetes mellitus by repeated OGTTs. In the
present study however, 48 subjects of 96 (50%) in the IGT category were misclassified,
of which 44 subjects shifted to NGT. To some degree, the lesser agreement in IGT can
be an artefact, caused by the narrow range of defined cutoff points for 2h glucose
concentrations in IGT. In addition, the background of IGT represents a diverse set of
metabolic abnormalities including insulin secretion defects and insulin resistance, and
to precisely establish IGT status remains a topic of continued discussion. With respect
to future prevention programs, it is important to realize that a diagnosis of DM or NGT
can be established by capillary plasma glucose. This knowledge can be used to create
cost-effective inclusion schemes. It is likely that subjects with IGT will be an important
target for diabetes prevention programs given the impressive results of lifestyle
intervention to prevent DM (24,25). Furthermore, a combination of lifestyle intervention
and drug treatment has been successfully utilized in several studies (25-27). Notably, in
the DPP study (28), 133,683 subjects had to be screened to enrol 3048 participants, an
1:43.9 ratio. Recently, we used capillary glucose measurements as a pre-screening tool
followed by an OGTT with venous plasma glucose measurements in a lifestyle
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intervention study (29). The ratio of screened (2715) subjects and detected IGT
subjects (385) subjects was 1:7.1, indicating that use of capillary measurements can
result in cost-effective inclusion schemes.
In conclusion, capillary glucose measurements in normal glucose tolerant and type 2
diabetes subjects are reliable and precise, using a commercially available glucose
meter. The present findings indicated that capillary plasma glucose measurements are
as suitable as venous plasma glucose measurements in the diagnosis and detection of
type 2 diabetes mellitus in epidemiological studies and may be cost-effective in
implementation in pre-screening procedures.
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Patients with type 2 diabetes are at increased risk of cardiovascular disease. However, it is insufficiently clear
at what point of the atherosclerosis process the acceleration occurs that is responsible for such an increased
risk. Therefore, we investigated Young's elastic modulus (YEM) and intima-media thickness (IMT) in 86
subjects with recently diagnosed type 2 diabetes (within 0 to 4 years before inclusion), 88 subjects with
impaired glucose tolerance and 234 control subjects with normal glucose tolerance, all selected from a
population-based cohort. Arterial stiffness, measured by YEM, was significantly increased in type 2 diabetes
whereas IMT was similar in all groups. In multivariable analysis, YEM was predicted by age, male gender,
presence of hypertension, sagittal diameter, and total cholesterol plasma concentration. When the data were
compared with similar data obtained in a collaborative cohort with subjects a decade older, a significant two-
fold increase in YEM and IMT was calculated comparing diabetes patients with NGT subjects. We conclude
that in subjects with recently diagnosed type 2 diabetes arterial stiffness was increased before IMT-thickening
had occurred. In diabetes of longer duration, both arterial stiffness and IMT were increased compared to
controls, suggesting acceleration of functional and structural vessel wall abnormalities.
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1. Introduction
Patients with type 2 diabetes have an increased incidence of macrovascular disease,
and approximately 60-70% of patients with type 2 diabetes die from atherosclerotic
vascular disease such as myocardial infarction or stroke (1,2). The main theory to
explain the increased risk of cardiovascular disease in type 2 diabetes holds that the
increase in risk is caused by an increased rate of atherosclerosis, although many
questions remain unanswered One of the main questions is at what stage of
atherosclerosis development the acceleration occurs. Is this at the phase of endothelial
dysfunction, arterial wall changes, plaque formation or plaque instability? Theoretical
arguments that diabetes affects each of these steps have been reviewed recently (3).
One of the problems to clarify this issue B that in general the time of occurrence to
clinical diagnosis of type 2 diabetes is uncertain In this report, we were able to narrow
this time window to zero to four years. We recruited subjects from a population cohort
(Monitoring Project for Cardiovascular Diseases (4) and its predecessor (5)) who were
free of clinically diagnosed diabetes but were at high risk for this disease and
participated in a diabetes screening in 1999 (6,7).
The slow progression of the atherosclerosis process in humans has resulted in the
search for surrogate markers to study determinants of atherosclerosis. Validated
surrogate markers of different stages of atherosclerosis exist, i.e. intima-media
thickness (IMT) and arterial stiffness (8-10). IMT measurements indicate structural
changes involving hyperplasia of arterial smooth muscle cells (8), whereas arterial
stiffness is considered to be a measure of early functional loss of elasticity and
compliance within the vascular system (9). The aim of our study is to assess whether
differences exist in IMT and Young's elastic modulus (YEM), a marker of arterial
stiffness, to clarify which clinical stage of atherosclerosis development is accelerated in
abnormal glucose metabolism.
2. Methods
2.1. Subjects
The Cohort study of Diabetes and Atherosclerosis Maastricht (CODAM) is a
prospective, population based, cohort study in Dutch subjects who have been stratified
according to glucose tolerance, i.e. normal glucose tolerance (NGT), impaired glucose
tolerance (IGT), or type 2 diabetes mellitus (DM), as described in Mensink et al. (7).
Subjects were recruited from a general population monitoring study in Maastricht and
two other Dutch towns (4,5). Inclusion criteria were: age over 40 years, and either a
Body Mass Index (BMI) > 25 kg/m*, a positive family history of DM, a history of
gestational diabetes, use of antihypertensive medication, a postprandial blood glucose
> 6.0 mmol/L (108 mg/dL), or glucosuria. Combinations of these separate inclusion
criteria were allowed. Exclusion criteria ware self-reported diabetes and glucosuria
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during the previous screening in 1998 in the monitoring study (4,5), the use of
medication that affects glucose metabolism and non-Caucasian ethnicity. The local
Medical Ethical Committee of the University of Maastricht and University Hospital
Maastricht approved the study. All participants gave written informed consent.
2.2. COOAM study
From February 1999 until March 2000, 2715 subjects identified through the Monitoring
Project for Cardiovascular Diseases (4) and Chronic Diseases (5) participated in the
glucose tolerance and diabetes screening phase of the CODAM study and the Study on
Lifestyle-intervention and Impaired Glucose Tolerance Maastricht (SLIM), a lifestyle
intervention study directed at a healthy diet and increased physical activity (7). The
screening phase and the subsequent classification according to the 1999 WHO criteria
for glucose tolerance (11) were described by Mensink et al. (7). Participants were
invited for inclusion in either the CODAM study (N=574) (6) or the SLIM study (N=114)
(7) and underwent a second oral glucose tolerance test (OGTT) with venous plasma
glucose measurements in order to establish their glucose tolerance status. Eventually,
a total of 574 subjects were included in the CODAM cohort study. These represented
147 recently diagnosed type 2 diabetes (100 newly diagnosed and 47 additional
subjects diagnosed between one and four years prior to the study), 129 had IGT (104
IGT, 25 IFG), and 298 were NGT subjects.
2.3. Measurements
Subjects visited the Clinical Research Unit twice with a time interval varying between 2
weeks and 10 months. Lipid lowering medication was stopped 10 days before the first
visit and all other medication was stopped the day before the visits. At the first visit,
glucose tolerance was measured by a standard 75-g OGTT and defined according to
the 1999 WHO criteria (11). Before OGTT, after an overnight fast, a blood sample was
taken for measurement of fasting plasma glucose concentrations, insulin, HbA1c, total
cholesterol, HDL- and LDL-cholesterol, triglycerides and non-esterified fatty acids
(NEFA's) (7,11-13). Blood pressure was measured twice on the right arm in supine
position after 5 minutes of rest (Maxi Stable 3, Speider & Keller, Germany).
Hypertension was defined as systolic blood pressure (SBP)/diastolic blood pressure
(DBP) 2140/90 (14), or use of antihypertensive medication. Height (in cm) and body
weight to the nearest 100 grams were measured without shoes and wearing light indoor
clothing. BMI was calculated by dividing weight by height in kg/rn^. At the second visit,
sagittal diameter (in mm) was measured at the level of the spina iliaca anterior superior
by a slide gauge with the subject in supine position on a hard couch with the subjects
hands folded under the head. Blood pressure was measured twice in the same way as
described in Visit 1. The average of the SBP and DBP measurements of both visits was
calculated. History of cardiovascular disease (CVD) was registered. Visit 2 also
comprised the ultrasound measurements as described below.
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2.4. Ultrasound Procedure
Carotid intima-media thickness (IMT) was measured with ultrasound in M-mode
(Ultramark 4+, ATL, Bothel, Washington, USA) by a linear array transducer of 7.5 MHz
positioned perpendicular to the common carotid artery in 7 consecutive repeated
measurements as described before (15). When measurements were obtained from one
side only, the median value of that side was used in the analysis. The intra-observer
coefficient of variation was 3.7 % (observer 1) as determined in 5 subjects and 4.0 %
(observer 2) as determined in 7 subjects. SBP and DBP were measured with a
validated automatic oscillometric blood pressure device (OMRON 705CP, Nieuwegein,
the Netherlands) on the right arm before the procedure, and after the third and seventh
measurement. The average of all SBP and DBP measurements during the procedure
was calculated. Brachial pulse pressure (PP) was defined as average SBP minus
average DBP and was only used to calculate Young's elastic modulus. Brachial mean
arterial pressure (MAP) was calculated as DBP + (PP / 3).
Young's elastic modulus (YEM) was assessed with an Ultramark 4+ (Ultramark 4+,
ATL, Bothel, Washington, USA) and with the use of an echo wall tracking system at the
same position in the common carotid artery (CCA) as used in IMT measurements. The
wall tracking system measures non-invasively the diastolic diameter d and distension
Ad, the change in diameter as function of time (16,17). YEM is defined as follows:
YEM = d / (IMT * ((AA/A) / PP)) (MPa),
where A is the diastolic lumen area (calculated by p*(0.5*d)*). AA the change in cross-
sectional area from diastole to systole (calculated by p*((d + Ad)' - d*) / 4), and IMT is
the IMT value resulting from the IMT measurement (16). Higher values of YEM are an
indication of higher arterial stiffness. All measurements were repeated seven times at
both left and right common carotid artery. Measurements were repeated when the intra-
measurement of diameter showed a standard deviation of more than 1% and of
distension showed a standard deviation of more than 10%. The diameters and
distensions of the right and the left common carotid artery were different between DM
and NGT subjects (data not shown). We used the average of the left common carotid
artery diameter and distension in analyses, because of the small number of missing
values on this side, and few subjects had the left hand side as the dominant side (6.3%).
Carotid ultrasound measurements were obtained in 86.9% of all 574 subjects. Both
IMT and YEM measurements were available in 408 subjects. Common reasons for
missing data or subjects were cardiac arrhythmia, longitudinal or oscillating movements
of the carotid artery, (neck) obesity, or logistic problems.
2.5. Statistical analyses
Statistical analyses were done by SPSS 9.0 for Windows. Differences between
included and excluded subjects, and between subjects newly diagnosed with diabetes
and subjects diagnosed between one and four years prior to this study, were examined
with a t-test. Plasma triglyceride and insulin concentrations, and YEM had a skewed
distribution and were log-transformed to satisfy conditions of normality. In the tables
however, their untransformed values have been used. Age and gender adjusted tests
for trend in continuous variables were calculated from linear regression analysis.
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Differences in dichotomous variables were calculated by Chi-square. The yearly
increments in IMT and YEM were calculated in DM and NGT subjects by linear
regression analysis with age as the independent variable (range 42-72 years). The
CODAM study and the Hoorn study (12) are part of a collaborative study and have
similar protocols for IMT measurements. Therefore, estimations can be made of the
yearly increments in IMT using the results of the Hoorn study (mean age 69 years) (12)
and the present data (mean age 59 years) based on a mean age difference of 7.0 years
for DM and 11.4 years for NGT subjects. In addition, to investigate determinants of IMT
and YEM, regression analyses were carried out for each potential determinant adjusting
for age and gender. Thereafter, multiple backward linear regression analyses were
done with the variables that were significant in the first set (p<0.05), and age and the
dichotomous variables gender, smoking and hypertension were entered in the
multivariate model. We controlled for glucose tolerance (DM, IGT, NGT) by including
dummy variables in the analyses. The best equation was selected by using backward
elimination analysis (dummy variables were kept in the equation regardless of
significance of their (i).
3. Results
The characteristics of the study groups are listed in Table 1. IMT and YEM were
measured in 261 men and 147 women, with a mean age of 58.3 ± 7.0 years and a
mean BMI of 27.8 ± 3.7 kg/m*. There were no differences between the groups in
gender, smoking habits, history of self-reported cardiovascular disease (CVD) and total
cholesterol concentration. Differences in metabolic characteristics were generally as
expected. The use of antihypertensive medication was two times higher in DM subjects
compared to NGT subjects (48.8% vs. 22.7%; p< 0.05) and the same was found for
lipid lowering medication (DM 30.2%; NGT 14.5%; p<0.05). Notably, the common
carotid artery IMT, adjusted for age and gender, was also similar between the groups.
When subjects with DM were split in newly diagnosed (DM0) and diagnosed
between one and four years prior to the study (DM 1-4), differences were found in
height, HbA1c, fasting glucose concentration, total and LDL cholesterol after
adjustment for age and gender. No differences were found in IMT. After additional
adjustment for hypertension, YEM became significantly different between DM0 and
DM1-4, 1.01 MPa and 0.79 MPa, respectively (p=0.043). Lipid lowering medication was
used more frequent in the DM1-4 subjects compared to DM0 subjects, i.e. 53.3%
versus 17.9%, respectively. Also, antihypertensive medication was more frequently
used by the DM 1-4 subjects, i.e. 70% compared to 37.5% in DM0 subjects,
respectively. This was predominantly caused by a more frequent use of ACE inhibitors,
diuretics and angiotensin antagonists. No differences were found in gender, smoking,
or self-reported CVD.
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3.1. Intima-media thickness
The age-related IMT increase in subjects with diabetes or NGT was estimated by data
from the CODAM study and the Hoorn study (12), and is shown in Table 2. In the
CODAM study, the IMT increase per year of age was similar between DM and NGT
subjects. 0 003 mm and 0.004 mm. respectively. The interobserver variability in IMT
between the observer of the Hoorn study and our CODAM study was 7.8% for IMT,
9.8% for distension, and 4.0% for diameter for 12 subjects on two occasions, making
comparison plausible The value for IMT in NGT subjects was 0.69 ±0.15 mm in our
CODAM study and 0.83 ±0.16 mm in the Hoorn study (12) Considering the mean age
difference of 11.4 y between NGT subjects from both studies, this resulted in an
estimated IMT increment of 0.012 mm per year of age (Table 2). In DM, IMT was 0.71 ±
0.17 mm in CODAM and 0.88 ± 0 16 mm in the Hoorn study (12). Considering a mean
age difference of 7.0 y between DM subjects, the increment in IMT is estimated at
0.024 mm per year of age in diabetes (Table 2). This estimated age-related IMT
progression in diabetes represented an acceleration by a factor 2 compared to that in
NGT subjects (p<0.05).
Investigating predictive determinants for IMT in our population, we carried out
backward multiple linear regression analyses with the variables that were significant in
an earlier step (p<0 05) as well as with the variables age, gender, smoking,
hypertension, and glucose tolerance status. This showed that a significant part of the
variance in IMT was predicted by left carotid diameter (12.4%) and by PP (0 9%) The
presence of IGT, DM, or fasting plasma insulin did not significantly contribute to the
prediction of IMT (Table 3).
3.2. Arterial stiffness
YEM was significantly higher in DM subjects compared to NGT subjects after
adjustment for age and gender (Table 1). After additional adjustments for hypertension,
the difference remained statistically significant (p=0.037). The increase in YEM per year
of age in our CODAM study was similar in DM and NGT subjects, 0 019 MPa and 0 022
MPa per year, respectively. Table 2 shows the estimated increase in YEM per year of
age in DM subjects compared to NGT subjects when comparing data from the CODAM
and the Hoorn study. The data point at a significant acceleration in arterial stiffness in
DM subjects at older age by a factor two (DM 0.022 MPa per year of age vs. NGT
0.011 MPa per year of age; p< 0.05).
In order to investigate predictive determinants for YEM in our population, we did
backward multiple regression analyses with variables that were significant in an earlier
step (p<0.05) as well as with the variables age, gender, smoking, hypertension, and
glucose tolerance status. This showed that a significant part of the variance of YEM
was predicted by the variables age (16.7%), the presence of hypertension (4.9%), male
gender (3.0%), sagittal diameter (1.3%) and total cholesterol concentration (1.6%),
resulting in a 27.5% explained variance of YEM The presence of DM, IGT, or fasting
insulin concentration did not significantly contribute to the prediction of YEM (Table 3).
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Table 1: Subject characteristics according to glucose tolerance status. Age and gender adjusted tests for
trend in continuous variables were calculated from linear regression analysis.
Age (years)
BMI (kg/m*)
Sagittal diameter (mm)
HbA1c (%)
Fasting glucose (mmol/l)
IMT (mm)
Carotid diameter (mm)
YEM* (MPa)
Total cholesterol (mmol/l)
HDL-cholesterol (mmol/l)
Triglycerides" (mmol/l)
SBP (mmHg)
DBP (mmHg)
Pulse pressure (mmHg)
MAP (mmHg)
Men (%)
Current smoking (%)
History of self-reported CVD
DM
(N = 86)
60.116.5
29.3 1 3.8
222.7 1 30.6
6.811.2
7.9±1.9
0.7110.17
7.8611.08
0.9410.54
5.2511.28
1.08 ±0.29
1.9811.28
147.4118.7
84.119.7
63.2115.8
105.2111.1
70.9
11.6
21.4
IGT
(N = 88)
58.1 16.4
28.31 3.6
214.4133.5
5.8 ± 0.4
5.9 ± 0.5
0.7110.14
7.6711.02
0.81 1 0.49
5.23 1 0.93
1.1610.32
1.6510.81
142.7120.1
84.019.7
58.7115.1
103.6 ± 12.1
64.8
14.8
23.3
NGT
(N = 234)
57.717.4
27.0 1 3.4
197.8 ±27.4
5.610.4
5.3 1 0.4
0.6910.15
7.40 1 0.95
0.7410.50
5.20 1 0.94
1.2710.35
1.31 10.56
134.4118.6
79.718.5
54.7 ±14.1
98.0110.9
61.1
15.0
19.4
p-value*
0.008
<0.001
<0.001
<0.001
<0.001
0.46
0.005
0.004
0.73
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
-
-
-
" p-value Is age and gender adjusted; * log-transformed; Data are given as mean i SD or percentages; IMT *
intlma-media thickness. YEM = Young's elastic modulus; SBP = systolic blood pressure: DBP = diastolic
blood pressure; MAP = mean arterial pressure; CVD = cardiovascular disease
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Table 2: Estimated increment in IMT and YEM per year of age in subjects with diabetes (DM) and normal
glucose tolerance (NGT). Data were from the present study (CODAM study) and the Hoom study (12).
CODAM study* Hoom study Increase per year*
"DM IMT (mm) 0.71 ± 0 17 0.88 ±0.16' 0.024
(N=86) (N=301)
NGT IMT (mm) 0.69 ±0.15 0 83 ±0.16* 0.012
(N=234) (N=278)
DM YEM(MPa) 0.94 ±0.54 1.10 ±0.65' 0.022
(N=86) (N=301)
NGT YEM(MPa) 0.74 ± 0.50 0.87 ± 0.44' 0.011
(N=234) (N=278)
* increase per year of age: 0.003 mm IMT in DM. 0.004 mm IMT in NGT; 0.019 MPa YEM In DM and 0.022
MPa YEM in NGT; ° age difference between CODAM and Hoom study: DM = 7.0 years. NGT = 11.4 years; "
significantly different from data CODAM by t-test (p<0.05); Data are given as mean ± SD.
Table 3: Results of backward multiple regression analysis of IMT and YEM*
IMT YEM
(N = 408) (N - 400)
standft p r* standft p r'
Diameter 0.319 <0.001 0.12
0.009pp
Age
Sagittal Diameter
Cholesterol
Hypertension
Gender
IGT
DM
Fasting insulin
0.101
-
-
-
-
0.009
-0.035
0.080
0.04!
-
-
-
-
-
0.85
0.48
0.11
0.332
0.104
0123
0 169
-0.158
0.022
0.071
-0.013
<0.001
0.032
0.005
<0.001
0.001
0.64
0.15
0.81
0.17
0.013
0.016
0.05
0.03
•
-
* log-transformed: Results are expressed as standardized ft and adjusted r-square; IMT = irrtima-media
thickness; YEM = Youngs elastic modulus; PP = pulse pressure; Gender: 0=male, 1=female; IGT = impaired
glucose tolerance; DM = type 2 diabetes mellitus
4. Discussion
The present cohort enrolled subjects who were stratified according to their recently
established glucose tolerance status as DM, IGT. or NGT. Remarkably, IMT was similar
among the three glucose (in)tolerant categories. An apparent acceleration seems to
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occur in IMT thickening in subjects with DM when data are used from a similar cohort
study with subjects who were a decade older and included subjects with diabetes of
longer duration. Main predictors of IMT are carotid artery diameter and PP. Arterial
stiffness, represented by YEM, was already increased in recently diagnosed DM
subjects compared to NGT subjects whereas IGT showed intermediate stiffness.
Predictors of YEM are age, male gender, presence of hypertension, sagittal diameter
and total cholesterol.
A remarkable finding in the present study is that IMT was similar in DM, IGT and
NGT subjects. In agreement with our results, a recent study by Hunt et al. (18) found
that carotid IMT was similar in subjects who developed DM or subjects who remained
free of diabetes during a prospective study. In response to increased luminal diameter
and wall stress caused by factors such as hypertension and arterial stiffening, IMT
thickening will decrease wall stress (Law of Laplace). In agreement with this theory, we
could establish that carotid diameter and pulse pressure, but not the pre-diabetic state
or DM, were independent predictors of IMT in the present study. These variables
predicted 13.3% of the variance in IMT indicating that other factors, e.g. inflammatory or
genetic markers (19), also contribute to IMT. Furthermore, our findings suggest that
acceleration occurs in IMT thickening during manifest diabetes. This supports the
finding in literature that IMT is increased in longstanding DM (20,21). Also, we found no
differences in CODAM between DM and NGT in self-reported histories of
cardiovascular events (including prior myocardial infarction, any other serious heart
condition, stroke, brain haemorrhage, or narrowing of blood vessels of the viscerae or
legs). These findings suggest that a substantial part of the increase in IMT can occur
during the DM state, and it should therefore be possible to prevent medical suffering
from cardiovascular events in IGT and DM subjects, when detected in time and treated
for the correct risk factors. These risk factors are not fully known at present, but there is
evidence that acceleration in IMT during diabetes is associated with clustering of risk
factors including insulin resistance, obesity, hyperlipidemia, and hypertension
(metabolic syndrome) (22), chronic hyperglycemia including Amadori adducts and
advanced glycation products (12,23.24), inflammation, and genes that act in a diabetes
background (19).
Arterial stiffness, represented by YEM, was increased in our recently diagnosed DM
subjects. Furthermore, we showed that the age-related increase in YEM is accelerated
in DM subjects compared to NGT subjects. YEM was mainly predicted by age and the
presence of hypertension. With ageing, the increase in large artery stiffness is related
to the degree of mechanical stress that results in fragmentation and disruption of elastic
lamellae and derangement of the orderly structure of the elastic laminae of the vessel
wall, which changes the collagen to elastin ratio (17). Furthermore, sustained
hypertension can result in accelerated arterial degeneration and to prematurely
occurring structural changes similar to those seen in ageing. It is of interest that YEM
was also predicted by sagittal diameter, a surrogate measure of visceral obesity and
related to cardiovascular risk (25), and total cholesterol. A 27.5% of the variance in
YEM was explained by these variables, which indicates that the largest part of YEM is
associated with other variables, not measured in the present study. Few data have
been published on the relation between obesity and arterial stiffness (26). In agreement
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with the present findings. Hegazi et a!. (27) showed that abdominal adiposity was a
strong determinant of arterial stiffness in type 2 diabetes. The relationship between
arterial stiffness and total cholesterol has not been fully elucidated however. To our
knowledge, only one study has found a positive relation between plasma total
cholesterol and aortic stiffness (28). When subjects with DM were classified as newly
diagnosed diabetes (DM0) or diagnosed with diabetes between one and four years
prior to the study (DM1-4), no differences were found between self-reported CVD, and
YEM was significantly decreased in DM1-4. It has been shown that certain
antihypertensives, such as nitrates, ACE inhibitors and diuretics, can prevent collagen
accumulation and therefore decrease arterial stiffness (29). Although lipid-lowering
medication was also more frequently used by subjects with DM1-4, data about an effect
on arterial stiffness is lacking. These data suggest that treatment of hypertension may
prevent future events in subjects with type 2 diabetes.
A strength of this study is that ultrasound measurements were done at a single
point at the common carotid artery and were repeated at least 5 times to keep the
inaccuracy of the measurement of IMT, diameter and distension within acceptable
range. Since YEM is calculated from IMT. diameter and distension (16,17), this
procedure enlarges the discriminative power and keeps the inaccuracy of YEM within
acceptable range. Therefore, relevant vessel wall properties to assess arterial changes
could be described in the present report (16,17). Furthermore, we could narrow the time
window of undiagnosed type 2 diabetes to zero to four years prior to the study.
Although blood pressure measured at the brachial artery can deviate substantially from
that at the carotid artery (17), use of brachial PP should not lead to a different
conclusion since over- or underestimation of YEM by using brachial PP has been the
same in all subjects. Because results of the present study could be analysed cross-
sectionally only, estimations were made using data from a similar study, the Hoorn
study (12). Whether the estimations of IMT and YEM acceleration do occur in diabetes,
remains to be determined by future follow up results.
In summary, arterial stiffness, measured as YEM, was significantly increased in
subjects with recently diagnosed type 2 diabetes whereas IMT was normal. The results
suggest that abdominal obesity contributed to the increased arterial stiffness in
diabetes, possibly via an indirect effect on hypertension. When the data were compared
with similar data of a cohort with subjects a decade older, a significant two-fold
acceleration had occurred in YEM and IMT in diabetes. The present findings suggest
that optimism is justified to prevent functional and structural arterial wall abnormalities
ultimately resulting in cardiovascular events in DM. Hyperglycemia may have a direct
effect upon the rate of IMT thickening, but the present results suggest that it gains
significance in combination with other risk factors such as hypertension. Follow up
results are needed to confirm the estimations of IMT and YEM acceleration in diabetes
as well as the possible prevention of future cardiovascular events by certain
antihypertensive or lipid-lowering medication or lifestyle intervention.
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Summary
Objective To evaluate whether high pulse pressure (PP) is associated with increased prevalence of
metabolic or cardiovascular disorders, target organ damage, or abnomial vessel wall properties, and to
assess factors contributing to PP. Design A cohort study, Cohort of Diabetes and Atherosclerosis Maastricht
CODAM. An oral glucose tolerance test was done and metabolic variables and carotid artery vessel wall
properties were determined. Setting Academic research institute. Participants Subjects (N=574) were
participants from CODAM, aged 42-72 yrs. Interventions None. Main Outcome Measures Carotid wall
properties, metabolic parameters, and cardiovascular and metabolic morbidity in quartiles of PP. Results Of
the subjects in the highest PP quartle, 39.4% (adjusted OR 2.1) had diabetes and 51.4% (adjusted OR 2.8)
had metabolic syndrome (Chi-square: p<0.001 for both compared to the lowest PP quartile). Subjects in
higher PP quartiles showed gradually increased carotid artery wall thickness and stiffness, and had more
organ damage of large arteries and the heart. Moreover, the highest PP qjartile showed evidence of
abnormal fatty acids and glucose metabolism, and insulin resistance. Conclusions Increased PP is not only
associated with hypertension and left venthcular hypertrophy, but also with increased artenal stiffness, type 2
diabetes, and the metabolic syndrome. Abnormal fatty acid and glucose metabolism in subjects with high PP
can contribute to, or even underlie, these associations.
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Introduction • -/i
The European Society of Hypertension recently published new guidelines to determine
overall cardiovascular risk in the hypertensive patient (1). It was recognized that
secondary organ involvement, i.e. target organ damage (TOD), could act as a risk
factor on its own Therefore it was recommended that TOD should be added to the
common risk factors already used to stratify for cardiovascular risk in subjects with
hypertension. Organ damage can be defined at the level of the heart, i.e left ventricular
hypertrophy (LVH), at the level of the vessel wall, i.e. intima media thickness (IMT) or
atherosclerotic plaque, and at the level of the kidneys, i.e. increase in serum creatinine
concentration and/or presence of microalbuminuria.
Hypertension increases the load on the heart, burdens the wall stress of the
arteries, and accelerates cardiovascular degeneration and disease (2). The predictive
value of systolic and diastolic blood pressure for death and morbidity of cardiovascular
disease (CVD) has been established (3). Blood pressure can be considered as the
summation of a steady component, the mean arterial pressure, and a pulsatile
component, the pulse pressure (2). Pulse pressure (PP) is the difference between
systolic and diastolic blood pressure and is determined by the pattern of left ventricular
ejection and arterial wall properties, such as stiffness. Recently, we showed that PP
was an independent contributor to intima-media thickness, a surrogate marker of
atherosclerosis (M Kruijshoop, CJH van der Kallen, APG Hoeks, EH Lambrichs, EJM
Feskens, EE Blaak, TWA de Bruin. Increased arterial stiffness but normal intima-media
thickness in recently diagnosed type 2 diabetes mellitus Manuscript submitted).
Furthermore, PP has been recognized as an independent predictor of carotid artery
plaque ulceration (4), cardiovascular disease (CVD), and all-cause mortality (5,6). PP
may be specifically relevant in older subjects aged > 60 y (7,8), type 2 diabetes PM)
(9), hyperlipidemia, and subjects with the metabolic syndrome (10). and may represent
different and additional information on future risk of cardiovascular disease than
diastolic and systolic blood pressure. This concept is supported by recent reports that in
humans specific genes are associated with PP but not with systolic or diastolic blood
pressures (11,12).
Recently, we initiated a population-based cohort study in the framework of the
Cohort study of Diabetes and Atherosclerosis Maastricht (CODAM). The CODAM
participants have been well characterized for cardiovascular risk factors, including
glucose intolerance (13,14) and carotid artery vessel wall properties by ultrasound It
was the aim of the present study to cross-sectionally evaluate in this cohort whether
subjects with the highest PP had increased co-morbidity, increased prevalence of
cardiovascular disorders, increased TOD (1), abnormal carotid artery vessel wall
properties, or metabolic abnormalities.
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Subjects and Methods
Subjects & measurements
The Cohort study of Diabetes and Atherosclerosis Maastricht (CODAM) is a
prospective, population-based, cohort study in the Netherlands. Based on the results of
their baseline examinations, participants of two large ongoing cohorts of the National
Institute for Public Health and the Environment in the Maastricht area (Monitoring
Project for Cardiovascular Diseases and Monitoring Project on Risk Factors for Chronic
Diseases (14)) were invited to participate in a screening for the CODAM study.
Inclusion criteria were: age over 40 years and either Body Mass Index (BMI) > 25
kg/m*, a positive family history of DM, a history of gestational diabetes, use of
antihypertensive medication, a postprandial blood glucose > 6.0 mmol/L (108 mg/dL),
or glucosuria. Subjects with known DM of long-duration and on insulin treatment were
excluded from participation. Subjects who were newly diagnosed with DM by the oral
glucose tolerance test (OGTT) at screening have been included. Included subjects
were stratified according to glucose tolerance, i.e. as normal glucose tolerant (NGT),
impaired glucose tolerant (IGT), or recently diagnosed DM (13,14). Subjects with
impaired fasting glucose (IFG) (N=25) were included in the IGT group. A total of 574
subjects from the CODAM cohort study population were analyzed in the present study.
Subjects visited the Clinical Research Unit twice with a time interval varying
between 2 weeks and 10 months. Lipid lowering medication was stopped 10 days
before the first visit and all other medication including antihypertensive drugs was
stopped the day before the visits. During the first and second visit, blood pressure was
measured twice on the right arm in supine position after 5 minutes of rest. The average
of both the systolic and diastolic blood pressure (SBP and DBP) measurements of both
visits was calculated and PP was defined as average SBP minus average DBP. Mean
arterial pressure (MAP) was calculated as DBP + (PP / 3). Hypertension was defined as
SBP/DBP >140/90 (15), or use of antihypertensive medication. In addition, SBP and
DBP were measured with a validated automatic oscillometric blood pressure device
during the second visit to calculate vessel wall properties (OMRON 705CP,
Nieuwegein, the Netherlands). A 12-lead electrocardiogram (ECG) was made with the
subject in supine position after 5 minutes rest and coded according to the Minnesota
Code System (16). BMI was calculated by dividing weight by height in kg/m*. Waist
circumference (in cm) was measured at the level midway between the lateral lower rib
margin and the spina iliaca anterior superior with the subject in standing position.
Questionnaires were filled out on lifestyle and documented medical history. Prior and
current use of medication was registered. At the second visit, a standard Doppler
device was used to measure SBP on both arms (a. radialis) and ankles (a. dorsalis
pedis) and the Ankle/Brachial Index (ABI) was calculated by the following formula: ABI
= highest SBP a. dorsalis pedis / highest SBP a. radialis.
Subject Definitions
Glucose tolerance was measured during the first visit by a standard 75-g OGTT with
venous plasma glucose measurements and defined according to the 1999 WHO criteria
(17). Metabolic syndrome was defined according to the Adult Treatment Panel (ATP) III
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of the National Cholesterol Education Program (NCEP) when 3 or more out of 5
variables (waist circumference, tnglycendes, HDL-cholesterol, fasting plasma glucose
concentration, and blood pressure) exceeded the predefined threshold (18) Smoking
status was considered positive in cases of current or ever smoking Coronary heart
disease (CHD) was considered present in case of documented prior myocardial
infarction, bypass surgery, percutaneous transluminal balloon dilation (PTCA), history
of coronary angiography, a pacemaker, or any other serious heart condition other than
myocardial infarction. Cardiovascular disease (CVD) was considered present when
CHD was present, or whether subjects had suffered from stroke, brain haemorrhage,
narrowing of blood vessels of the vi scerae or legs, prior operation of blood vessels, or
documented peripheral artery disease including the viscerae or legs.
Target Organ Damage
Target Organ Damage (TOD) was defined according to the criteria of the European
Society of Hypertension 2003 (1) as follows: TOD-IMT intima-media thickness (IMT) >
0.90 mm, TOD-MA microalbuminuria > 20 mg/L (19), TOD-LVH LVH either as Sokolow-
Lyons index without the presence of a bundle branch block (SV1 + RV5 or 6 > 38 mm)
(missing N=286) or as Cornell voltage QRS duration product > 2440 mm*ms (20,21)
(missing N=329), or when the ECG was coded 3.1 or 3.3 according to Minnesota
(missing N=15) (total missing N=12), and TOD-CREAT serum creatinine in men > 115
umol/L; in women > 107 (imol/L (11). We extended the criteria for vessel wall damage
(IMT) by adding criteria for endothelial dysfunction and peripheral vascular disease
(PVD). Endothelial dysfunction, of which plasma soluble intercellular adhesion molecule
(sICAM) concentrations is a marker (22,23), was considered present when plasma
sICAM concentrations exceeded the 90th percentile, determined in NGT subjects, i.e.
450 ng/mL (TOD-SICAM). TOD-PVD was considered present when the ABI was below
0.90 (24,25).
Laboratory Measurements
Fasting blood samples were drawn to measure fasting insulin concentration, HbA1c,
total and high-density lipoprotein (HDL)-cholesterol, tnglycendes and free fatty acids
(FFA). Glucose was measured by the hexokinase method, as described previously
(13,14). Insulin was determined using a two-sided immunoradiometric test by the
Endocrinological Laboratory at the University Hospital Vrije Universiteit Amsterdam, the
Netherlands, using paired monoclonal antibodies (Medgenix Diagnostics, Fleurus,
Belgium). This test is insulin specific and does not show cross reactivity with pro-insulin
and split products. Intra- and inter-assay coefficients of variation were 5% and 6%,
respectively. The HOMA-index was calculated as described by Matthews et al (26).
HbA1C was determined by HPLC by the Department of Clinical Chemistry of the
Academic Hospital Maastricht, the Netherlands. Total cholesterol, HDL-cholesterol and
triglycerides were measured by enzymatic methods (Roche, Mannheim, Germany) by
the Department of Clinical Chemistry of the University Hospital Vrije Universiteit
Amsterdam (The Netherlands). Low-density lipoprotein (LDL)-cholesterol was
calculated according to Friedewald et al. (27) An enzymatic colorimetric method (Wako
NEFA C, Richmond, USA) was used for the quantitation of FFA at the Department of
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Clinical Chemistry of the Erasmus Medical Centre (Rotterdam, The Netherlands) C-
reactive protein (CRP) was measured at the Laboratory of Toxicology, Genetics and
Pathology of the National Public Health Institute, Bilthoven (The Netherlands) with a
high-sensitive kit (Latex, Roche Diagnostics Nederland BV, Almere, the Netherlands).
Plasma creatinine was determined with a Roche kit (Roche Diagnostics Nederland BV,
Almere, the Netherlands). SICAM, apolipoprotein B (apoB) and complement factor 3
(C3) were determined in serum by autoanalyzer. A morning urine sample was collected
and the concentration of albumin was determined by rate nephelometry (Array Protein
System, Beckman, PaloAlto, USA).
Ultrasound procedures
Carotid IMT was measured with ultrasound in M-mode (Ultramark 4+, ATL, Bothel,
Washington, USA) by a linear array transducer of 7.5 MHz positioned perpendicular to
the common carotid artery (CCA) in 7 consecutive measurements, as described before
(28-30). The median value of the seven measurements was calculated for the left and
right side. The average of the left and right median was used as the representative IMT
value. When less than five measurements could be done, the measurement was
considered missing. When measurements were obtained from one side only, the
median value of that side was used in analysis. The inter-observer coefficient of
variation was 3.9 %, determined in 7 subjects on two occasions. The intra-observer
coefficient of variation was 3.7 % with observer 1, determined in 5 subjects, and 4.0 %
with observer 2, determined in 7 subjects. SBP and DBP were measured with a
validated automatic oscillometric blood pressure device (OMRON 705CP, Nieuwegein,
the Netherlands) on the right arm before the procedure, and after the third and seventh
.maasuraoift'tf wtew .•roaas&vn'ig' Ate rAgM antf Astf siote. Trie average of aiV systolic ana'
diastolic measurements during the procedure was calculated. Brachial PP was defined
as average SBP minus average DBP and was used only to calculate Young's elastic
modulus (YEM).
YEM was assessed with an Ultramark 4+ (Ultramark 4+, ATL, Bothel, Washington,
USA) and with the use of an echo wall tracking system at the same position in the CCA
as used in IMT measurements. The wall tracking system measures non-invasively the
diastolic diameter d and distension Ad, the change in diameter as function of time
(29.30). YEM is defined as follows:
YEM = d / (IMT * (AA/A) / PP)) (MPa),
where A is the diastolic lumen area (calculated by p*(0.5*d)*), AA the change in cross-
sectional area from diastole to systole (calculated by p*((d + Ad)* - d*) / 4), and IMT is
the IMT value resulting from the IMT measurement (29). YEM provides information on
the mechanical properties of the wall material independent of the geometry (1) and can
be considered a marker of arterial stiffness All measurements were done seven times
at both left and right CCA. Measurements were repeated when the diameter showed a
standard deviation of more than 1% and distension showed a standard deviation of
more than 10%. The diameters and distensions of the right CCA was different from the
left CCA in DM and NGT subjects. We used the average of the left CCA diameter and
distension in analyses and calculation of YEM, because of the small number of missing
values, and few subjects had the left hand side as the dominant side (6.3%).
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Statistical analysis
SPSS 10.0 for Macintosh was used for analyses. First, the subjects were classified
according to quartiles of PP. Analysis of covahance (General Linear Models procedure)
was used to calculate means adjusted for age. gender, BMI and waist circumference,
and to calculate 95% confidence intervals (Cl) of the continuous variables Tests for
trend in mean risk factor values across PP quartiles were calculated from linear
regression analysis for continuous variables. For dichotomous variables odds ratios
with 95% Cl were calculated, adjusted for age, gender, BMI. and waist circumference,
based on logistic regression analysis Plasma triglyceride and urinary albumin
concentrations, the HOMA-index, YEM, and CRP showed skewed data distribution and
were log-transformed to satisfy conditions of normality. In tables and figures however,
their untransformed median values have been used for clarity To study determinants of
PP, univariate regression analyses were carried out with the variables from Table 1 and
2 that were significantly different between the PP quartiles SBP and DBP were not
used as variables for regression analysis because they were used to calculate PP.
Likewise, YEM was not used in regression analysis as its calculation includes PP.
Multiple backward linear regression analysis ves done with the variables that were
significant in univariate analysis (p<0 05) Also, smoking, presence of DM or IGT, use of
antihypertensive medication, and MAP were entered in the multiple model.
Results
Pulse pressure quartiles
The study population consisted of 352 men and 222 women (total N=574), with mean
age 59.1 ± 7.0 y and mean BMI 28.6 ± 4.3 kg/m*. The population was classified into PP
quartiles and the characteristics are listed in Tables 1 and 2 After adjustment for age
and gender, highly significant differences among PP quartiles were found in BMI, waist
circumference, blood pressure parameters including ABI. and vessel wall properties.
Each of the carotid wall properties, i.e. carotid IMT, carotid diameter and YEM, showed
significant graded increments over PP quartiles and had the highest values in the
subjects with the highest PP (Table 1). With regard to metabolic markers, after
adjustment for age, gender, BMI and waist circumference, quartiles of PP showed
significant associations with H)A1c, fasting and 2 h post-load glucose, FFA and the
HOMA-index (Table 2). There were no differences between the quartiles in total
cholesterol. HDL- and LDL-cholesterol, triglycerides, apoB, CRP, C3, creatinine, and
sICAM concentrations (Table 2).
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Table 1: Characteristics, blood pressure and vessel wall properties according to quartiles of pulse pressure
(PP, mmHg), adjusted for age and gender*; Data are given as mean (95% confidence interval).
Male (%)
Age (years)
BMI (kg/m*)
Waist circumference (cm)
Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
Pulse pressure (mmHg)
Mean arterial pressure
(mmHg)
Ankle/Brachial Index a.
dorsalis
Urinary albumin
concentration*" (mg/L)
IMT mean (mm)
Diameter left CCA (mm)
YEM left CCA"* (MPa)
Resting heart rate (b/min)
Smoking (%)
PP1
N=152
PPS48
65.8
55.2
(54.2-56.2)
27.1
(26.4-27.8)
95.7
(93.8-97.6)
121.8
(119.8-123.7)
78.3
(76.9-79.8)
43.3
(42.3-44.5)
92.8
(91.3-94.4)
1.14
(1.12-1.16)
3.3
0.66
(0.64-0.69)
7.3
(7.1-7.4)
0.52
59.9
(58.1-61.7)
64.9
PP2
N=135
49<PPs56
61.5
57.9
(56.8-59.0)
28.9
(28.1-29.6)
100.5
(98.6-102.4)
134.8
(132.8-136.7)
82.2
(80.7-83.7)
52.6
(51.5-53.7)
99.7
(98.2-101.3)
1.13
(1.11-1.15)
3.6
069
(0.66-0.71)
7.5
(7.4-7.7)
0.60
61.4
(59.6-63.2)
73.3
PP3
N=145
57£PP<66
62.1
60.4
(59.4-61.4)
29.0
(28.3-29.7)
100.8
(98.9-102.6)
143.9
(142.0-145.8)
83.3
(81.8-84.8)
60.5
(59.5-61.6)
103.5
(102.0-105.0)
1.13
(1.11-1.14)
3.4
0.72
(0.69-0.75)
7.7
(7.5-7.8)
0.73
63.8
(62.0-65.5)
66.9
PP4
N=142
PP>67
55.6
63.1
(62.0-64.1)
29.4
(28.7-30.1)
101.0
(99.1-103.0)
163.9
(161.9-165.9)
85.2
(83.6-86.7)
78.7
(77.6-79.8)
111.4
(109.8-113.0)
1.06
(1.04-1.08)
4.3
0.73
(0.70-0.76)
8.0
(7.8-8.1)
0.89
62.5
(60.7-64.3)
70.4
P-
value"
0.95
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
O.001
<0.001
<0.001
O.001
0.018
0.63
* Standardized to the age and gender distribution of the total study population (except for age which is
standardized to the gender distribution only); *' logistic regression analysis for continuous variables and Chi-
square for dlchotomous variables. BMI. Body Mass Index; " * unadjusted median value shown in table, but p-
value was calculated with log-transformed values, adjusted for age and gender; IMT, mtima-media thickness;
CCA, common carotid artery; YEM. Young's elastic modulus
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Tabte 2: Metabolic blood parameters according to quartiles of pulse pressure (PP. mmHg). adjusted for age,
gender. BMI and waist circumference*: Data are given as mean (95% confidence interval).
HbA1c(%)
Fasting glucose (mmol/L)
Glucose concentration 2 h
(mmol/L)
Free fatty acids (mmol/L)
HOMA-index*"
Total cholesterol (mmol/L)
HDL-cbolesterol (mmol/L)
LDL-cholesterol (mmol/L)
Triglycerides*** (mmol/L)
Apolipoprotein B (g/L)
C-reactive protein'" (mg/L)
Complement factor 3 (g/L)
Creatmme (umol/L)
Soluble intercellular
adhesion molecule (ng/mL)
PP1
N-152
PPS48
5.9
(5.8-6.0)
5 8
(5.6-6.1)
7.1
(6.5-7.7)
0.49
(0.46-0.53)
1.70
508
(4.91-5.25)
1.21
(1.15-1.26)
3.19
(3.04-3.34)
1.30
1.09
(1.05-1.13)
208
1.75
(1.70-1.81)
73.7
(71.5-75.9)
348.1
(332 0-364.2)
PP2
N=135
49SPPS56
5.9
(5.7-6.0)
5.8
(5.5-6.0)
7.3
(6.8-7.9)
051
(0.48-0.54)
2.28
524
(508-541)
1 14
(1.08-1.19)
3.33
(3.18-3.47)
1.50
1.13
(1.09-1.18)
286
1.83
(1.78-1.88)
722
(70.1-74.4)
346.1
(330 0-3623)
PP3
N=145
57SPPS66
6.0
(5.8-6.1)
6.1
(5.9-S.3)
8.1
(7.M.7)
0.54
(0.51-0.57)
2.09
541
(5.25-5.57)
1.21
(1.16-1.27)
3.48
(3.34-3.63)
1.40
1.17
(1.13-1.21)
2 38
1.80
(1 75-1.85)
70 1
(68 1-72.2)
364.2
(348 6-379 7)
PP4
N«142
PP267
6.3
(6.1-6.4)
6.7
(6.4-6.9)
8.6
(7.9-9.2)
0.57
(0.54-0.61)
2.61
5.14
(4.98-5 32)
1.20
(1.14-1.25)
3.21
(3.06-3.36)
1.40
1.12
(1.08-1 17)
3.13
1.82
(1.77-1.87)
71.7
(69 5-74.0)
353.2
(336 6-369.8)
P-
value"
0.001
<0.001
<0.001
0.001
0028
0.32
0.75
0.50
0.34
019
0.11
017
013
0.39
* Standardized to the age and gender distribution of the total study population; " linear regression analyst*;
* " unadjusted median value shown in table, but p-value was calculated with log-transformed values, adjusted
for age and gender; HbA1c, glycosylated haemoglobin; HDL. high-density hpoprotein. LDL. low-density
lipoprotein
Target Organ Damage
In Table 3, the prevalence and odds ratio (OR) with 95% confidence interval (Cl) of
target organ damage (TOD) in the PP quartiles has been listed. After adjustment for
age, gender, BMI and waist circumference, PP was significantly associated with a
higher TOD-IMT and TOD-PVD. However, TOD-SICAM, target organ damage reflecting
endothelial cell activation mostly at the level of the capillaries, was not different
between the PP quartiles. TOD-LVH was almost four-and-a-half times as frequent in
the highest PP-quartile compared to the lowest PP-quartile. There were no differences
between the quartiles in the OR for target organ damage at level of the kidneys, TOD-
CREAT and TOD-MA.
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Clinical Disorders
Hypertens/on, CHD and CVD The association with the prevalence of clinical disorders
was assessed. As a result cf the study design, 99.3% had hypertension defined as
SBP/DBP >140/90 or antihypertensive medication in the highest PP quartile (Table 3).
However, only 54.6% of the subjects in the highest PP quartile with hypertension used
antihypertensive medication. Between quartiles, there were no differences in the use of
ACE-inhibitors or lipid medication (data not shown), but nitrates were used more often
in the highest PP quartile compared to the lowest quartile (12.7% vs. 7.9%,
respectively). Although the prevalence of CHD and CVD increased with quartiles of PP
(Table 3), the OR's did not reach statistical significance after adjustment for age,
gender, BMI and waist circumference.
Type 2 D/abetes From Table 2, it had become apparent that higher fasting glucose and
2 h post-load glucose plasma concentrations existed in higher PP quartiles. Fifty-six of
the 142 subjects (39.4%) in the highest PP quartile had DM resulting in an OR of 2.1
(Cl 1.1-3.8) for DM in the highest PP quartile, adjusted for age, gender, BMI and waist
circumference, compared to the lowest PP quartile (p<0.05) (Table 3). The OR for IGT
did not reach statistical significance in the highest PP quartile, but was significantly
increased in the lower PP quartiles (PP2 and PP3 both OR=1.8; Cl 1.0-3.3) suggesting
that subjects had progressed from IGT to DM in the highest PP quartile.
Ms/a6o//c Syndrome The OR for metabolic syndrome after adjustment for age, gender,
BMI and waist circumference was 2.8 (Cl 1.5-5.3) in the highest PP quartile (51.4%),
which was significantly different from the lowest PP quartile (26.3%)(Table 3). In all PP
quartiles the prevalence of the metabolic syndrome was significantly higher than in
PP1. Metabolic syndrome and DM together represented 59.8% (85/142) of the subjects
in the highest PP quartile. Of the subjects with metabolic syndrome in the highest PP
quartile, 60.3% (44/73) also had DM. Furthermore, 8.5% (12/142) of the subjects had
DM but no metabolic syndrome.
Effect of exclusion of subjects using antihypertensive medication
We repeated the analyses described above after exclusion of subjects using
antihypertensive medication (N=208). This resulted in identical conclusions. The only
exceptions were that the prevalence rates of CVD and TOD-PVD were no longer
significantly different between PP quartiles, compared to the entire study population
(Table 3).
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TaMe 3: Frequency and odds ratios (OR) with confidence interval (Cl) in parentheses, adjusted for age.
gender. BMI and waist circumference, of Target Organ Damage (TOD) and dirwcal disorders according to
quartites of pulse pressure (PP, rtnmHg); Data are given in percent.
TOD-IMT
TOD-PVD
TOD-SICAM
TOD-LVH
TOD-CREAT
TOD-MA
Hypertension
(2140/90)
(%)
OR(CI)
(%)
OR (Cl)
<%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
(%)
Antihypertensive (%)
Medication
CHD
CVD
DM
IGT
MS
(%)
OR(CI)
(%)
OR (Cl)
<%)
OR (Cl)
(%)
OR (Cl)
(%)
OR (Cl)
PP1
N=152
PPS48
4.3
1
0 7
1
11.2
1
121
1
0.7
1
8 0
1
298
24.5
162
1
197
1
17.8
1
15.8
1
26.3
1
PP2
N=135
49sPPs56
9.6
2.0 (0.7-5.8)
2.3
2.4 (0.2-23 9)
12.7
1.0(0.5-2.1)
11.5
1.1 (0.3-3.3)
0.5
0.5 (0.0-9 7)
6.9
0 7 (0.2-2.0)
46.7
319
18.7
1 0(0 5-19)
203
0.9(0.5-16)
17.0
0.7(0.4-1.3)
259
1.8* (1.0-3.3)
46.7
2.1* (1.2-3.9)
PP3
N=145
57sPPi66
157
3.3* (1.2-3.8)
1.4
1.2(0 1-14.0)
16.6
14(0 7-2.8)
288
3.2* (1.2-8.3)
0
-
10.0
0 9 (0 3-2.5)
75.2
35.2
15.4
0 7(0.3-1.3)
187
0 7(04-1.3)
283
1.3(0.7-2.4)
262
1.8* (10-3.3)
44 1
1.7(0.9-3.1)
PP4
N=142
PP267
16.8
3.4* (1.2-9.5)
12.1
10.r (1.3-87.6)
8.5
0 6(0 3-15)
352
4.4* (1.5-12.4)
0.4
0.4 (0.0-6.7)
153
1.8(0 7-4.7)
89.3
64.2
255
1.3(0 7-2 5)
333
1.5(0.8-2.7)
394
2.1* (1.1-3.8)
225
1 5(0.8-2.9)
51.4
2.8* (15-5 3)
p-vatue
(Chi-
square)
0.005
<0.001
0.19
0.02
061
0.63
<0 001
<0.001
0.12
0.011
<0.001
019
<0.001
TOD-IMT, target organ damage defined according to intima-media thickness; TOD-PVD, target organ
damage defined according to the presence of peripheral vascular disease; TOD-SICAM. target organ damage
defined according to the concentration of plasma soluble intercellular adhesion molecule; TOD-LVH, target
organ damage defined according to the presence of left ventricular hypertrophy; TOD-CREAT. target organ
damage defined according to concentration of plasma creatinine; TOD-MA, target organ damage defined
according to the presence of microalbuminuria; CHD = coronary heart disease; CVD = cardiovascular
disease; DM = type 2 diabetes mellitus; IGT = impaired glucose tolerance; MS = metabolic syndrome;'
significantly different from PP1
Determinants of pulse pressure
In univariate regression analysis adjusted for age, gender, BMI and waist
circumference, the variables FFA, HbA1c, 2 h post-load glucose concentration, HOMA-
index, CRP, ABI, IMT, diameter of the left CCA, and urinary albumin concentration were
significantly associated with PP. In subsequent backward regression analysis, smoking,
presence of DM or IGT, use of antihypertensive medication, and MAP were added to
these variables. Of these variables, age, gender, FFA, ABI, MAP, IMT, diameter of the
left CCA, and waist circumference together predicted 54.6% of the variance in PP
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(Table 4). MAP predicted the largest part of the variance in PP, i.e. 41.3%. Correlation
between PP and MAP was r=0.643 and between PP and ABI r=-0.231. Addition of
fasting insulin concentration or the HOMA-index to the model did not result in a
significant contribution to the explained variance.
Table 4: Results of slepwise multiple regression analysis of pulse pressure (N=411); age, gender, BMI, waist
circumference, smoking, presence of type 2 diabetes or impaired glucose tolerance, use of antihypertensive
medication, and mean arterial pressure were added to the multivariate model as well as the variables
significant in univariate regression analysis.
Age
Gender (O=male, 1=female)
Free fatty acids
Ankle/Brachial Index
Mean arterial pressure
Intima-media thickness
Diameter of the left common carotid artery
Waist circumference
stand, ft
0.215
0.100
0.101
-0.138
0.537
0.066
0.151
-0.094
Pulse Pressure
P
<0.001
0.014
0.004
<0.001
<0.001
0066
<0.001
0.016
r*
0.067
0.011
0.011
0.028
0.413
0.003
0.007
0.006
Results are expressed as standardized ft and adjusted r-square.
Discussion
The present study showed that increased PP is not only associated with hypertension
and LVH, but also with serious clinical metabolic disorders such as DM and the
metabolic syndrome, as well as with metabolic abnormalities, specifically increased
plasma concentrations of glucose, FFA, and the HOMA-index. In the highest PP
quartile (PP>67 mmHg), 39.4% of subjects had DM and more than half of the study
population (51.4%) had metabolic syndrome according to the NCEP definition (18). This
was partly explained by a larger degree of insulin resistance, represented by the
significantly higher HOMA-index, in the highest PP quartile. A higher PP was also
associated with abnormal vessel wall properties that reflect increased arterial stiffness.
A small but statistically significant part of the variance in PP was explained by plasma
FFA and vessel wall characteristics. The present data suggest a close association
between DM, metabolic syndrome and PP. Plasma FFA represent a newly identified
determinant of PP and may contribute to the well-known, but unexplained, connection
between high blood pressure and DM.
The CODAM study consists of a sample of high-risk subjects from a population-
based cohort and only baseline measurements have been done. However, the CODAM
cohort study allows simultaneous cross-sectional comparisons between glucose
intolerance categories, the metabolic syndrome, carotid artery vessel wall properties,
and other risk factors for CVD including blood pressure parameters. One of the
weaknesses in population studies of blood pressure variables is that it is virtually
impossible to withhold treatment for hypertension, because at least 2 to 4 weeks
without medication seems optimal. In the present study, antihypertensive treatment was
not withheld for more than the day prior to measurement. This may have affected the
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average level of blood pressure, but it is generally accepted that PP remains unaltered
when hypertension is treated (31). In addition, Mourad et al. (32) showed that the
increase in PP with age is independent of the presence of antihypertensive drug
treatment. The present finding that carotid artery wall properties like IMT and diameter
contribute to PP is a potentially adequate explanation for the observation that the
increase in PP with age is independent of use of antihypertensive medication (32),
because arterial stiffness also increases with age.
Determinants of pulse pressure
PP was predicted by carotid vessel wall properties, specifically IMT and carotid
diameter. This supported our previous results (M Kruijshoop, CJH van der Kallen, APG
Hoeks. EH Lambnchs, EJM Feskens, EE Blaak, TWA de Bruin. Increased arterial
stiffness but normal intima-media thickness in recently diagnosed type 2 diabetes
mellitus. Manuscript submitted). Furthermore, PP was predicted by age, gender, FFA,
and waist circumference, as well as by other blood pressure related variables, such as
ABI and MAP. Most of these variables have been frequently shown to be related to
hypertension or PP. Age and gender are known to influence arterial wall properties and
therefore influence PP (2.33). Waist circumference is a marker of abdominal obesity
which directly leads to hypertension (34). ABI is calculated with systolic blood pressure
and is a marker of atherosclerosis present in peripheral vessels (24,25). PP and MAP
represent different parts of the same biological variable blood pressure, and are highly
associated with each other However, the small but significant contribution of FFA to PP
is a new finding. To our knowledge, only one prospective population study showed a
direct association between the development of hypertension and increased
concentrations of FFA (35).
Free fatty acids and pulse pressure
One of the striking findings in the present study is the gradient of the HOMA-index,
glucose and FFA over the PP quartiles, which maintained its significance after
adjustment for BMI, waist circumference, age and gender. An impaired insulin-induced
suppression of plasma FFA has been reported in essential hypertension (36) as well as
in insulin resistant states (37). Indeed, a prospective association between plasma FFA
and the development of hypertension has been found (35). In the present study, an
increasing gradient in arterial stiffness was observed over the PP quartiles concomitant
with an increase in plasma FFA levels, and this was confirmed by the significant
contribution of FFA to PP in multivariate analysis. However, it is not clear how the
small, but statistically significant effect of FFA should be interpreted, i.e. as a direct
effect of FFA, or as a result of indirect effects on gene transcription and expression. It
should be realized that plasma FFA levels are under tight control. Indirect metabolic
effects of FFA include inhibition of phosphatidyl 3-kinase (PI3K) (38) and activation of
transcription factors like PPAR-gamma (39). Moreover, increased plasma FFA can
result in retention of lipoproteins and albumin-bound FFA to the proteoglycan matrix
(40,41) with a direct effect on stiffness. Taken all evidence into account, plasma FFA
can represent a newly uncovered factor that contributes indirectly to increments in
arterial stiffness and PP.
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Mechanisms of comorbidity with high pulse pressure
Subjects in the highest quartile of PP showed a significantly greater proportion of
clinical disorders, including DM. In addition, 51.4% of subjects in the highest PP quartile
fulfilled the criteria of the NCEP definition of metabolic syndrome, compared to 26.3% in
the lowest quartile of PP. The observed frequency of metabolic syndrome in the lowest
PP quartile is somewhat higher than the true population frequency in the Netherlands
which may be caused by a relative over-sampling in CODAM of subjects at risk of DM.
However, the prevalence found (26.3%) is approximately the same as the estimated
population frequency of metabolic syndrome in the US of 25% (42). Subjects with
metabolic syndrome are at a high risk of future DM (18). Lipid profiles however (total
cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol) were identical in the 4
quartiles, which means that plasma lipid proteins had similar potential effects on the
progression to metabolic syndrome or DM in all quartiles. The present results suggest
that individuals in the highest PP quartile were subjected to specific other factors
associated with the progression to metabolic syndrome and DM. Such factors are likely
to be higher BMI, waist circumference, and blood pressure, but also the gradient of FFA
and the HOMA-index. Several published arguments exist to explain why plasma FFA
can contribute to abnormalities in the highest PP quartile, and can be involved in
metabolic processes that underlie the progression from IGT to DM as well (35, 43-45).
Taken all evidence together, FFA represent a pleiotropic metabolic factor which may be
implicated in increments in PP and in progression from IGT to DM by multiple
mechanisms. However, plasma FFA levels may not be the correct representation of
these mechanisms, because FFA have intercellular effects.
Conclusions
The present data advance our understanding of high PP and document the relationship
of high PP (5 67) with DM, metabolic syndrome, and metabolic abnormalities including
fatty acid and glucose metabolism. Increased PP is associated with serious clinical
metabolic disorders and not only with hypertension, LVH, increased MAP, and
increased carotid artery stiffness. In the highest population quartile of PP (> 67), more
than half (59.8%) of the subjects showed either metabolic syndrome or DM. Plasma
FFA were newly identified as a small, but independent, metabolic determinant of PP in
multivariate analysis, in addition to age, carotid IMT and carotid diameter. Moderately
elevated plasma FFA in subjects with high PP can reflect underlying metabolic
abnormalities involved in the well-known associations between high blood pressure,
diabetes and the metabolic syndrome.
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Type 2 diabetes mellitus represents a metabolic disorder of multiple aetiology, which is
characterized by chronic hyperglycemia caused by impaired insulin action and
secretion (1). It can cause long-term damage, dysfunction and failure of various organs.
Patients with type 2 diabetes are at increased risk of developing coronary heart
disease, cerebrovascular disease and peripheral vascular disease, and approximately
60 to 70% of the patients with type 2 diabetes die from myocardial infarction and stroke
(2). The main theory to explain the increased risk of cardiovascular disease (CVD) in
type 2 diabetes holds that the increase in risk is caused by an increased rate of
atherosclerosis, which principally occurs in large and medium-sized elastic and
muscular arteries The prevalence of type 2 diabetes is expected to increase from its
present level of 150 million to 300 million by 2025 (3) Furthermore, approximately 20 to
25% of the subjects in Western populations have impaired glucose tolerance (IGT)(1)
or the metabolic syndrome (1.4), and both are considered to represent a pre-diabetic
state. More information is needed on the relationship between different levels of blood
glucose concentrations, disturbances in blood glucose concentrations, or the metabolic
syndrome and the development of atherosclerosis Therefore, a prospective, population
based cohort study was created to study the effects of glucose tolerance on
atherosclerosis, the Cohort study Diabetes and Atherosclerosis Maastricht (CODAM).
The first results of this study have been described in this thesis.
7.1: Diagnosis of type 2 diabetes
Subjects of the CODAM study were stratified according to glucose tolerance after a 75-
g oral glucose tolerance test (OGTT) with venous blood glucose sampling This is
considered the gold standard to diagnose (or exclude) type 2 diabetes mellitus and is
recommended ri epidemiological studies by the WHO (1). However, an OGTT with
venous sampling may not be feasible in large epidemiological studies In 1999, the
WHO has adjusted the diagnostic criteria for type 2 diabetes mellitus, impaired and
normal glucose tolerance (IGT and NGT) in venous plasma and whole blood, as well as
in capillary plasma and whole blood (1). Capillary glucose measurements may provide
an alternative because they are easier, less expensive and less invasive to obtain.
Furthermore, it was shown that modern hand-held glucose measuring devices have
excellent technical characteristics and yield similar results as reference laboratory
methods (5,6). In the Diabetes Prevention Program study (DPP) (7), the ratio of
screened and detected subjects with IGT was 1 out of 43.9 subjects when the following
procedure was followed: 1) an initial screening including a capillary or venous glucose
determination (fasting or non-fasting); 2) administration of an OGTT to diagnose IGT
according to modified criteria of the American Diabetes Association (8). Instead, the
inclusion protocol of the CODAM study used high risk criteria to invite subjects for
screening with a capillary 75-g OGTT (Chapter 2, Table 1) and resulted in a more
favourable ratio of screened and detected subjects with IGT, i.e. 1 out of every 7.1
subjects (Chapter 3). Therefore, use of capillary glucose measurements in combination
with specific inclusion criteria can result in cost-effective inclusion schemes for future
diabetes prevention programs.
The screening for the CODAM study was done with a Glucometer Elite® (Bayer), a
commercially available glucose meter, which measures capillary blood glucose
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(Chapter 3). Inclusion in the CODAM study was done by venous blood glucose
measurements, and we compared capillary measurements done with the Glucometer
Elite® with venous blood glucose measurements drawn through a canula and analysed
in a laboratory with standard enzymatic assays in a subset of the cohort (Chapter 4).
We showed that the consistency in classification according to the 1999 WHO criteria (1)
between capillary and venous glucose measurements was 78% (k=0.65, p<0.001).
Sensitivity and specificity to diagnose type 2 diabetes by capillary glucose
measurements were 84% and 98%, respectively. Among the subjects with diabetes, 17
out of 111 subjects (15.3%) were classified as IGT by capillary glucose criteria
compared with classification by venous glucose criteria and thus remained glucose
intolerant. Only 1 subject was classified as normal glucose tolerant (NGT). In subjects
with NGT, 12 out of 143 subjects (8.4%) were classified as IGT and none as having
type 2 diabetes. However, in subjects with IGT, 48 out of 96 subjects (50.0%) were
differently categorised of which 44 were diagnosed as NGT according to capillary
levels. Therefore, we concluded that capillary glucose measurements are sufficiently
reliable and precise to detect subjects with NGT and type 2 diabetes when using
Glucometer Elite®, but that subjects with IGT cannot be diagnosed as reliably with
capillary glucose measurements.
The finding that IGT cannot be diagnosed as reliably with capillary glucose
measurements compared to NGT and type 2 diabetes may partly be an artefact caused
by the narrow range of defined cut-off points for 2-hour glucose concentrations in IGT.
Small deviations (i.e. 0.2 mmol/L) can result in large numbers of misclassification. In
addition, the background of IGT represents a diverse set of metabolic abnormalities
including insulin secretion defects and insulin resistance, and to precisely define IGT
status remains a topic of continued discussion (9-12). The upper cut-off value has been
firmly established as the point between risk of microvascular complications, such as
diabetic retinopathy, and minimal risk of complications. On the other hand, the lower
cut-off value for IGT is based on consensus rather than on evidence. More research is
needed to see whether modification of the lower value is worthwhile in identifying
subjects at risk of type 2 diabetes and CVD.
7.2: Type 2 diabetes and arterial wall properties
The increased risk of CVD in type 2 diabetes is thought to be caused by an increased
rate of atherosclerosis. The atherosclerotic process in itself is slow and relatively
benign. Therefore, it can take many years until the first clinical manifestations present
itself and result in cardiovascular events (13). Clinical manifestations of CVD however,
are 2 to 4 times more frequent in diabetes than in the control population. As discussed
in Chapter 1, clustering of multiple risk factors for atherosclerosis, inflammation and/or
a combination of these processes as well as presently unknown factors, are thought to
be crucial in the development of CVD events. Furthermore, lipid retention in the arterial
wall is considered a very important part of the atherosclerotic process. Lipid retention
was shown to be accelerated by advanced glycation end-products (AGEs) which can
trap soluble plasma lipoproteins in the arterial wall (14). The specific interaction of LDL
with the negatively charged glycosaminoglycans of proteoglycans in the arterial intima
increase the susceptibility of LDL to oxidation processes (15). Also, high concentrations
144
General discussion
of free fatty acids (FFA) are often found in plasma of subjects with type 2 diabetes (16)
and FFA can increase the affinity of the matrix for LDL to the proteoglycan matrix
(15.17).
The slow and silent progression of atherosclerosis in humans has resulted in a
search for surrogate markers to study determinants of atherosclerosis and the influence
of disease modifiers on atherosclerosis progression Two of these surrogate markers
are intima-media thickness (IMT) and arterial stiffness. IMT measurements include
among others structural changes involving hyperplasia of arterial smooth muscle cells
(18). but are also subject to remodelling Arterial stiffness is considered to be a
measure of early functional loss of elasticity and compliance within the vascular system
(19). An increase in carotid IMT was shown to be associated with an increase in
cardiovascular events by several prospective cohort studies (13) and in general reflect
increased vascular aging Furthermore. IMT has been validated as a marker of vascular
damage and of future cardiovascular risk (20). Arterial stiffness can be represented by
different parameters, i.e the distensibility coefficient, the compliance coefficient, or
Young's elastic modulus (YEM) (21). Reproducibility of these parameters is adequately
sufficient to be used in epidemiological studies (22,23), and it has been shown that both
distensibility and YEM are strong independent predictors of future CVD (24,25) In the
present study, we used IMT and YEM as validated surrogate markers of
atherosclerosis.
In the CODAM study, ultrasound measurements were done at a single point in the
common carotid artery. This enabled the calculation of both surrogate markers of the
atherosclerotis process, i.e IMT and arterial stiffness at the same arterial site, namely
between 10-20 mm of the bifurcation of the common carotid artery Our protocol to
accept ultrasound measurements was very strict to reduce the chance of including
erroneous results in analysis which might have affected the outcomes. Reasons for
missing data on ultrasound measurements, or subjects, in the CODAM study were
cardiac arrhythmia (extrasystoles. atrial fibrillation) (26), longitudinal or oscillating
movements of the carotid artery which may indicate enhanced atherosclerosis (27),
(neck) obesity, or logistic problems. In general, subjects who did not complete the
ultrasound measurements were more obese than subjects who successfully underwent
all measurements (Chapter 2). It can be speculated that complete measurements of the
missing subjects would, most likely, have strengthened our present findings, especially
the data on arterial stiffness, because obesity was a predictor of arterial stiffness in the
present study (see section 7.2.2). In future studies, missing data may be prevented by
improving ultrasound protocols in such manner that movements of the carotid artery or
cardiac arrhythmia has no influence on the performance and outcome of the
measurements. See also section 7.6.2 and 7.6.3.
7.2.1: Intima-media th ickness
Intima-media thickness (IMT) has been reported to be increased in subjects with type 2
diabetes (28-37) However, most of these studies recruited diabetes patients fom
clinics. It is likely that these patients had diabetes of longer duration than subjects
detected by screening or at least had a clinical manifestation that warranted diagnostic
procedures and/or treatment in the clinic. A longer duration may well have resulted in
the increased IMT reported in literature (28-37). In contrast, we found similar IMT
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among subjects with recently diagnosed type 2 diabetes, IGT and NGT (Chapter 5).
Recently, Hunt et al. also reported that common carotid artery IMT was similar in pre-
diabetic and non-diabetic subjects (38). Moreover, we could establish that carotid
diameter and pulse pressure, but not the pre-diabetic state or type 2 diabetes itself,
were independent predictors of carotid IMT.
With increasing age, arterial remodelling can result in increased IMT as a
compensatory response to counteract increased arterial wall stress caused by an
increased luminal diameter (Law of Laplace). Due to the fact that ultrasound protocols
were similar in the Hoorn study (39) and the present CODAM study, we could estimate
the yearly increment in IMT, albeit in a crude manner (Chapter 5). From the published
data of the Hoorn study, it appeared that subjects with diabetes aged 70 years or older
had higher IMT than NGT subjects (39). Our estimation suggests that, between 59 and
69 years of age, an acceleration occurs in IMT thickening in subjects with recently
diagnosed type 2 diabetes compared to subjects with NGT. This supports the finding in
the literature that IMT can be increased in longstanding type 2 diabetes (28-37), as well
as the concept that arterial wall properties, measured as IMT, deteriorate more rapidly
during hyperglycemia and with clustering of risk factors, such as obesity and
hypertension, than with increasing age alone. Furthermore, the estimation also
suggests that a substantial part of the increase in IMT occurs during the diabetic state
and, therefore, may be prevented. In the interpretation of these data, it should be
recognized that IMT is not a static measure, but is subject to remodelling.
7.2.2: Arterial stiffness
Arterial stiffness can be described by the distensibility and compliance coefficients, or
Young's elastic modulus (YEM), as described before. More specifically, the distensibility
and compliance coefficients indicate arterial adaptation, whereas YEM represents
arterial remodelling (18,19). In the present study, the distensibility coefficient and YEM
were predicted by the same variables, i.e. age, gender, hypertension, total cholesterol,
and sagittal diameter. These variables explained 38.4% of the variance in the
distensibility coefficient and 27.8% of the variance in YEM As the contributing variables
were identical and because the distensibility coefficient is used in the calculation of
YEM, we focused on YEM in Chapter 5. YEM was significantly higher in subjects with
type 2 diabetes compared to subjects with IGT or NGT. In Chapter 2, we showed that
the compliance coefficient was similar among subjects with type 2 diabetes, IGT and
NOT, but that the distensibility coefficient was significantly different between these
three groups. Therefore, we conclude that arterial stiffness, and more specifically
arterial adaptation and remodelling, was already significantly increased in recently
diagnosed type 2 diabetes. This may indicate that factors other than hyperglycemia are
responsible for this early increase, and that early prevention or reduction of arterial
stiffness may be a realistic future aim in diabetes. It is not fully clear yet why arterial
stiffness is already higher in recently diagnosed type 2 diabetes. Clustering of several
factors, including hypertension, obesity and increased free fatty acids, against the
background of hyperglycemia, may play an important role.
We furthermore estimate the increase h YEM to be accelerated in subjects with
diabetes compared to NGT subjects by data from the Hoorn study (39) and the present
study (Chapter 5). This estimation could indicate that, once type 2 diabetes has
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developed, hyperglycemia can have an effect additive to the effect of age and
hypertension on increasing arterial stiffness, probably by the effect of AGEs that cause
structural changes in the vessel wall (15).
7.3: Type 2 diabetes and cardiovascular disease (CVD)
We already mentioned that the risk of CVD is increased two to fourfold in subjects with
type 2 diabetes compared to non-diabetic subjects, and over 50% of all patients with
type 2 diabetes die from coronary heart disease (40). When patients with diabetes
develop CVD, they sustain a worse prognosis for survival than do CVD patients without
diabetes (41). Both type 2 diabetes and CVD have common risk factors such as age,
obesity, hypertension and dyslipidemia. Clustering of these risk factors are often seen
in type 2 diabetes, but usually precede the onset of diabetes by several years.
In Chapter 2. we showed that hyperglycemia is associated with risk factors for CVD.
such as elevated plasma cholesterol, triglycerides, free fatty acids and insulin
concentrations, as well as with increased body fatness and increased abdominal fat.
Furthermore, subjects with type 2 diabetes had significantly more hypertension,
peripheral vascular disease, and endothelial and renal dysfunction. Moreover, carotid
arterial stiffness, a surrogate marker of atherosclerosis, was already increased in
subjects with recently diagnosed type 2 diabetes. Self-reported CVD and coronary
heart disease were somewhat higher in subjects with type 2 diabetes than in subjects
with NGT. 25.7% versus 20.1% and 20.0% versus 16.9% respectively, but these
differences were not statistically significant. This may be due to the fact that these
subjects were diagnosed early in the disease process. We conclude therefore, that
subjects in the CODAM study with recently diagnosed type 2 diabetes are at increased
risk of CVD and already have some pre-clinical vascular damage, although not
sufficiently to have caused significantly more cardiovascular events.
7.4: Progression to type 2 diabetes: influence of free fatty
acids ana blood pressure
Several factors are involved in the progression from IGT to type 2 diabetes, which also
increase the risk of CVD, i.e. obesity, hypertension, dyslipidemia, and hyperglycemia. In
Chapter 5, we showed that hypertension was one of the determinants of arterial
stiffness and that pulse pressure (PP), the difference between systolic and diastolic
blood pressure, was an important determinant of IMT. Therefore, we divided the
subjects in quartiles of PP to analyse whether subjects with the highest PP had
increased clinical disorders, such as type 2 diabetes mellitus and the metabolic
syndrome (Chapter 6). We observed that cohort participants in the highest quartile of
PP, i.e. > 67 mmHg, had a significantly greater proportion of type 2 diabetes and
metabolic syndrome. This may be partly explained by a larger degree of insulin
resistance, represented by the significantly higher HOMA-index, in the highest PP
quartile. As classical lipid profiles were similar in the quartiles, we suggested that
individuals in the highest PP quartile were subjected to other specific factors that are
associated with progression to type 2 diabetes. These factors may be a higher BMI,
147
Chapter 7
waist circumference, and hypertension, but also higher free fatty acids (FFA). We found
that fasting FFA plasma concentration increased over quartiles of PP, and was a small,
but significant predictor of PP in the present CODAM study (Chapter 6). Plasma FFA
concentration is tightly regulated and whether the effect of FFA on PP is direct or
indirect, for instance via effects on gene expression, remains to be determined.
Several arguments have been published to explain why plasma FFA may be
involved in metabolic processes that underlie the progression from IGT to type 2
diabetes. Many factors may contribute to this progression, including a relative
impairment of uptake and oxidation of FFA which can result in an elevated plasma FFA
concentration (42). Elevated plasma FFA can cause the development of insulin
resistance (43) which may result in an increased supply of FFA to the liver and
increased gluconeogenesis, a hallmark of diabetes. Therefore, FFA are a serious
candidate implicated in the progression from impaired glucose tolerance to type 2
diabetes. Furthermore, our results were in agreement with the Paris Prospective Study
which showed that FFA were associated with the development of hypertension (44).
Taken all evidence together, FFA may represent a pleiotropic metabolic factor that may
be implicated in increments in PP and in progression from IGT to type 2 diabetes.
7.5: Implications of the CODAM study
In Chapter 2, we showed that self-reported CVD and coronary heart disease were not
significantly different between subjects with recently diagnosed type 2 diabetes, IGT or
NGT in the CODAM study. However, once type 2 diabetes is present, we estimate that
IMT and arterial stiffness, two surrogate markers of atherosclerosis, may increase more
over time than would be expected compared to normal subjects (Chapter 5). This has
also been shown in several studies (28-37,39). One possibility is that, when plasma
glucose exceeds the diagnostic threshold of diabetes, the effect of risk factors for CVD
increase to such extent that the aging process of the vessels of subjects with diabetes
seems to be accelerated compared to normal subjects, and CVD events occur earlier
and more frequently than would be expected at that age. We schematically show this
hypothesis in Figure 1, in which we outlined a possible relationship between age and
CVD events for different situations.
With increasing age, the risk on CVD is increasing. Once it increases above a
hypothetical threshold, CVD events start to occur. Four different situations have been
outlined. Line P represents individuals who are protected against CVD events, either
genetically or by lifestyle, or both. Line N represents the normal situation that occurs in
most individuals. Line S represents individuals who are susceptible for CVD events
such as subjects with familial combined hyperlipidemia (FCH) or familial
hypercholesterolemia, who are at risk of myocardial infarction before the age of 60 (45).
Line DM represents subjects who are hyperglycaemic and develop type 2 diabetes.
These subjects follow the normal line N until diabetes is present at point X1 or X2. It is
even possible that subjects that develop type 2 diabetes in the future are at a higher
risk compared to subjects who don't develop type 2 diabetes, as clustering of risk
factors precedes the development of type 2 diabetes in these subjects. In this case, the
line should be between line N and line S. After point X1 or X2, the point at which
diabetes is presenting, the risk on CVD increases faster, probably exponentially, which
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results in an earlier occurrence of a CVD event than when type 2 diabetes is not
present. In epidemiological studies, a higher risk of CVD events in type 2 diabetes has
been shown (2,8). Recently. Scuteri et al. published results from the Baltimore
Longitudinal Study that showed that components of the metabolic syndrome interact
synergistically on vascular thickness and stiffness which results in amplified vascular
aging (46). These results are in agreement with our hypothesis of increased vascular
aging against a background of hyperglycemia. Whether this increased risk is caused by
clustering of different risk factors, increased oxidative stress or inflammation of the
arterial wall remains to be determined by future research.
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Figure 1: Hypothetical relationship between age and cardiovascular events for different situations. P •
protected (D); N = normal (O); DM = diabetes ( • ) ; S = susceptible for cardiovascular events, for example
subjects with familial hypercholesterolemia ( • ) ; the horizontal line represents the threshold at which
cardiovascular events become clinically manifest
7.6 Technical considerations
7.6.1: Diagnosis and treatment of type 2 diabetes
Early diagnosis of type 2 diabetes and proper treatment may reduce, or even prevent,
future CVD events. For an early diagnosis or type 2 diabetes, we recommend screening
for diabetes of every hypertensive patient, especially those with a high pulse pressure.
This screening can be very useful and cost effective because we showed in Chapter 6
that -40% of the subjects with a pulse pressure > 67 mmHg had type 2 diabetes, with a
resulting odds ratio of 2.1 compared to subjects with a pulse pressure s 48 mmHg.
Capillary glucose measurements may be used for this screening because they are
relatively easy to use and fairly cheap compared to venous glucose measurements.
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Moreover, we showed in Chapter 4 that sensitivity and specificity of these
measurements were high enough to detect type 2 diabetes in a reliable manner.
Several landmark studies have shown a beneficial effect of treatment of one risk
factor with medication on the cardiovascular risk in type 2 diabetes (47-49). Moreover,
several programs that aimed at changing lifestyle, with or without added medication,
already showed that progression from IGT to type 2 diabetes can be reduced or
delayed (49-53). That a combination of treatments, beneficial to all cardiovascular risk
factors, is to be recommended in type 2 diabetes was recently demonstrated by the
STENO-2 study (54,55). In the STENO-2 study, multiple risk factors were treated at the
same time (behaviour modifications, as well as treatment of hyperglycemia,
hypertension, dyslipidemia and microalbuminuria, and giving aspirin) for secondary
prevention. The risk of cardiovascular and microvascular events, such as retinopathy,
nephropathy, and neuropathy, was reduced by 50 percent (54,55).
7.6.2: Methods to measure arterial stiffness
As a large part of the missing values were caused by oscillating movements of the
carotid artery, it may be argued that the pulse wave velocity technique (PWV) is a
better method than the ultrasound wall track technique to measure arterial stiffness.
However, if arterial segments are not straight, measurement of the distance may be a
weak and unreliable point in PWV measurements, especially if the proximal and distal
pulse waves are recorded from two different arterial axis sites where the pulse waves
propagate in opposite directions, such as the carotid and radial artery (26). So, it can be
expected that measurements can be obtained in nearly all subjects by this technique,
but these measurements may be inaccurate. In the carotid femoral PWV measurement
for example, which could have been used as an alternative for ultrasound
measurements in the present study, this problem arises (26). In addition, abdominal
obesity, particularly in men, and large bust in women can make distance measurements
inaccurate (26). As obesity, especially abdominal obesity, is far more prevalent in the
type 2 diabetes population, it remains a question whether PWV will result in accurate
and valid measurements of arterial stiffness. Therefore, strict validation studies
between PWV and ultrasound measurements of arterial stiffness in different
populations are urgently needed. These will also have the advantage to facilitate the
comparison between studies using either technique. An ultimate solution may be the
development of faster ultrasound protocols for carotid artery wall evaluation, because
this may solve current problems encountered.
7.6.3: Blood pressure measurements
In the CODAM study, arterial vessel wall characteristics were calculated with pulse
pressure (PP) measured at the brachial artery as a substitute for carotid artery PP.
Blood pressure measured at the brachial artery can deviate from blood pressure
measured at the carotid artery although (the few) available data suggest that the
differences are relatively small. For example, in a study by Waddell et al., brachial
blood pressures measured with a Dinamap were only 8 mmHg higher than carotid
blood pressures measured with applanation tonometry in normal subjects (56).
Applanation tonometry allows non-invasive recording of the arterial pressure waveform
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and magnitude in both central and peripheral arteries (26) The difference between
brachial and carotid blood pressure was lower in subjects with moderate and severe
coronary heart disease. 6.5 and 2.6 mmHg, respectively. This indicates that
distensibility. compliance and Young's elastic modulus may have been underestimated
when measuring PP in the brachial artery instead of using applanation tonometry to
measure pressure in the carotid artery However, some controversy exists about
measuring blood pressure by applanation tonometry It has been shown that
overestimation is a possibility and several investigators found the magnitude of PP
obtained by applanation tonometry to be unreliable (27). Moreover, applanation
tonometry can not be applied to all subjects and at all arterial sites (57)
Another method to measure local PP uses a transfer function from the pressure
wave measured at an other site (58). However, from the radial artery PP. only carotid
arteries and ascending aorta PP can be assessed by this technique (27) Furthermore,
the transfer function is an average over many subjects which may lead to loss of
specific information of individuals Therefore, this technique seems to be limited.
PP differences between central and peripheral arteries tend to decrease with aging
(59) Therefore, it is unlikely that possible differences between brachial PP measured in
the present study and the actual carotid PP would have resulted in other conclusions
than presented in this thesis, because subjects were mostly elderly (mean age 59.1 ±
7.0 yrs). Moreover, over- or underestimation of distensibility, compliance and YEM by
using brachial PP has been systematically similar in all subjects in this study. This fact
enabled comparison between subjects with type 2 diabetes and with IGT or NGT.
However, for future studies we recommend that either local PP is measured by
applanation tonometry. or that arterial wall properties are compared under isobaric
conditions, especially when different populations are compared. Recently, a new
promising method to assess local pressure has been published (60). Local pressure
waveforms can be derived from arterial cross-sections by iteratively calibrating an
exponential relationship between pressure and arterial cross-section to end diastolic
and mean arterial pressure (60). This results in an estimate of the wall rigidity (a), but
can also be used to derive PWV, YEM, distensibility and compliance as a function of
the distending pressure during the cardiac cycle. A large advantage is that this method
can be applied to any artery in the arterial tree. Therefore, this method seems very
suitable to compare arterial wall properties under isobaric conditions between different
populations.
7.7: Conclusions
In this thesis, we showed that capillary glucose measurements can result in more cost-
effective inclusion schemes in screening studies than venous glucose measurements.
Furthermore, several pieces of evidence were identified to support the theory that a
higher incidence of cardiovascular disease in type 2 diabetes can be related to an
accelerated course of atherosclerosis and vessel wall abnormalities IMT is not
increased in subjects with type 2 diabetes when recently diagnosed, but may accelerate
during the diabetic state Arterial wall stiffness however, is already increased at
diagnosis of type 2 diabetes.
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The present data, when confirmed by others or in longitudinal studies, provide a
positive perspective to the early treatment of implicated risk factors in type 2 diabetes.
Specifically, hyperglycemia remains an obvious target for treatment whereas
hypertension and fatty acid abnormalities appear to be the most relevant new targets.
No differences seem to exist in the prevalence of cardiovascular events between
subjects with and without diabetes in the CODAM study when diagnosed in an early
stage. This observation emphasizes the importance of early detection of type 2
diabetes and appropriate treatment of cardiovascular risk factors, especially in subjects
at high risk of developing type 2 diabetes and cardiovascular disease.
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Chapter 1 describes the background and aims of this thesis. Type 2 diabetes mellitus
is the most common form of diabetes and is estimated to increase in a pandemic
manner over the next 10 to 20 years (1). Although the early symptoms are often not
severe, the long-term effects of hyperglycemia result in, or are associated with, micro-
and macrovascular disease like retinopathy, neuropathy, and atherosclerosis (2,3).
Ultimately, this can lead to blindness, renal failure, and cardiovascular events such as
myocardial infarction and stroke. Different risk scores have been developed to enable
physicians to calculate an individual's risk on future cardiovascular events and initiate
appropriate treatment (4-7).
The atherosclerosis process is often slow and principally occurs in large and
medium-sized arteries. Two theories exist nowadays to explain the process of
atherosclerosis, i.e. the response-to-injury hypothesis and the response-to-retention
hypothesis. The response-to-injury hypothesis states that atherosclerosis is a process
of endothelial injury or activation and of inflammation. Hyperlipidemia, endothelial
dysfunction and permeability, blood flow, and Ipoprotein oxidation are thought to be
causes of the early atherosclerosis process. In contradiction with this theory, the
response-to-retention hypothesis states that lipid retention in the arterial wall is the key
pathogenic event that is necessary for the formation of an atherosclerotic lesionm, and
hyperlipidemia, lipoprotein modification, turbulent blood flow and alterations in
endothelium, smooth muscle cells and the matrix only contribute to the atherosclerosis
process. Both theories have their merit. However, recent findings favour the response-
to-retention hypothesis (8). Factors such as hyperlipidemia, smoking, hypertension,
turbulent blood flow and lipoprotein oxidation can increase the harmful effects of lipid
retention in the arterial wall and contribute to the development of an atherosclerotic
lesion into an atherosclerotic plaque. The response-to-injury theory may be more
appropriate to describe the development to an unstable vulnerable plaque (9).
As the nature of the atherosclerosis process is slow, surrogate markers such as
intima-media thickness and arterial stiffness measurements have been used to
investigate determinants of atherosclerosis at an early stage and/or to assess disease
modifiers (10). Prospective studies have shown that both intima-media thickness and
arterial stiffness can be used as good indicators of cardiovascular risk (11).
Type 2 diabetes mellitus and cardiovascular disease share common risk factors.
Clustering of several of these risk factors is common and is recently defined as the
metabolic syndrome (12). As the presence of type 2 diabetes increases the
cardiovascular risk two to four times, it is crucial to understand how atherosclerosis
develops and progresses in subjects with type 2 diabetes. There is evidence that
subjects in the pre-diabetic state are already at high risk for cardiovascular events (3)
and early detection of insulin resistance is likely to identify those persons who are at
risk of developing dyslipidemia, hypertension, and ultimately diabetes.
Chapter 2 describes the subjects, methods, and design of the CODAM study, as well
as some results. We showed that hyperglycemia is associated with a number of
metabolic and vascular abnormalities. Furthermore, significantly more target damage at
the level of the large vessels and kidneys was found in subjects with type 2 diabetes, as
well as increased inflammatory markers. Therefore, we concluded that subjects with
recently diagnosed type 2 diabetes were already at increased cardiovascular risk and
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even showed some vascular damage. This was mostly due to, or associated with,
metabolic abnormalities.
Chapter 3 presents the results of the preliminary screening of the CODAM and SLIM
study (N=2820 subjects). Abnormal glucose homeostasis was found in 826 subjects
(30.4%): 226 subjects had type 2 diabetes mellitus (8.3%), 385 subjects had impaired
glucose tolerance (14.2%), and 215 subjects had impaired fasting glucose (7.9%).
Increasing age and BMI were both positively related to the prevalence of type 2
diabetes and impaired glucose tolerance. The high prevalence of disturbances in
glucose homeostasis underscores the importance of early interventions in those at risk
for developing diabetes.
Chapter 4 presents the results of a comparative study between capillary blood glucose
measurements done with a Glucometer Elite® and venous blood glucose
measurements determined in our laboratory. We showed that capillary glucose
measurements are reliable and sufficiently precise to detect subjects with normal
glucose tolerance and type 2 diabetes mellitus. Subjects with impaired glucose
tolerance could not be diagnosed as reliably with capillary glucose measurements.
Nevertheless, use of capillary glucose measurements resulted in a more favourable
ratio of screened and detected subjects with impaired glucose tolerance in our study
compared to the situation where other inclusion procedures were used.
Chapter 5 showed that intima-media thickness of the common carotid artery was
similar among subjects with recently diagnosed type 2 diabetes, impaired glucose
tolerance and normal glucose tolerance. Pulse pressure and carotid diameter, but not
the pre-diabetic state or type 2 diabetes, were independent contributors to IMT On the
other hand, an apparent acceleration occurs in IMT thickening in subjects with type 2
diabetes when data were used from a similar cohort study with older subjects and
included subjects with diabetes of longer duration In the interpretation of these data, it
should be recognized that IMT is not a static measure but is subject to remodelling.
This suggested that a substantial part of the increase in IMT occurs during the diabetic
state and may be prevented.
Arterial stiffness, represented by Young's elastic modulus, was already increased in
subjects with recently diagnosed type 2 diabetes. Furthermore, is seems that the
increase in arterial stiffness is accelerated in subjects with type 2 diabetes compared to
subjects with normal glucose tolerance. Clustering of several risk factors, including
hypertension, obesity and total cholesterol, against a background of hyperglycemia,
may play an important role in the increase in arterial stiffness. Follow up studies are
needed to confirm our initial estimates of accelerated increase in intima-media
thickening and arterial stiffness as well as the effect of medication or lifestyle
intervention on the prevention of future cardiovascular events.
Chapter 6 showed that increased pulse pressure is not only associated with
hypertension and left ventricular hypertrophy, but also with serious clinical metabolic
disorders such as type 2 diabetes mellitus and the metabolic syndrome, as well as
other metabolic abnormalities, specifically increased plasma concentrations of glucose,
fatty acids, and insulin. In the highest pulse pressure quartile (2 67 mm Hg), 39.4% of
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subjects had type 2 diabetes whereas more than half of the study population (51.4%)
had metabolic syndrome according to the National Cholesterol Education Program
(NCEP) definition (12). Plasma free fatty acids were identified as a novel, independent,
metabolic determinant of pulse pressure in multivariate regression analysis, in addition
to age, gender, carotid intima-media thickness and diameter, waist circumference,
ankle/brachial index and mean arterial pressure. Several data suggested that an
increase of free fatty acids can increase blood pressure (13-15), and a prospective
association between plasma free fatty acids and the development of hypertension has
been shown (16). Moderately elevated plasma free fatty acids in subjects with high
pulse pressure can therefore reflect an underlying, pivotal metabolic abnormality
involved in the observed association of hypertension with diabetes and the metabolic
syndrome.
Chapter 7 discusses the main results and puts them into perspective. Furthermore, a
hypothetical model about the relationship between type 2 diabetes and cardiovascular
complications is described. Suggestions for future research are made.
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In Hoofdstuk 1 wordt de achtergrond van dit proefschrift beschreven. Type 2 diabetes
mellitus, of ouderdomssuikerziekte, is de meest voorkomende vorm van diabetes. De
schatting is dat de prevalentie van type 2 diabetes pandemisch zal gaan stijgen in de
aankomende 10 tot 20 jaar. Hoewel de symptomen in het begin vaak niet ernstig zijn
kunnen de lange termijn effecten van chronische hyperglycemie leiden tot micro- en
macrovasculaire ziektes zoals retinopathie, neuropathie en atherosclerose. Uiteindelijk
kunnen deze ziektes leiden tot blindheid, nierfalen en cardiovasculaire complicaties
zoals een hartinfarct of beroerte. Er zijn verschillende formules ontwikkeld om het
risico van een patient op hart- en vaatziektes in de toekomst te berekenen zodat de
patient op de juiste wijze behandeld kan worden.
Het atherosclerose proces, dat tot hart- en vaatziektes leidt, verloopt vaak
langzaam en vindt vooral plaats in de grote en middelgrote arterien. Momenteel
bestaan er twee theorieen die het atherosclerose proces verklaren, namelijk de
response-to-injury (respons-op-verwonding) hypothese en de response-to-retention
(respons-op-vasthouden) hypothese. De response-to-injury hypothese verkondigd dat
atherosclerose een proces is veroorzaakt door beschadiging en activatie van het
endotheel en van ontstekingsprocessen. Hyperlipidemie, endotheel dysfunctie and
permeabiliteit, bloedstroming, and lipoproteine oxidatie worden aangewezen als
oorzaken van het vervroege atherosclerose proces. In tegenstelling met deze theorie
verkondigt de response-to-retention hypothese dat lipide retentie in de arteriele
vaatwand de pathogene sleutel gebeurtenis is die nodig is voor de vorming van een
atherosclerotische lesie en dat hyperlipidemie, lipoproteine modificatie, turbulente
bloedstroming en veranderingen in het endotheel, de gladde spiercellen en de matrix
alleen bijdragen aan het atheroslerotische proces. Beide theorieen hebben hun
voordelen. Recente bevindingen echter spreken voor de respons-to-retention
hypothese. Factoren zoals hyperlipidemie, roken, hypertensie, turbulente
bloedstroming en lipoproteine oxidatie kunnen de schadelijke effecten van het
vasthouden van vetten in de arteriele wand vergroten en daardoor bijdragen aan de
ontwikkeling van een atherosclerotische lesie naar een atherosclerotische plaque. De
response-to-injury hypothese is waarschijnlijk geschikter om de ontwikkeling tot een
onstabiele kwetsbare plaque te beschrijven.
Omdat het atherosclerose proces langzaam verloopt worden er surrogaat markers
zoals intima-media dikte en arteriele stijfheid metingen gebruikt om determinanten van
vroege atherosclerose te onderzoeken en om factoren die het verloop van hart- en
vaatziektes wijzigen te bepalen. Prospectieve studies hebben aangetoond dat zowel
intima-media dikte als arteriele stijfheid goede indicatoren zijn van het risico op hart- en
vaatziektes.
Type 2 diabetes en hart- en vaatziektes delen gemeenschappelijke risicofactoren.
Over het algemeen komt clustering van verschillende van deze risicofactoren veel voor.
Pas geleden is deze clustering gedefinieerd als het metabole syndroom. Omdat de
aanwezigheid van type 2 diabetes het risico op hart- en vaatziektes 2 tot 4 keer
vergroot is het van cruciaal belang om de ontwikkeling en het verloop van
atherosclerose bij personen met type 2 diabetes te begrijpen. Het is hewezen dat
mensen in het voorstadium van type 2 diabetes al een verhoogd risico op hart- en
vaatziektes hebben en een vroege detectie van insuline resistentie kan
hoogstwaarschijnlijk die personen identificeren die het risico lopen om dyslipidemie,
hypertensie, en uiteindelijk type 2 diabetes te ontwikkelen.
162
Samcnvattirtg
Hoofdstuk 2 beschrijft de proefpersonen. onderzoeksmethodes. en de opzet van de
CODAM studie alsook enkele resultaten We toonden aan dat hyperglycemie
geassocieerd is met een aantal metabole en vasculaire afwijkingen. Verder werd er
significant meer doel orgaan schade gevonden op het nivo van de grote vaten en
nieren en werden er verhoogde nivo's van inflammatoire markers gevonden bij mensen
met type 2 diabetes. Daardoor kwamen we tot de conclusie dat mensen met recent
gediagnostiseerde type 2 diabetes reeds een verhoogd risico op hart - en vaatziektes
hebben en zelfs al enige vaatschade vertonen. Dit wordt voornamelijk veroorzaakt door
metabole afwijkingen.
In Hoofdstuk 3worden de resultaten van de voorafgaande screening van de CODAM
studie gepresenteerd (N=2820 proefpersonen). Een afwijkende glucose homeostase
werd gevonden bij 826 mensen (30.4%): 226 personen hadden type 2 diabetes mellitus
(8.3%), 385 personen hadden een verstoorde glucose tolerantie (14.2%), en 215
personen hadden een verstoorde nuchtere glucose concentratie (7.9%). Toegenomen
leeftijd en BMI waren beide positief gerelateerd aan de prevalence van type 2 diabetes
en verstoorde glucose tolerantie. De hoge prevalentie van verstoringen in glucose
homeostase onderstreept het belang van vroege interventie in die personen die risico
lopen op het ontwikkelen van diabetes.
In Hoofdstuk 4 worden de resultaten gepresenteerd van een vergelijkende studie
tussen capillaire bloed glucose metingen bepaald met een Glucometer Elite® en
veneuze bloed glucose metingen bepaald in ons laboratorium. We toonden aan dat
capillaire glucose metingen betrouwbaar en nauwkeurig genoeg zijn om mensen met
normale glucose tolerantie of type 2 diabetes mellitus op te sporen Mensen met een
verstoorde glucose tolerantie konden niet zo betrouwbaar worden opgespoord met
capillaire glucose metingen. Niettemin resulteerde het gebruik van capillaire glucose
metingen wel in een gunstigere ratio van gemeten personen tov opgespoorde
proefpersonen met een verstoorde glucose tolerantie in onze studie vergeleken met
een situatie waarin andere inclusie procedures werden gevolgd
In Hoofdstuk 5 lieten we zien dat de intima-media dikte van de carotis communis
arterie gelijk was bij proefpersonen met recent gediagnostiseerde type 2 diabetes,
verstoorde glucose tolerantie en normale glucose tolerantie. Polsdruk en de diameter
van de carotis, maar niet het voorstadium van type 2 diabetes of type 2 diabetes zelf,
droegen onafhankelijk bij aan intima-media dikte. Het lijkt erop dat er een versnelling
optreedt in de verdikking van de intima-media bij proefpersonen met type 2 diabetes
wanneer we naar de data kijken van een gelijkwaardige cohort studie waarin oudere
proefpersonen en proefpersonen met een langere duur van diabetes dan in onze studie
zijn ingesloten. Bij de interpretatie van deze data dient rekening te worden gehouden
met het feit dat intima-media dikte geen statische maat is, maar onderhevig is aan
aanpassingen. Dit suggereert dat een aanzienlijk deel van de toename in intima-media
dikte optreedt wanneer type 2 diabetes aanwezig is en dus vroegtijdig voorkomen zou
kunnen worden.
Arteriele stijfheid, vertegenwoordigd door Youngs elastische modulus, was reeds
toegenomen bij proefpersonen met recent gediagnostiseerde type 2 diabetes. Verder
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lijkt het erop dat de toename in arteriele stijfheid versneld is bij personen met type 2
diabetes vergeleken met mensen met een normale glucose tolerantie. Clustering van
verschillende risicofactoren waaronder hypertensie, overgewicht en totale cholesterol
concentratie tegen een achtergrond van hyperglycemie zou een belangrijke rol kunnen
spelen in de toename van arteriele stijfheid. Vervolgstudies zijn nodig om onze eerste
schatting van versnelde intima-media verdikking en toename van arteriele stijfheid
alsmede het effect van medicatie of leefstijl interventies op de preventie van
toekomstige hart- en vaatziektes te bevestigen. 5 > * s >»-
Hoofdstuk 6 Net zien dat een verhoogde polsdruk niet alleen samenhangt met
hypertensie en linker ventrikel hypertrofie, maar ook met andere ernstige klinische
metabole stoornissen zoals type 2 diabetes mellitus en het metabool syndroom, alsook
met metabole afwijkingen, in het bijzonder verhoogde plasma concentraties van
glucose, vetzuren en insuline. In het hoogste polsdruk kwartiel (> 67 mmHg) was 39.4%
van de proefpersonen diabeet terwiji meer dan de helft van de studie populatie (51.4%)
aan het metabool syndroom leed volgens de definitie van het National Cholesterol
Education Program (NCEP). Naast leeftijd, geslacht, intima-media dikte en diameter
van de carotis, middelomtrek, enkel/arm index en de gemiddelde arteriele druk werden
plasma vrije vetzuren geidentificeerd als een nieuwe, onafhankelijke, metabole
determinant van polsdruk in meervoudige regressie analyse. Verschillende data
suggereerde dat een toename van vrije vetzuren de bloeddruk kan laten toenemen, en
een prospectieve associatie tussen plasma vrije vetzuren en de ontwikkeling van
hypertensie is aangetoond. Middelmatig toegenomen plasma vrije vetzuren bij
personen met een hoge polsdruk kunnen daarom een onderliggende, centrale
metabole abnormaliteit weerspiegelen die betrokken kan zijn bij de geobserveerde
associatie van hypertensie met diabetes en het metabool syndroom.
In Hoofdstuk 7 worden de belangrijkste resultaten besproken en vergeleken met
resultaten van ander onderzoek. Verder wordt er een hypothetisch model beschreven
over de relatie tussen type 2 diabetes en cardiovasculaire complicaties en worden er
suggesties gegeven voor toekomstig onderzoek.
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Ruim 12.000 bloedbuizen, 51.660 cupjes en bijna 72 liter bloed verder ben ik nu
eindelijk aan het allerlaatste onderdeel van mijn promotie-onderzoek toegekomen: het
dankwoord. De aantallen zeggen het al. Dit project had ik niet kunnen doen zonder de
hulp van een heleboel mensen.
Als eerste wil ik alle proefpersonen van de CODAM studie hartelijk danken voor hun
vrijwillige (!) medewerking. Zonder jullie hadden we nooit de gegevens gehad waarmee
dit proefschrift tot stand is gekomen. Bedankt voor de tijd die jullie vrij wilden maken om
aan dit onderzoek mee te doen.
Ten tweede wil ik natuurlijk mijn promotor bedanken, prof. Dr. TWA de Bruin. Tjerk,
hartelijk bedankt voor al je goede suggesties en sturing die er van jouw kant kwamen.
Toen ik net begon dacht ik dat het overdreven was om minimaal 1 keer in de week af te
spreken om je op de hoogte te houden van het reilen en zeilen van het project. Achteraf
bleek echter dat het een prima strategie was waardoor je zeer goed wist wat er zich
afspeelde tijdens elke fase van het onderzoek. Vooral in de afrondingsfase van dit
proefschrift stond je deur altijd open en kon ik altijd even met je van gedachten
wisselen over hoe ik de zaken het beste aan kon pakken. Heel veel succes met je
nieuwe baan in de Verenigde Staten.
Ook mijn co-promotoren, Dr. EE Blaak en Dr. EJM Feskens, wil ik hartelijk
bedanken. Ellen, ondanks je drukke bezigheden ben je altijd geinteresseerd geweest in
hoe het ging met het verzamelen en meten van de proefpersonen, en, toen dit eenmaal
afgerond was, hoe het stond met de manuscripten. Je was altijd bereid om artikelen
door te lezen en je gestructureerde kijk op de zaken heb ik altijd zeer gewaardeerd.
Edith, je werkt bij het RIVM en bent daardoor niet altijd even gemakkelijk bereikbaar.
Toch heb ik het idee dat we een goede samenwerking hebben gehad. Onze tripjes van
en naar elkaar waren altijd heel informatief en vooral ook gezellig. Je ervaring met
statistiek van grote databases heeft zeker bijgedragen aan de kwaliteit van de artikelen
on LiitoincJolijU uoli son «Jit piwofootIrifI.
Behalve Ellen en Edith ben ik ook Carla van der Kallen veel dank verschuldigd.
Carla, het is jammer dat er geen 3 co-promotoren mogen worden benoemd, want ik
heb veel gehad aan al je hulp bij statistische analyses en het doorlezen van de
manuscripten. Daarnaast konden we ook heerlijk kletsen over van alles en nog wat, iets
dat zeker een welkome afwisseling is als je de hele dag naar je beeldscherm zit te
kijken!
Ik wil de leden van de beoordelingscommissie hartelijk bedanken voor het vrijmaken
van tijd om dit proefschrift door te lezen en goed te keuren.
Andere mensen die van (mentaal) belang zijn geweest voor het slagen van het
onderzoeksproject zijn Rob van Dam, Griet Bos en Ronald Henry. Rob, bedankt voor
het selecteren van de personen voor de screening uit de MORGEN studie en de
gezelligheid op de congressen. Griet, mijn collega- en spiegel-aio aan de VU, bedankt
voor het uitwisselen van protocollen en het gedachten wisselen over problemen waar
we beide vrijwel tegelijkertijd tegenaan liepen. Ronald, fijn dat er nog een aio was die
zoveel proefpersonen moest "echo-en" en met wie ik kon discussieren over alles wat
hiermee te maken heeft, van het protocol tot het doen van de berekeningen aan toe.
Ellen Lambrichs en Eefje Corpeleijn, bedankt dat jullie mijn paranimfen willen zijn op
deze bijzondere dag! Ellen, ik ben blij dat ik jou naast me had staan bij het uitvoeren
van de echo-metingen, die verreweg de meeste tijd hebben gekost. Samen hebben we
geleerd hoe we de metingen moesten doen en kwamen we erachter dat dat lichamelijk,
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en na pakweg een jaar ook mentaal. behoorlijk zwaar kan zijn. Gelukkig konden we
elkaar tot het einde toe motiveren om toch nauwkeurig te blijven werken. Zonder jou
was het me nooit gelukt om alle metingen te doen. Heel veel dank daarvoor. Daarnaast
vond ik het heel gezellig om een tijd je kamergenoot te zijn! Eefje, bedankt voor alle
gezelligheid in de kroeg. de fietstochtjes, de culturele avondjes. de vele gezellige
saampjes eten avondjes en natuurlijk niet te vergeten de gezellige weekendjes weg
waar we net mee begonnen zijn. Ik hoop dat er nog vele avondjes en weekendjes
zullen volgen! Verder wil ik je bedanken voor het doorlezen van dit proefschrift in een
voor jou erg drukke periode Heel veel succes met het afronden van jouw proefschrift!
Bijna 600 mensen hebben deelgenomen aan het onderzoek waarop dit proefschrift
gebaseerd is. Vrij snel bleek dat we deze nooit allemaal binnen de gestelde tijd zouden
kunnen meten en werd besloten dat we studenten in zouden gaan zetten. Aniqa Bashir,
Maaike Berbee, Aartje van Kranenburg, Anneke van Lieshout, Anke Pronk, Marjon
Smoors, en Janneke Wijnakker, heel erg bedankt voor jullie hulp bij het doen van de
suikertesten. In het begin was het misschien nog een beetje eng om te prikken maar
uiteindelijk draaiden jullie daar je hand niet meer voor om. Fijn ook dat de meesten van
jullie later nog de wetenschapsstage op het MME-lab kwamen lopen. Ik vond het heel
bijzonder om jullie ontwikkeling van beginnend student naar beginnend arts mee te
maken . Esther de Zwart, Maartje van den Broek en Wietske Middelkamp, bedankt
voor jullie hulp bij de anthropometrie. ECG- en bloeddruk-metingen. Zonder jullie
hadden we nooit zoveel mensen op een ochtend kunnen meten. George Ledoux, heel
erg bedankt voor je werk in het laboratorium in de laatste periode van het onderzoek.
Marloes van der Molen, Liesbeth van Loon, Noortje Jansen en Martijn Brouwers,
mijn wetenschapsstagiaires, bedankt voor al jullie hulp. Marloes, jij kwam als een van
de eerste studenten op ons onderzoek af hoewel al snel bleek dat wat we in gedachten
hadden helaas niet zou gaan werken. Gelukkig wilde je nog wel stage lopen wat een
heel gezellige periode was. Liesbeth, jij wilde zelf data verzamelen en moest de
proefpersonen nogmaals oproepen voor de LPL-test die je wilde gaan doen Vaak
kwam je mijn kamer binnengestormd met allerlei vragen over statistiek en metingen die
ik ook niet altijd direct ton beantwoorden. Gelukkig konden mijn collega's van het
MME-lab je dan wel vaak helpen. Noortje, bedankt voor alle metingen die je hebt
verricht en alle berekeningen die je hebt gedaan. Dit laatste was zeker niet de leukste
klus, maar toch bleef je altijd vrolijk. Ik kom je vast nog wel eens tegen in de stad of
tijdens carnaval! Martijn, ook jij hebt jouw aandeel in de berekeningen gehad waarvoor
ik je heel dankbaar ben. Jij kwam vaak met khtische vragen die ervoor zorgden dat ik
weer even terug moest denken waarom we bepaalde beslissingen ook al weer
genomen hadden. Het is fijn je niet alleen als stagiaire maar ook als collega te hebben
leren kennen en dan nog wel een die ook thuis is in de echo-wereld.
Naast Martijn en Carla wil ik ook mijn overige (oud)collega's van het MME-lab
bedanken voor nun gezelligheid en interesse in het "diabetes-project": Marleen van
Greevenbroek, Steven Meex, Anna Georgieva, Vicky Vermeulen, Josephine van Lin,
Margee Robertus, Mohammed Elhasnaoui, Erik Keulen, Riny Wieers en Petra Eurlings.
Erik, bedankt voor alle keren dat ik met vragen over het echo-en' bij je terecht kon en
alle gezelligheid. Riny, zonder jou waren alle metingen nooit afgekomen en was het
lang zo gezellig niet geweest op de kamer... Steven, Anna en Martijn, veel succes met
jullie proefschrift! Mohammed, bedankt voor je interesse en de vele gezellige discussies
over van alles en nog wat . . .
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Ook mijn (oud)collega's van Humane Biologie mag ik natuurlijk niet vergeten! Drie
jaar heb ik als een van de werknemers bij julllie op de gang mogen zitten. Als eerste wil
ik mijn kamergenoten Tanja, Use, Marja en Marco bedanken voor alle telefoontjes van
de proefpersonen die jullie beantwoord hebben wanneer ik weer eens aan het meten
was. Het was echt niet mijn bedoeling jullie secretaresse te laten voelen! Bedankt ook
voor alle gezelligheid en steun. Naast mijn kamergenoten had/heb ik ook nog een
aantal "kroeggenoten": Jos, Luc, Joost, Freddy, Michiel, Chris en Eefje. Bedankt voor
alle leuke momenten! Jos, bedankt voor het bepalen van alle glucose monsters en je
hulp bij het labwerk als dat nodig was. Luc, bedankt voor het bijbrengen van de liefde
voor het onderzoek. Joost, bedankt voor al je gezelligheid en het delen van alle
frustrates rond het afronden van een proefschrift. Freddy, bedankt voor al je steun en
gekkigheid. Michiel, bedankt voor al je adviezen en voor je serieuze en laag-nivo
gesprekken. Chris, bedankt voor alle video-avondjes. Ook alle andere collega's van
HB, zowel nieuw als oud, wil ik heel erg bedanken voor hun steun, interesse en
gezelligheid.
Daarnaast wil ik alle mensen die ik ook vaak in de kroeg, op de "uni" of daarbuiten
zag en die ik hierboven niet heb genoemd ook graag bedanken voor de zo broodnodige
afleiding, o.a. Marjan Smook (het was gezellig je kamergenootje te zijn), Daphne
Pannemans (bedankt voor de keren in de kroeg, tijdens carnaval en bij Rowen Heze
concerten), Renate de Groot (bedankt voor de avondjes eten en alle kletsjes op de uni),
Ron Keulen, Riet Daamen, Joan Senden en vele anderen. Ook mijn collega's van de
UM-sport wil ik niet vergeten. Heel erg bedankt voor alle sportieve afleiding!
Naast alle mensen die ik ken via de universiteit en het sportburo heb ik ook nog een
druk leven daarbuiten gehad. Ook deze mensen zijn altijd geinteresseerd geweest en ik
kon altijd bij ze terecht voor gezellige avondjes bijkletsen of lekker op stap gaan. Eline,
lief vriendinnetje, bedankt voor alle keren dat we zijn wezen stappen en de belangrijke
en minder belangrijke zaken des levens bespraken. Ik ben blij dat ik je al 20 jaar (!) mijn
vriendinnetje mag noemen. Ruth, pas sinds relatief korte tijd hebben we weer contact
na ons "buurmeisjes-verleden", maar het is weer supergezellig! Je bent altijd in voor
leuke dingen en ik ga zeker nog eens mee in je bootje varen. Nicole, soms zien en
spreken we elkaar langere tijd niet, maar dat maakt niets u i t . w e kletsen toch zo weer
verder. Ik hoop dat we nog vaak samen op stap gaan. Blanche, allebei houden we veel
van praten, dansen en lerse pubs, de ingredienten voor vele gezellige dagen.ik hoop
dat we elkaar nog vaak zien! Ook al mijn overige vriendjes en vhendinnetjes, die ik al
vele, vele jaren ken van 'thuis thuis' en die me heel dierbaar zijn, wil ik graag bedanken
voor alle gezelligheid en interesse: Daphne en Gerard, Edwin en Marian, Monique en
Wijnand, Bas en Anja, Marc en Monique, Theo en Jositha, en Esther en Jaap. Ik ken
jullie nu al heel erg lang en hoop nog vele jaren van jullie en jullie kids te kunnen
genieten! Mijn oude dispuutsgenootjes mag ik ook zeer zeker niet vergeten. Zij hebben
gezorgd voor veel steun, afleiding en gezellige weekendjes. Bedankt daarvoor!
Als laatste wil ik mijn papa, mama, broer(tje) Jan-Willem en zus(je) Rosalie
bedanken voor hun onvoorwaardelijke steun en geloof in mij. Zonder jullie was ik nooit
de persoon geworden die ik nu ben en had ik niet het doorzettingsvermogen gehad om
dit proefschrift tot een goed einde te brengen.
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